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Motor	   neuron	   diseases,	   like	   spinobulbar	  muscular	   atrophy	   (SBMA)	   and	   amyotrophic	  
lateral	  sclerosis	  (ALS)	  are	  characterized	  by	  the	  presence	  of	  inclusions	  or	  aggregates	  of	  
proteinaceous	  materials.	   In	   SBMA,	   inclusions	  are	   formed	  by	   testosterone	  dependent	  
aggregates	  of	  mutant	  androgen	   receptor	   (AR)	  with	  an	  elongated	  polyglutamine	   tract	  
(ARpolyQ),	   while	   in	   ALS	   inclusions	   contain	   several	   aggregated	   proteins	   including	  
TDP43,	   ubiquilin,	   optineurin.	   Exceptions	   are	   familial	   ALS	   forms	   linked	   to	   superoxide	  
dismutase	   1	   (SOD1)	   mutations,	   to	   mutated	   TDP43	   and	   to	   C9ORF72	   poly-­‐dipeptides	  
(DPRs),	   in	  which	  aggregates	  are	  mainly	  composed	  of	  mutant	  SOD1,	  mutant	  TDP43	  or	  
DPRs,	   respectively.	   In	   general,	   protein	   aggregation	   is	   due	   to	   generation	   of	   aberrant	  
protein	   conformations	   (misfolding)	   combined	   to	   a	   failure,	   in	   neuronal	   cells,	   of	   the	  
protein	   quality	   control	   (PQC)	   system,	  which	  may	   be	   insufficient	   to	   correctly	   remove	  
the	   misfolded	   proteins.	   In	   other	   target	   tissue,	   such	   as	   the	   muscles,	   a	   different	  
physiological	  PQC	  regulation	  may	  be	  helpful	   to	  remove	  misfolded	  proteins	  related	  to	  
MNDs.	  	  
The	  PQC	  system	  requires	  the	  activities	  of	  chaperones,	  degradative	  systems	  ubiquitin-­‐
proteasome	  (UPS)	  and	  autophagy.	  After	  misfolded	  protein	  recognition	  by	  chaperones,	  
the	  dynein	  motor	  complex	  plays	  a	  crucial	  role	  to	  efficiently	  remove	  these	  species	  via	  
autophagy,	   transporting	   them	   to	   autophagosome	   and	   assisting	   autophagosome-­‐
lysosome	  fusion.	  	  
In	  this	  thesis,	  I	  have	  investigated	  the	  implications	  of	  protein	  misfolding	  in	  SBMA	  and	  in	  
ALS.	   Taking	   advantage	   of	   a	   comparative	   analysis	   of	   misfolded	   proteins	   response	   in	  
skeletal	   muscle	   and	   in	   spinal	   cord	   of	   SMBA	   mice,	   we	   proved	   that	   autophagy	   is	  
dramatically	   perturbed	   in	   muscles.	   Indeed,	   we	   found	   the	   up-­‐regulation	   of	   most	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autophagic	   markers	   (Beclin-­‐1,	   ATG10,	   p62/SQSTM1,	   LC3).	   In	   addition,	   the	   chaperon	  
small	   Heat	   Shock	   Protein	   B8	   (HSPB8)	   and	   its	   co-­‐chaperone	   BCL2-­‐Associated	  
Athanogene	   3	   (BAG3),	   required	   for	   autophagy,	  were	   robustly	   up-­‐regulated	   together	  
with	   other	   specific	   HSPB8	   interactors	   (HSPB2	   and	   HSPB3).	   Interestingly,	   the	  
BAG3:BAG1	   ratio,	   increased	   in	   muscle,	   suggesting	   preferential	   misfolded	   proteins	  
routing	   to	   autophagy	   rather	   than	   to	   proteasome.	  Misfolded	   proteins,	   recognized	   by	  
HSPB8-­‐BAG3	   complex,	   are	   actively	   transport	   by	   dynein	   to	   MTOC	   to	   be	   inserted	   in	  
autophagosome	  and	  degraded	  by	  autophagy,	  
Then,	  we	  analysed	  the	  role	  of	  dynein	  mediate	  transport	  in	  the	  autophagic	  removal	  of	  
misfolded	   proteins.	   In	   immortalized	   motoneuronal	   NSC34	   cells,	   we	   found	   that	   the	  
reduction	   of	   dynein	   protein	   levels,	   obtained	   using	   a	   specific	   siRNA,	   resulted	   in	  
autophagy	   inhibition	  and	  in	  unexpected	  testosterone	  dependent	  ARpolyQ	  aggregates	  
reduction.	   Also,	  we	   found	   that	   pharmacological	   dynein	   inhibition,	  with	   erythro-­‐9-­‐(2-­‐
Hydroxy-­‐3-­‐nonyl)	   adenine	   hydrochloride	   (EHNA),	   in	  NSC34	   cells	   expressing	   ARpolyQ,	  
mutant	  SOD1,	  truncated	  TDP43	  form	  or	  C9ORF72	  DPRs,	   induced	  a	  great	  reduction	  of	  
mutant	  protein	  aggregates,	  even	  in	  presence	  of	  an	  autophagy	  inhibitor	  (3-­‐MA),	  but	  not	  
of	  a	  proteasome	  inhibitor	  (MG132).	  By	  performing	  fractionation	  studies	  we	  found	  that	  
EHNA	  increased	  the	  ARpolyQ	  levels	   in	  PBS	  and	  Triton-­‐X100	  fractions.	  Surprisingly,	  we	  
found	   that	   ENHA	   effects	  were	   paralleled	   by	   an	   increased	   expression	   of	   BAG1,	   a	   co-­‐
chaperone	  which	   routes	  misfolded	   proteins	   to	  UPS,	   but	   not	   of	   BAG3	   suggesting	   the	  
prevalence	   of	  UPS	   functions.	   Indeed,	  when	   dynein	   activity	  was	   blocked,	   BAG3:BAG1	  
ratio	  was	  decreased,	  thus	  in	  favour	  of	  BAG1	  expression,	  suggesting	  the	  involvement	  of	  
the	  pro-­‐degradative	  activity	  of	  BAG1	  on	  ARpolyQ	  aggregates.	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Collectively,	   these	   data	   show	   that	   mutant	   ARpolyQ	   induces	   a	   potent	   autophagic	  
response	  in	  muscle	  cells.	  This	  may	  be	  useful	  to	  evaluate	  the	  SBMA	  progression.	  
In	   parallel,	   dynein	   blockage	   perturbs	   autophagy	   and	   modifies	   the	   response	   of	   PQC	  
system	   to	   misfolded	   protein.	   This	   results	   in	   reduced	   aggregation	   of	   MNDs-­‐related	  
misfolded	  proteins,	  a	  phenomenon	  that	  may	  occurs	  via	  an	   increase	   in	  their	  solubility	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Motor	   neuron	   diseases	   (MNDs)	   are	   a	   group	   of	   young	   and	   adult	   onset	   neurological	  
disorders	  characterised	  by	  the	  loss	  of	  motor	  neuron	  which	  control	  essential	  voluntary	  
muscle	   activity	   such	   as	   walking,	   speaking,	   swallowing	   and	   breathing.	  Motor	   neuron	  
loss	  results	  in	  muscle	  weakness	  and	  atrophy	  that,	  with	  different	  progression	  rate,	  may	  
lead	   to	   death.	   In	  MNDs,	   upper,	   lower	   or	   both	  motor	   neurons	   are	   affected.	   In	   fact,	  
upper	  motor	  neurons	  localized	  in	  the	  brain	  and	  lower	  motor	  neurons	  localized	  in	  the	  
brain	   stem	   and	   in	   the	   spinal	   cord	   are	   closely	   related	   in	   the	   control	   of	   movements.	  
MNDs	  are	  classified	  according	  to	  their	  sporadic	  or	  inherited	  manifestations	  and	  to	  the	  
localization	   of	   the	   neurons	   involved.	   In	   fact,	   some	   MNDs	   are	   inherited	   and	   finely	  
associated	  with	  localization	  of	  involve	  neurons,	  but	  most	  MNDs	  have	  unknown	  causes	  
and	   great	   differences	   between	   disease	   manifestations.	   Lower	   motor	   neurons	   are	  
involved	  in	  Kennedy’s	  disease,	  also	  referred	  to	  as	  spinal	  and	  bulbar	  muscular	  atrophy	  
(SBMA),	   as	   well	   as	   in	   spinal	   muscular	   atrophy	   (SMA)	   and	   in	   progressive	   muscular	  
atrophy	  (PMA);	  upper	  motor	  neurons	  are	  involved	  in	  primary	  lateral	  sclerosis	  (PLS)	  and	  
in	  spastic	  paraplegias;	  both	  upper	  and	   lower	  motor	  neurons	  are	  normally	  affected	   in	  
amyotrophic	   lateral	   sclerosis	   (ALS)	   and	   in	   progressive	   bulbar	   palsy	   (PBP)(Figlewicz	  &	  
Orrell,	  2003).	  In	  this	  thesis	  we	  will	  be	  discuss	  data	  obtained	  on	  the	  SBMA	  and	  ALS.	  
	  
Spinal	  and	  bulbar	  muscular	  atrophy	  (SBMA)	  
SBMA	  was	  described	  in	  1897	  by	  Japanese	  neurologist,	  H.	  Kawahara	  (Kawahara,	  1897),	  
and	  has	  been	  known	  as	  Kennedy’s	  disease	  since	  1968,	  when	  W.	  Kennedy	  reported	  the	  
clinical	  details	   related	   to	   the	  disease	   (Kennedy	  et	  al.,	  1968).	  SBMA	  patients	  normally	  
show	  weakness	  and	  wasting	  of	  the	  facial,	  bulbar,	  and	  limb	  muscles,	  along	  with	  sensory	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disturbances	   and	   endocrinological	   abnormalities	   (Katsuno	   et	   al.,	   2012;	   Parodi	   &	  
Pennuto,	  2011).	  
SBMA	   is	   an	   X-­‐linked	   disease	   caused	   by	   abnormal	   CAG	   repeat	   expansion	   in	   the	   first	  
exon	  of	   the	  androgen	  receptor	   (AR)	  gene,	   localized	  on	  chromosome	  Xq11-­‐12,	   that	   is	  
translated	   in	   poly-­‐glutamine	   (polyQ)	   tract	   in	   AR	   protein.	   The	   CAG	   repeat	   ranges	  
between	  9	  and	  36	  in	  normal	  individuals	  and	  is	  over	  38	  (up	  to	  68)	  in	  patients	  (Grunseich	  
et	  al.,	  2014a;	  La	  Spada	  et	  al.,	  1991).	  	  SBMA	  was	  the	  first	  to	  be	  identified	  in	  a	  series	  of	  
nine	   different	   neurodegenerative	   diseases	   in	   which	   polyQ	   elongations	   in	   totally	  
unrelated	  proteins	  have	  been	  identified.	  In	  fact,	  an	  abnormal	  polyQ	  tract	  is	  present	  in	  
the	   huntingtin	   protein	   responsible	   for	   Huntington’s	   disease	   (HD),	   in	   the	   ataxin-­‐1,	   -­‐2	  
and	  -­‐3,	  in	  the	  Cav2.1	  P/Q	  voltage-­‐dependent	  calcium	  channel,	  in	  ataxin-­‐7	  and	  in	  TATA-­‐
binding	  protein	  (TBP)	  responsible	  respectively	  for	  spinocerebellar	  ataxia	  (SCA)	  type	  1,	  
2,	  3,	  6,	  7	  and	  17,	  and	  in	  atrophin-­‐1	  protein	  responsible	  for	  dentatorubral-­‐pallidoluysian	  
atrophy	  (DRPLA)	  (Tab.	  1).	  
Table	  1	  –	  Polyglutammine-­‐Associated	  Diseases,	  adapted	  from	  (Fan	  et	  al.,	  2014)	  
	   	   	   Expanded	  CAG	  Repeats	  
PolyQ	  Diseases	   Locus	   Protein	   Normal	   Pathological	  
SBMA	   Xq11–q12	   Androgen	  receptor	   6–36	   38–68	  
SCA1	   6p23	   Ataxin-­‐1	  	   6–39	   41–83	  
SCA2	  	   12q24	   Ataxin-­‐2	   14–32	   34–77	  
SCA6	  	   19p13	   CACNA1A	  	   4–18	   21–30	  
SCA7	   3p21–p12	   Ataxin-­‐7	   7–18	   38–200	  
SCA17	   6q27	   TBP	   25–43	   45–63	  
MJD/SCA3	  	   14q24–q31	   Ataxin-­‐3	   12–40	   62–86	  
HD	   4p16.3	   Huntingtin	  	   6–35	   36–121	  
DRPLA	  	   12p13	   Atrophin-­‐1	   3–38	   49–88	  
polyQ,	   polyglutamine;	   SCA,	   spinocerebellar	   ataxia;	   HD,	   Huntington’s	   disease;	   MJD,	   Machado–Joseph	  
disease;	   DRPLA,	   dentatorubropallidoluysian	   atrophy;	   SBMA,	   spinal	   bulbar	   muscular	   atrophy;	   CACNA1A,	  
calcium	   channel,	   voltage-­‐dependent,	   P/Q	   type,	   a	   1A	   subunit;	   TBP,	   thymine–adenine–thymine–adenine	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Similar	   to	   other	   polyQ	   diseases,	   in	   SBMA	   the	   age	   at	   onset	   of	   the	   disease	   has	   been	  
inversely	  linked	  to	  the	  size	  of	  the	  CAG-­‐repeat	  expansions	  (Atsuta	  et	  al.,	  2006),	  usually	  
between	   30	   and	   60	   years	   old,	   but	   early	   nonspecific	   symptoms,	   such	   as	   tremor	   and	  
muscle	   cramps,	   make	   it	   difficult	   to	   identify	   the	   precise	   time	   of	   onset.	   Also,	   SBMA	  
patients	   may	   be	   misdiagnosed	   with	   other	   neuromuscular	   diseases;	   altogether	   the	  
prevalence	  is	  1-­‐2	  per	  100.000	  individuals.	  
Degeneration	  of	  lower	  motor	  neurons	  localized	  in	  the	  anterior	  horn	  of	  the	  spinal	  cord	  
and	  in	  the	  brainstem	  characterizes	  SBMA.	  Subsequently,	  muscles	  innervated	  by	  these	  
neurons	  are	  affected	  and	  patients	  show	  myopathy	  followed	  by	  muscle	  atrophy	  (Sorarù	  
et	   al.,	   2008;	   Harding	   et	   al.,	   1982;	   Kennedy	   et	   al.,	   1968).	   Dorsal	   root	   ganglia	   (DRG)	  
sensory	  neurons	  and	  cells	   involved	   in	  male	  reproductive	  functions	  are	  also	  known	  to	  
be	  affected.	  	  
Recent	  data	  suggest	  that	  muscle	  tissues	  can	  be	  a	  player	  in	  the	  pathogenesis	  of	  SBMA.	  
This	   evidence	   modifies	   the	   classical	   view	   of	   SBMA	   as	   a	   disease	   exclusively	   of	   the	  
primary	  motor	  neuron	  and	  indicates	  that	  mutant	  AR	  plays	  its	  toxicity	  also	  in	  the	  muscle	  
(Lieberman	   et	   al.,	   2014;	   Cortes	   et	   al.,	   2014).	   Indeed,	   skeletal	   muscle	   is	   one	   of	   the	  
major	  targets	  of	  androgens	  and	  muscle	  degeneration	  may	  not	  only	  be	  a	  consequence	  
of	  chronic	  denervation	  due	  to	  motor	  neuron	  loss.	  Previous	  studies	  show	  that:	   i)	  both	  
myogenic	  and	  myopathic	  features	  are	  present	  in	  muscle	  biopsies	  of	  patients	  (Sorarù	  et	  
al.,	   2008);	   ii)	   knock-­‐in	  mutant	   AR	  male	  mice	   develop	  myopathy	   before	   the	   onset	   of	  
spinal	  cord	  pathology	  (Yu	  et	  al.,	  2006a);	  iii)	  over-­‐expression	  of	  muscle-­‐specific	  insulin-­‐
like	   growth	   factor	   (IGF-­‐1)	   or	   peripheral	   	   administration	   of	   IGF-­‐1	   mitigates	   SBMA	  
symptoms	  in	  transgenic	  mice	  (Rinaldi	  et	  al.,	  2012;	  Palazzolo	  et	  al.,	  2009),	  supporting	  a	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primary	   contribution	   of	   skeletal	   muscle	   in	   the	   disease	   pathogenesis.	   Moreover,	  
abnormally	  increased	  levels	  of	  creatine	  kinase	  in	  the	  serum	  of	  SBMA	  patients	  are	  not	  
usually	   expected	   when	   studying	   a	   neurogenic-­‐only	   disorder	   (Mariotti	   et	   al.,	   2000).	  
Collectively,	  these	  results	  suggest	  that	  AR	  toxicity	  can	  occur	   in	  muscles	  before	  motor	  
neurons	   and	   that	   skeletal	   muscle	   structure	   and	   function	   alterations	   may	   be	   cell-­‐
autonomous.	  In	  conclusion,	  AR	  toxicity	  in	  skeletal	  muscles	  is	  sufficient	  to	  cause	  disease	  
and	  lead	  to	  the	  denervation-­‐induced	  atrophy	  (Monks	  et	  al.,	  2007).	  Accordingly,	  muscle	  
degeneration	   in	   SBMA	   mouse	   models	   may	   be	   both	   intrinsic	   and/or	   motor	   neuron-­‐
dependent.	  
Although	   AR	   is	   expressed	   in	   other	   areas	   of	   the	   central	   nervous	   system,	   such	   as	   the	  
cortex,	  cerebellum,	  hippocampus,	  hypothalamus	  and	  olfactory	  bulb,	  AR	  toxicity	  mainly	  
affects	  lower	  motor	  neuron	  functions	  and	  targets	  (Rocchi	  &	  Pennuto,	  2013;	  Roselli	  et	  
al.,	   1989).	   The	  main	   clinical	   features	   are	  weakness,	   atrophy	   and	   fasciculation.	   Thus,	  
SBMA	  progression	  (Fig.	  1)	  starts	  from	  tremor	  of	  the	  hand,	  first	  noticed	  when	  patients	  
used	  their	  hands,	  for	  example,	  when	  holding	  a	  glass.	  Gradually,	  SBMA	  patients	  noticed	  
muscular	  weakness,	  predominantly	   in	  the	  lower	  extremities,	   leading	  to	  the	  need	  of	  a	  
handrail	  when	  climbing	  stairs.	  Next,	  patients	  became	  affected	  by	  dysarthria,	  dysphagia	  
and	  needed	  to	  use	  a	  walking	  stick,	  and	  subsequently	  a	  wheelchair.	  At	  the	  later	  stages,	  
patients	  developed	  pneumonia	  due	  to	  aspiration	  and	  required	  in-­‐hospital	  care	  (Atsuta	  
et	  al.,	  2006).	  Therefore,	  the	  majority	  of	  SBMA	  patients	  do	  not	  die	  from	  motor	  neuron	  
complications	   and	   have	   a	   normal	   life	   expectancy	   (Atsuta	   et	   al.,	   2006).	   Androgen	  
insensitivity	   typically	   occurs	   variably	   during	   adolescence	   with	   testicular	   atrophy,	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oligospermia/azospermia	   with	   reduced	   fertility	   and	   gynecomastia	   (Battaglia	   et	   al.,	  
2003;	  Nagashima	  et	  al.,	  1988).	  
SBMA	   affects	   only	   adult	   males,	   even	   if	   females	   present	   subclinical	   disease	  
manifestations	  when	   homozygous;	   then	   SBMA	   is	   sex	   dependent	   and	  well	   correlates	  
with	   testosterone	   levels.	   This	  molecular	  mechanism	   is	   at	   the	   basis	   of	   the	   androgen-­‐
dependence	  of	  the	  disease	  and	  has	  been	  studied	  in	  mice	  models	  of	  SBMA.	  With	  these	  
mice,	   it	   was	   found	   that	   male	   ARpolyQ	   mice	   subjected	   to	   chemicals	   or	   surgical	  
castration	  ameliorate	   the	  disease	  phenotype,	  whereas	   female	  ARpolyQ	  mice	   treated	  
with	   testosterone	   show	   SBMA	   symptoms	   and	   features	   (Yu	   et	   al.,	   2006a;	   Chevalier-­‐
Larsen	  et	  al.,	  2004;	  Katsuno	  et	  al.,	  2002).	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Figure	  1	  -­‐	  Age	  distribution	  of	  ADL	  milestones	  for	  223	  SBMA	  patients.	  (from	  Atsuta	  et	  al.,	  2006)	  	  
	  
	   	  
onset of each ADL milestone showed a considerable wide-
ranged distribution from 25 to 30 years when assessed from
the 10th to 90th percentile range. Although there were no
significant differences in the mean number of CAG repeats
in the AR gene of the patients in which we assessed the age at
onset of each ADL milestone (Fig. 1), suggesting that age
distributions at each milestone were derived from genetically
uniform patients, we tested the hypothesis that the wide range
in ages of onset at each milestone may be due to individual
differences in CAG-repeat lengths.
Age at onset of each ADL milestone
correlates well with CAG-repeat length
As shown in Fig. 2, the onset age of the individual ADL
milestones examined showed significant correlations with
the CAG-repeat length of the patients reporting on these
symptoms (r = !0.853 to !0.447, P < 0.016–0.001). Of
these, age at onset of hand tremor, requirement of a handrail,
use of a wheelchair, developing pneumonia requiring
in-hospital care and death were strongly correlated with
the CAG repeats with r < !0.5. Furthermore, the onset
ages of pneumonia and death were highly correlated with
the CAG repeats with r = !0.78 and !0.85, respectively,
indicating that these specific events, the onset ages of
which the patients or their families were able to indicate
more definitely, showed a more significant correlation with
the CAG-repeat length than other ADL milestones.
Since 47 repeats was the median CAG-repeat length of the
entire patient group, we further compared the Kaplan–Meier
curves for age at onset of hand tremor, muscular weakness
and requirement of a handrail between the patient group with
47 CAG repeats or more and those with <47 CAG repeats
(Fig. 3). We assessed only these three ADL milestones, since
the number of patients in these groups was sufficient to per-
form a log rank test analysis. The patients with <47 CAG
repeats showed regression curves shifted by "10 years com-
pared with those with #47 CAG repeats (Fig. 3, P < 0.001 in
log rank test). Together, these observations strongly suggest
that the onset age of each ADL milestone is highly dependent
on CAG-repeat length in the AR gene.
CAG-repeat length does not correlate
with the rate of disease progression
assessed by ADL milestones
In order to assess whether CAG-repeat length influences the
disease progression rate, we examined the relationship
between the time intervals from onset age of muscular weak-
ness to that of requirement of a handrail when going up stairs,
use of a cane, use of a wheelchair, development of pneumonia
and death and the CAG-repeat lengths in these groups
(Fig. 4). We did not find any significant correlations of
the intervals among the onset age of the various milestones
with the CAG-repeat length, suggesting that the progression
rate of the disease is not significantly influenced by the
CAG-repeat size.
In addition, we examined the declining regression assessed
by those ADL milestones in individual patients with #47
CAG repeats compared with those with <47 (Fig. 5). These
regression lines were divergent from each other, possibly
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Fig. 1 Age distribution of ADL milestones for 223 SBMA patients. The mean number of CAG repeats in the AR gene of the
patients does not differ significantly as shown at the right.
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Androgen	  Receptor	  
AR	  is	  a	  protein	  belonging	  to	  the	  nuclear	  receptor	  superfamily	  of	  transcription	  factors	  
responsible	   for	   the	   biological	   actions	   of	   androgenic	   steroids.	   Like	   other	   nuclear	  
receptors,	  AR	  is	  activated	  by	  ligand.	  	  
The	  human	  AR	  gene	   (Fig.	  2)	  was	   cloned	   in	  1988	   (Chang	  et	  al.,	   1988;	  Trapman	  et	  al.,	  
1988;	  Lubahn	  et	  al.,	  1988)	  and	  well	  characterized	   in	   the	   following	  years.	  Because	  AR	  
gene	   is	   localized	   in	   the	   X-­‐chromosome,	   females	   have	   two	   copies	   of	   the	   gene,	  while	  
males	  only	  one,	  but	   in	   the	   first	   case	  one	   is	   inactivated	  by	   random	  X-­‐inactivation.	  AR	  
open	   reading	   frame	   (ORF)	   is	   composed	   by	   8	   exons	   encoding	   for	   approximately	   919	  
amino	   acids,	   organized	   in	   different	   functional	   domains:	   i)	   The	   N-­‐terminal	  
transactivation	  domain,	  encoded	  by	  exon	  1,	  contains	  the	  polyQ	  and	  other	  amino	  acid	  
stretches	  (polyproline	  (polyP)	  and	  polyglycine	  (polyG)	  tracts);	   ii)	   the	  highly	  conserved	  
DNA-­‐binding	  domain,	  where	  exons	  2	  and	  3	  encode	  for	  two	  Zinc-­‐fingers;	  iii)	  C-­‐terminal	  
ligand	   binding-­‐domain	   encoded	   by	   exons	   4	   to	   8,	   that	   contain	   the	   nuclear	   targeting	  
sequence	  and	  the	  steroid	  binding	  domain	  (Brinkmann,	  2001).	  The	  N-­‐terminal	  region	  is	  
highly	   polymorphic	   in	   polyQ	   tract	   and	   the	   elongated	   form	   is	   linked	   to	   SBMA.	   PolyQ	  
functions	  are	  unknown,	  but	  it	  has	  been	  postulated	  that	  the	  Q-­‐rich	  regions	  are	  involved	  
in	  protein-­‐protein	  interactions.	  Also,	  polyP	  and	  polyG	  tract	  functions	  are	  still	  unknown.	  
N-­‐term	   is	   also	   responsible	   of	   N/C	   interaction	   of	   AR	   that	   induces	   antiparallel	   AR	  
dimerization.	  AR	  dimer	  protects	  the	  ligand	  in	  the	  LBD	  binding	  pocket	  and	  this	  results	  in	  
AR	   stabilization.	   Expanded	   polyQ	   impairs	   N-­‐term	   AR	   interaction	   with	   co-­‐activators	  
and/or	  other	   transcriptional	   components,	   resulting	   in	  mild	   repression	  of	   target	   gene	  
transcription.	   Nevertheless,	   expanded	   polyQ	   leads	   to	   AR	   aggregation,	   and	   the	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consequent	   reduction	   of	   the	   total	   amount	   of	   receptor	   protein	   able	   to	   promote	  
transcription.	   In	   parallel,	   a	   large	   number	   of	   clinical	   and	   experimental	   observations	  
suggest	   that	   AR	   loss-­‐of-­‐function	   explains	   only	   the	   endocrinological	   SBMA	   features	  
(Neuschmid-­‐Kaspar	  et	  al.,	  1996).	  In	  fact,	   in	  AR	  endocrine	  disorders,	  such	  as	  androgen	  
insensitivity	  syndrome,	  no	  neurological	  signs	  are	  present.	  Instead,	  in	  SBMA,	  expanded	  
ARpolyQ	  activation	  leads	  to	  motor	  neuron	  death,	  clearly	  showing	  the	  gain	  of	  new	  toxic	  
function.	  Moreover,	  SBMA	  animal	  models	  expressing	  the	  expanded	  ARpolyQ	  showed	  
motor	  neuron	  dysfunction	  even	  in	  the	  presence	  of	  the	  endogenous	  wild-­‐type	  receptor.	  
Finally,	   the	   expression	   of	   expanded	   ARpolyQ	   in	   neuronal	   cells	   alters	   several	   cell	  
functions,	  leading	  to	  cell	  death.	  AR	  activation	  and	  toxicity	  are	  mediated	  by	  its	  ligands	  
testosterone	   (T)	   and	   dihydrotestosterone	   (DHT).	   Indeed,	   inactive	   AR	   in	   cytoplasm	   is	  
associated	  with	  the	  heat	  shock	  protein	  (Hsp)	  70,	  Hsp90	  and	  Hsp40	  which	  maintain	  the	  
correct	   protein	   folding	   of	   AR.	   After	   ligand	   interaction,	   AR	   is	   released	   from	   the	  
cytoplasmic	   soluble	   complex	   and	   translocates	   into	   the	   nucleus,	   where	   it	   normally	  
activates	  the	  transcription	  of	  target	  genes	  (Fig.	  3).	  
The	  polyQ	  tract	  alters	  the	  structure	  of	  AR,	  which	  changes	  from	  its	  usual	  random	  coil	  to	  
a	   parallel	   β-­‐sheet	   that	   leads	   to	   a	   oligomeric	   fibrils	   structure,	   as	   the	   first	   step	   of	  
aggregation	  (Wyttenbach,	  2004).	  
The	  formation	  of	  toxic	  mutant	  AR	  oligomers	  or	  aggregates	  activates	  a	  series	  of	  events	  
that	  lead	  to	  cell	  degeneration	  (Jochum	  et	  al.,	  2012;	  Muchowski	  &	  Wacker,	  2005;	  Taylor	  
et	  al.,	  2003).	  
The	  SBMA	  histopathological	  hallmark	   is	  the	  presence	  of	  nuclear	   inclusions	  containing	  
ARpolyQ	  in	  motor	  neurons	  and	  brainstem,	  as	  well	  as	  in	  non-­‐neuronal	  tissues	  (Yu	  et	  al.,	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2006a;	  Li	  et	  al.,	  1998).	  AR	  aggregates	  were	  also	  observed	  in	  the	  cytoplasm	  of	  sensory	  
neurons	  where	   they	   seem	   to	   be	   associated	  with	   axonal	   degeneration	   (Suzuki	   et	   al.,	  
2008).	  Although	  several	   studies	   show	  that	   inclusions	  prevent	  mutant	  protein	   toxicity	  
by	   sequestering	   them	   into	   an	   aggregate	   structure	   that	   initially	   contributes	   to	   their	  
degradation.	  Next,	  accumulation	  of	  misfolded	  proteins	  seems	  to	  play	  a	   role	   in	  SBMA	  
neurodegeneration	  (Miller	  et	  al.,	  2011;	  Rusmini	  et	  al.,	  2007).	  In	  fact,	  the	  sequestration	  
of	  molecular	   chaperones	   and	  proteasome	   subunits	   suggests	   that	  motor	  neurons	   are	  
unable	  to	  fold	  and	  degrade	  mutant	  AR,	  resulting	  in	  aggregates	  accumulation.	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Figure	  3	  -­‐	  Mechanism	  of	  action	  of	  the	  androgen	  receptor.	  (from	  Poletti,	  2004)	  
	   	  
dihydrotestosterone (DHT), seems to enhance AR sta-
bility through an interacting domain identified in a se-
quence (FXXLF motif) present in the N-terminal
region. The stabilization of the AR by its ligands is a
particular feature of AR, since PR, ERs, GR, and thy-
roid hormone receptors undergo rather agonist-induced
receptor degradation [70]. Interestingly, the length of the
polyGln tract in the N-terminal domain of AR is in-
versely correlated with the receptor stability [162,163],
and this is possibly due to a lower capability of AR with
elongated polyGln tracts to generate correct N/C inter-
actions (see below). It has also been proposed that the
N/C interaction induces an antiparallel arrangement of
the monomers composing the AR dimer (see Fig. 2),
protecting the ligand in the binding pocket of the LBD,
and resulting in stabilization of the AR which may be
required for AR mediated transactivation [70]. This
mechanisms is highly relevant for AR function since AR
dimerization (which also involves the D-box present in
the C-terminal region of the second Zn finger in the
DBD) is a necessary step for optimal DNA-binding;
dimer formation occurs after ligand binding and prior
to coupling of the DBD to the hormone-responsive
element (HRE) of the target gene. The fact that dimer-
ization occurs through an inter-molecular NH2–COOH-
terminal interaction involving the LBD of one molecule
and the NH2 terminal portion of another, and that this
interaction is modified by polyGln length in the anti-
parallel orientation of the AR monomers upon dimer-
ization [111,112], may result in a partial loss of AR
transcriptional activity as a function of the size of the
polyGln tract [93,141].
Two out of three main transactivation regions (AF,
activating functions) have been detected in the NH2
terminus; the main AF in the NH2 terminus, named AF-
1 spans between amino acids 51–211 (encompassing the
polyGln tract), and is fully active only in the ligand-
activated AR, presumably because it is hindered by the
interactions of the AR with the Hsp complex bound to
the LBD. The other transcriptional regulatory domain
present in the NH2 terminus, is called AF-5 and spans
between residues 370 and 494. Finally, the NH2 termi-
nus of AR contains an inhibitory domain (ID; Fig. 1)
located in an 81-amino acid segment lying upstream of
the DNA-binding domain (DBD). The ID interacts di-
rectly with DBD and represses its binding to the ARE
[123]; the AF-2 is located in the C-terminus.
2.1.2.4. Post-translational modification of the androgen
receptor
Phosphorylation. At least seven phosphorylation sites
are present in the AR, six out of seven are in the N-
Fig. 2. Mechanism of action of the androgen receptor. Testosterone (T) or its 5a-reduced metabolite DHT (transformed by the 5a-reductase type
II¼ 5a-RII) bind AR inducing the dissociation of the heat shock proteins (Hsp); the receptor dimerizes through an N/C terminal interaction,
stabilized by the D-box present in the second Zn-finger, and translocates into the nuclei; the AR dimers bind androgen responsive elements (ARE)
located in the promoter region of androgen responsive genes; by recruiting co-activators capable to interact with the general transcription factors
TFIID, TFIIH (H), TFIIB (B), TFIIF (F), and TFIIE (E) the activated AR dimers allow to the RNA polymerase II (RNA pol II) to transcribe the
gene.
4 A. Poletti / Frontiers in Neuroendocrinology 25 (2004) 1–26
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Different	   studies	   show	   the	   different	   roles	   of	   AR	   aggregates	   in	   impairing	   of	   neuronal	  
cell	   functions.	   Three	   types	   of	   aggregates	   have	   been	   identified	   because	   of	   different	  
localization	  and	  functions:	  cytoplasmic,	  neuropil	  and	  nuclear.	  i)	  Cytoplasmic	  aggregates	  
formed	  in	  cell	  culture	  are	  partially	  soluble,	  detectable	  in	  SDS-­‐PAGE	  and	  redistributed	  in	  
cytoplasm	   by	   removing	   the	   ligand;	   this	   confirms	   that	   cells	   might	   use	   aggregates	   to	  
prevent	  polyQ	  toxic	  functions.	  ii)	  In	  cell	  culture	  neuropil	  aggregates	  are	  present	  in	  few	  
cells	   (4-­‐6%	   of	   total	   transfected	   cells),	   but	   they	   could	   play	   an	   important	   role	   in	   the	  
morphological	  modification	  observed	   in	  neurites	  of	   SBMA	  cell	  models.	   In	   fact,	   these	  
aggregates	  could	  alter	  neurite	  functions	  by	  blocking	  the	  organelle	  transport	  along	  the	  
microtubules.	   iii)	   Nuclear	   aggregates	   are	   typically	   present	   in	   the	   brain	   of	   SBMA	  
patients	  and	   in	   transgenic	  animals.	  Usually,	   in	   the	   transfected	  cell	  model,	  only	  a	   few	  
neurons	   present	   aggregates.	   Additionally,	   nuclear	   inclusions	   are	   rare	   and	   observed	  
only	   when	   a	   very	   long	   polyQ	   tract	   (more	   than	   90Q)	   is	   present.	   In	   nuclear	  
compartment,	  AR	  aggregates	  sequester	  the	  steroid	  receptor	  co-­‐activator	  1	  (SRC1)	  and	  
the	   CREB-­‐binding	   protein	   (CBP)	   with	   consequent	   alteration	   of	   transcription.	   These	  
aggregates	  are	   insoluble	  and	  are	  usually	  detectable	   in	  WB	  since	   they	  are	   retained	   in	  
staking	  gel	  on	  SDS-­‐PAGE.	  
It	   is	   clear	   that	   polyQ	   tract	   alters	   the	   folding	   of	   AR	   leading	   to	   misfolded	   proteins	  
formation.	  The	  cells	  try	  to	  active	  protective	  pathway	  in	  order	  to	  prevent	  the	  formation	  
of	  potentially	  toxic	  misfolded	  species,	  as	  well	  as	  their	  accumulation.	  This	  protection	  is	  
exerted	  mainly	  by	  the	  protein	  quality	  control	  (PQC)	  system	  management	  of	  misfolded	  
proteins.	  PQC	  system	  could	  not	  be	  sufficient	   to	  remove	  misfolded	  AR	   in	  post-­‐mitotic	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cells	  such	  as	  motor	  neurons,	  particularly	   in	  aged	  cells	  were	  the	  activity	  of	  the	  PQC	   is	  
normally	  decreased.	  	  
	  
Amyotrophic	  lateral	  sclerosis	  (ALS)	  
ALS	  or	  Lou	  Gehrig’s	  disease	  covers	  a	  spectrum	  of	   syndromes	  characterized	  by	  motor	  
neurons	  degeneration	  described	  by	  Jean	  Matin	  Charcot	  in	  1869	  as	  a	  progressive	  adult	  
onset	  disease.	  Most	  upper	  and	  lower	  motor	  neurons	  are	  involved	  in	  this	  disease,	  only	  
motor	  neurons	  involved	  in	  eyes	  and	  bladder	  control	  are	  not	  affected	  (Majoor-­‐Krakauer	  
et	  al.,	  2003).	  The	  degeneration	  of	  motor	  neurons	  leads	  to	  loss	  of	  ability	  to	  initiate	  and	  
control	  voluntary	  movements	  in	  the	  muscle.	  Patients	  may	  lose	  the	  ability	  to	  speak,	  eat,	  
move	  and	  breathe.	  ALS	  progression	   is	  uncontrollable	  and	  patients	  die	   in	  a	   few	  years	  
from	  early	  symptoms	  (3,5	  +/-­‐3	  years)	  because	  of	  respiratory	  muscle	  failure,	  with	  great	  
variations	  in	  relation	  to	  the	  age	  of	  onset	  (Eisen	  et	  al.,	  1993).	  Generally,	  ALS	  onset	  age	  is	  
60-­‐70	   and	   occurs	   in	   western	   nations	   with	   an	   incidence	   of	   1-­‐2	   case	   every	   100.000	  
people/year	  and	  a	  prevalence	  of	  4-­‐6	  patients	  every	  100.000	  people.	  In	  Italy	  there	  are	  
ca.	  6.000	  patients	  (25.000	  in	  USA).	  Young	  onset	  of	  disease	  is	  also	  found.	  Disease	  occurs	  
in	  both	  sexes	  with	  higher	  prevalence	   in	  male	  (1,5:1	  ratio),	  probably	  due	  to	  hormonal	  
protection	   in	   women	   and	   a	   greater	   exposure	   among	   men	   to	   supposed	   risk	   factors	  
(Orsini	  et	  al.,	  2015;	  Pasinelli	  &	  Brown,	  2006).	  	  
Neurologists’	  early	   studies	  did	  not	   consider	   the	  genetic	   contribution	   to	  ALS,	  but	  was	  
included	   after	   the	   first	   description	   of	   ALS	   families.	   These	   cases	   account	   for	  
approximately	   10%	   of	   the	   total	   ALS	   incidence	   and	   are	   named	   familial	   ALS	   (fALS).	  
Usually,	  fALS	  is	  inherited	  as	  an	  autosomal	  dominant	  mutation.	  A	  high	  number	  of	  genes	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and	  mutations	  have	  been	  linked	  to	  fALS,	  and	  even	  more	  (about	  100	  genes)	  have	  been	  
associated	  with	  ALS	  since	  2006	  (Lattante	  et	  al.,	  2015).	  These	  genes	  were	  classified	  for	  
penetrance	  and	  risk	  and	  considered	  “major”	  or	  “minor”	  genes	  if	  they	  were	  particularly	  
related	  to	  one	  geographic	  cohort.	  “Major”	  genes	  (Fig.	  4)	  responsible	  for	   fALS	  are	  the	  
Cu/Zn	   superoxide	   dismutase-­‐1	   (SOD1)	   gene	   in	   13%,	   the	   TAR	   DNA	   binding	   protein	  
(TARDBP)	  gene	  in	  3%,	  the	  fused	  in	  sarcoma	  (FUS)	  gene	  in	  5%	  and	  the	  C9ORF72	  in	  30-­‐
50%	  of	  cases.	  Other	  mutations	  occur	  in	  VAMP	  (vescicle-­‐associated	  membrane	  protein)-­‐
associatetd	   protein	   B	   (VAPB)	   gene,	   sentaxin	   (SETX)	   gene,	   optineurin	   gene,	   matrin-­‐3	  
gene,	   dynactin	   gene	   and	   others	   (Johnson	   et	   al.,	   2014;	   Pokrishevsky	   et	   al.,	   2012;	  
Maruyama	   et	   al.,	   2010;	   Pasinelli	   &	   Brown,	   2006).	   In	   sporadic	   ALS	   (sALS)	   only	   few	  
mutations	  have	  been	  identified	  to	  contributing	  to	  the	  disease,	  but	  recently	  the	  C9orf72	  
exanucleotide	   expansion	   has	   been	   linked	   to	   a	   great	   numbers	   of	   sALS,	   fALS	   and	   ALS	  
with	  frontotemporal	  dementia	  (FTD)	  symptoms	  (named	  ALS/FTD)	  (Renton	  et	  al.,	  2011;	  
DeJesus-­‐Hernandez	  et	  al.,	  2011).	  	  
The	   proteins	   responsible	   for	   ALS	   have	   very	   different	   functions	   and	   the	   type	   of	  
mutations	   in	   the	   gene	   sequence	   are	   numerous.	  More	   than	   150	  missense	  mutations	  
have	  been	   reported	   in	   SOD1	  gene	  and	  40	  mutations	   in	   TARDBP	  gene	   (Tortelli	   et	   al.,	  
2013;	  Gendron	  et	  al.,	  2013).	  These	  mutations	  contribute	   in	  different	  ways	   to	  ALS;	   in	  
fact	  mutations	  are	  scattered	  in	  wide	  portion	  of	  gene	  and	  may	  exacerbate	  different	  ALS	  
type.	  ALS	  related	  proteins	  have	  different	  functions	  but	  acquire	  aberrant	  conformations	  
(misfolded)	  that	  lead	  to	  aggregate	  formation.	  Otherwise,	  mutations	  alter	  structure	  and	  
functions	  of	  proteins	  responsible	  for	  the	  misfolded	  proteins	  response.	   In	  any	  case,	   in	  
this	  condition,	  the	  impairment	  of	  degradative	  pathways	  leads	  to	  protein	  aggregation.	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Notably,	   the	   C9ORF72	   exanucleotide	   expansion	   may	   encode	   (by	   a	   peculiar	   type	   of	  
translation	   (see	   below))	   for	   long	   dipeptides	   (DPRs)	   (polyGP,	   polyGA,	   polyGR,	   polyPA	  
and	  polyPR)	  which	  may	  also	  lead	  to	  aggregate	  formation	  (Mori	  et	  al.,	  2013).	  
The	  presence	  of	  misfolded	  protein	  species	  and	  aggregates	  is	  also	  responsible	  for	  other	  
neurodegenerative	   disorders	   such	   as	   Huntington’s,	   Parkinson’s	   and	   Alzheimer’s	  
diseases.	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Figure	  4	  -­‐	  Major	  genetic	  causes	  in	  familial	  and	  sporadic	  ALS	  (from	  Lattante	  et	  al.,	  2015)	  	  
	   	  
(SALS) patients of European extraction, with a mutation
frequency that is population-specific [16–20]. It is impor-
tant to note that familial and ‘apparently’ sporadic cases
are often difficult to distinguish for several reasons: the
family history is not always well known in ALS and FTD
patients, cases can be misdiagnosed, and the disease may
not occur because of small family size or premature death
of some individuals [21].
With the advent of improved technology, several studies
have been conducted to find new causative genes, focusing
on FALS patients, who are expected to have a higher
frequency of mutations than SALS patients [22]. From
2006 to now more than 100 genes have been reported as
being associated with ALS. Different ALS bioinformatics
repositories which list ALS and FTD genes are available,
such as ALSoD (http://alsod.iop.kcl.ac.uk) [23], ALSGene
(www.alsgene.org) [24], Alzheimer Disease and Fronto-
temporal Dementia Mutation Database (http://www.
molgen.vib-ua.be/ADMutations) [25], and the Human
Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/
index.php [26]. Several these genes are considered low risk
or very low penetrance genes that we refer to here as ‘minor
genes’ because they have been identified in one cohort but
never confirmed in another with different geographic ori-
gins. In addition to C9orf72 and SOD1, genes considered as
‘major’ ALS-causing genes are TAR DNA binding protein
(TARDBP) [27–29] and fused in sarcoma (FUS) [30,31],
which account for about 3% of FALS and 1.5% of SALS, and
5% of FALS and 1% of SALS, respectively. These mutations
have been validated by a multitude of studies, with
patients from different geographic origins (reviewed in
[32]). Both TDP-43 (encoded by TARDBP) and FUS contain
RNA-binding domains and have an important role in RNA
processing, suggesting that dysfunction in RNA metabo-
lism is involved in ALS pathogenesis (reviewed in [33]).
ALS patients carrying TDP-43 mutations were also found
to have cognitive deficits, prompting clinicians to better
investigate cognitive impairment in ALS patients. Al-
though very rare, some ALS patients carrying a FUS
mutation have been described to have cognitive im-
pairment [34–36].
In 2011, the view on ALS and FTD as a spectrum
disorder was further solidified by the discovery of the
causative gene C9orf72 [11,12]. The locus had already been
associated with ALS and FTD by linkage analysis and
genome-wide association studies (GWAS) [37–41]. Differ-
ent research groups performed direct sequencing of the
coding region, narrowing it down to a 3.6 Mb region, but
were unable to isolate the candidate gene [42]. Several
years later, technological advancements allowing the en-
richment of DNA target regions and deep resequencing, in
combination with conventional segregation analysis, led
to the identification of a hexanucleotide repeat expansion
Table 1. Clinical, pathological and genetic features of the ALS/FTD spectruma
Disorder ALS ALS/FTD FTD











Unusual verbal, physical, or sexual behavior































aAlthough the clinical signs of ALS and FTD are discordant, there is an overlap in the pathological and genetic markers in these diseases. Furthermore, patients who






TRENDS in Genetics 
Figure 1. ajor genetic causes in familial and sporadic amyotrophic lateral
sclerosis (ALS). The approximate percentages of mutation carriers are depicted for
sporadic and familial ALS, with C9orf72 repeat expansions being the most
common genetic abnormality in both patient populations. The frequency of these
mutations is variable among patient populations; the approximate frequency rates
obtained from French and Italian populations are depicted in this diagram.
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Superoxide	  dismutase	  1	  
SOD1	  gene	  (Fig.	  5)	  is	  the	  first	  fALS	  gene	  and	  was	  identified	  by	  Rosen	  in	  1993	  (Rosen	  et	  
al.,	   1993).	   Its	   discovery	   offered	   the	   first	   insight	   into	   the	   study	   of	   the	   molecular	  
mechanisms	   at	   the	   basis	   of	   ALS.	   Subsequently	   to	   SOD1	   identification,	   many	   groups	  
produced	   different	   ALS	   models	   based	   on	   different	   SOD1	   mutations,	   to	   study	   the	  
mechanisms	  and	  progression	  of	  ALS.	  Most	  of	  these	  models	  are	  still	  widely	  used.	  
SOD1	  gene	  is	  highly	  conserved	  during	  evolution.	  The	  protein	  is	  ubiquitously	  expressed	  
and	   may	   reach	   1-­‐2%	   of	   the	   total	   proteins	   of	   central	   nervous	   system	   (Pardo	   et	   al.,	  
1994).	   SOD1	   is	   an	   antioxidant	   enzyme	   localized	   in	   cytosol,	   where	   it	   converts	  
superoxide	  to	  molecular	  oxygen	  and	  hydrogen,	  to	  prevent	  oxidative	  damage	  mediated	  
by	  oxygen	   radicals.	  However,	   this	   is	   not	   only	   function	  of	   SOD1,	   in	   fact	   yeast	   studies	  
have	  shown	  that	   less	  than	  1%	  of	  total	  SOD1	  is	  required	  to	  exert	   its	  primary	  function,	  
opening	   the	  possibility	   that	   SOD1	  enzyme	  may	  play	  other	   still	   unknown,	  but	  equally	  
important	   functions	   (Reddi	   &	   Culotta,	   2013;	   Corson	   et	   al.,	   1998).	   In	   parallel,	   clear	  
evidence	  has	  shown	  that	  SOD1	  loss	  of	  function	  plays	  a	  secondary	  role	  in	  disease,	  but	  it	  
is	  clear	  that	  in	  ALS	  patients	  SOD1	  acquires	  an	  undefined	  new	  toxic	  function	  (Saccon	  et	  
al.,	  2013).	  This	  is	  well	  examined	  in	  SOD1-­‐fALS	  and	  many	  functions	  have	  been	  proposed	  
to	  possibly	  explain	  the	  role	  of	  mutated	  SOD1	  in	  ALS	  pathology.	  	  
The	  majority	   of	   SOD1	  mutations	   destabilize	   the	   native	   protein	   folding	   and	   structure	  
(Shaw	  &	  Valentine,	   2007;	   Furukawa	  &	  O’Halloran,	   2005;	   Rodriguez	   et	   al.,	   2005)	   and	  
because	   of	   this,	   mutant	   SOD1	   associates	   into	   aggregates.	   Aggregates	   of	   SOD1	   have	  
been	  observed	  post-­‐mortem	  in	  motor	  neurons	  of	  ALS	  patients	  and	  the	  mutations	  that	  
increase	   instability	   also	   increase	   aggregation,	  which	   is	   correlated	  with	   a	   decrease	   of	  
Introduction	  
	  
	   	  
26	  
survival	   time	   (Byström	   et	   al.,	   2010;	   Wang	   et	   al.,	   2008).	   SOD1	   aggregates	   are	   also	  
observed	  in	  motor	  neurons	  of	  sALS	  patients,	  suggesting	  that	  they	  could	  be	  a	  common	  
ALS	  feature.	  Recently,	  different	  authors	  proposed	  other	  toxic	  mechanisms	  of	  SOD1	  in	  
ALS:	  a)	  mutant	  SOD1	  expressing	  glia	  cells	  (astrocytes	  and	  microglia)	  are	  toxic	  to	  motor	  
neurons;	   b)	   SOD1	   is	   a	   zinc	   sensor	   able	   to	   activate	   ER	   stress	   and	  mutations	   in	   SOD1	  
resulting	   in	   chronic	   ER	   stress	   and	   ERAD	   dysfunction;	   c)	  mutant	   SOD1	  may	   results	   in	  
abnormal	  autophagy;	  d)	  SOD1	  can	  be	  a	  transcription	  factor	  and	  regulate	  transcription;	  
e)	   SOD1	   can	   bind	   mRNAs	   and	   play	   a	   role	   in	   their	   stabilization;	   f)	   SOD1	   can	   be	  
considered	  as	  a	  signalling	  molecule	  able	  to	  integrate	  signals	  from	  oxygen	  and	  glucose	  
(reviewed	  by	  Bunton-­‐Stasyshyn	  et	  al.,	  2014).	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Figure	  5	  -­‐	  Schematic	  representation	  of	  mutations	  in	  the	  SOD1	  gene	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FRAMESHIFT MUTATION
The addition or deletion of a
nucleotide, which shifts the
reading frame during translation
such that the protein sequence
from that point onwards is
altered.
CASPASES
Cysteine proteases involved in
apoptosis, which cleave at
specific aspartate residues.
Apoptotic neuronal death by caspase 3
Although the primary toxic property of familial-ALS-
linked mutations in SOD1 remains unresolved, the final
event in the death cascade has been established as activa-
tion of CASPASE type 3, one of the major cysteine–aspartate
proteases responsible for the degradation of many key cel-
lular constituents during apoptotic cell death. Initial evi-
dence for such a role came from the finding that increas-
ing the expression of the anti-apoptotic factor Bcl2 slowed
disease onset and improved the survival of SOD1G93A
mice by 3–4 weeks24. Activation of caspase 3 is a central
feature in cell death mediated by mutant SOD1, appear-
ing in motor neurons25–27 and astrocytes27 at the time of
the earliest motor neuron death in all three of the best-
studied mouse models. For one mutant (SOD1G93A), the
release of cytochrome c from mitochondria is followed28
by activation of caspase 9, which might be the effector
for the subsequent activation of caspase 3 and caspase 7.
A much earlier event in the mechanism of toxicity in
SOD1 mutants is activation of caspase 1. This occurs
months before neuronal death and before the appearance
of the disease phenotype25,27. In vitro, this temporal cas-
cade of caspase activation occurs within the same neu-
ronal cells27, although this has not been firmly established
sites for a structural zinc and a catalytic copper,
although three mutations alter one of the four residues
that coordinate the copper, and at least seven splicing or
FRAMESHIFT MUTATIONS truncate the final 20–30 amino
acids. Although early measurements of SOD1 activity in
patient blood indicated that a loss of enzymatic activity
was central to the mechanism of disease14,15, a transgenic
mouse expressing the familial-ALS-linked mutant
SOD1G93A developed progressive motor neuron disease
despite markedly elevated SOD1 activity levels16.
This finding was extended by three sets of mice that
expressed different SOD1 mutants. In each of these
cases, the mutations caused disease with elevated17 or
unchanged18,19 SOD1 activity. These observations are in
contrast to examples of mice in which SOD1 is com-
pletely deleted; these animals live uncompromised life-
spans and do not develop overt motor neuron disease20.
Furthermore, some mutants, such as SOD1G37R, retain
full specific activity21. In addition, neither the age of
onset nor rapidity of progression of human disease cor-
relate with dismutase activity levels22,23. The inevitable
conclusion is that the mutants have acquired one or
more toxic properties, irrespective of the amount of
SOD1 activity that each of them retains.
808 |  NOVEMBER 2001 | VOLUME 2  www.nature.com/reviews/neuro



























































V118     stop122
T    G +PLE stop123 











G127     stop133 






















Figure 1 | ALS-causing mutations lie throughout the SOD1 polypeptide. a | Mutations in the 153-amino-acid superoxide
dismutase 1 (SOD1) polypeptide that are known to cause amyotrophic lateral sclerosis (ALS). b | The positions of these mutations in
the three-dimensional structure of crystallized human SOD1 (Protein Data Bank entry 1SPD) were highlighted using Rasmol (R. Sayle,
Biomolecular Structures Group, GlaxoWellcome Research & Development). Mutations are scattered throughout the protein — at
turns of the β-barrel, within β-sheets of the β-barrel, within the active site channel, at the dimer interface, and at copper-coordinating
residues in the active site. Some mutated positions are marked with spacing-filling models of the amino-acid side chains. The
positions of others are simply coloured yellow in the polypeptide chain. The 20 amino acids of the carboxyl terminus are truncated in
several mutants and are coloured in green. The remaining polypeptide backbone is grey.
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TARDBP	  
TARDBP	  gene	  (Fig.	  6)	  was	  identified	  in	  2006	  by	  two	  groups	  that	  observed	  the	  TDP-­‐43	  
protein	  (encoded	  by	  TARDBP	  gene)	  in	  ubiquitinated	  neuronal	  cytoplasmic	  inclusions	  of	  
sALS	  and	  fALS	  patients	  (Arai	  et	  al.,	  2006;	  Neumann	  et	  al.,	  2006).	  Almost	  all	  mutations	  
are	  localized	  in	  the	  C-­‐terminal	  glycine-­‐rich	  region	  and	  are	  responsible	  for	  the	  presence	  
of	   a	   classical	   ALS	   phenotype,	   which	   however,	   can	   be	   sometime	   associated	   with	  
dementia.	   TDP-­‐43	   is	   an	   RNA-­‐binding	   protein	   involved	   in	   microRNA	   biogenesis,	   pre-­‐
mRNA	   splicing	   and	   stability	   of	  mRNA	   (Iguchi	   et	   al.,	   2013).	   TDP-­‐43	   normally	   localizes	  
into	   the	   nuclei,	   but	   in	   TDP-­‐43	   pathology	   is	   redistributed	   in	   cytoplasm	   and	   forms	  
aggregates	  in	  affected	  neuronal	  and	  glial	  cells	  (Arai	  et	  al.,	  2006;	  Neumann	  et	  al.,	  2006).	  
Also,	   animal	   models	   overexpressing	   wild	   type	   or	   mutated	   TDP-­‐43	   clearly	   develop	  
spastic	  paralysis	  and	  neuronal	   inclusions,	  characteristic	  of	  ALS.	   Interestingly,	  not	  only	  
the	   described	   single	   point	   mutations	   have	   been	   associated	   with	   ALS	   but	   also	   the	  
characteristic	  25-­‐kDa	  C-­‐terminal	   fragment	   (CTFs)	  was	  observed	  to	  be	  correlated	  with	  
disease	   development	   and	   progression	   (Swarup	   &	   Julien,	   2011;	   Wils	   et	   al.,	   2010;	  
Wegorzewska	  et	  al.,	  2009).	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Figure	  6	  -­‐	  Schematic	  representation	  of	  mutations	  in	  the	  TDP-­‐43	  gene	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FUS	  
FUS	  gene	  mutations	  responsible	  for	  4%	  of	  fALS	  were	  identified	  in	  2009	  by	  Kwiatkowski	  
et	  al.	   (Kwiatkowski	  et	  al.,	  2009).	  FUS	  mutations	  are	   localized	  in	  the	  C-­‐terminus	   in	  the	  
nuclear	   localization	  signal	   (NLS)	  sequence.	  The	  mutations	  cause	  aberrant	  cytoplasmic	  
distribution	   of	   FUS	   protein	   (Kwiatkowski	   et	   al.,	   2009).	   Patients	   exhibit	   classical	   ALS	  
phenotype	  without	  cognitive	  impairment	  and	  with	  different	  progressions	  even	  among	  
carriers	   of	   the	   same	   mutations	   (Iguchi	   et	   al.,	   2013).	   FUS	   shares	   structures	   and	  
functions	   with	   TDP-­‐43,	   in	   fact	   both	   proteins	   regulate	   alternative	   pre-­‐mRNA	   splicing	  
and	   transcription	   (Lagier-­‐Tourenne	  et	   al.,	   2012),	   although	   they	  have	  different	  mRNA	  
targets.	  FUS	  was	  observed	   in	  neuronal	  cytoplasmic	   inclusions	  positive	  for	  GRP78/BiP,	  
p62/SQSTM1	  and	  ubiquitin	  (Seelaar	  et	  al.,	  2010).	  Interestingly,	  mutated	  FUS	  is	  not	  co-­‐
localized	   with	   TDP-­‐43,	   but	   some	   studies	   show	   that	   wtFUS	   is	   present	   in	   TDP-­‐43	  
aggregates	  of	  sALS	  (Deng	  et	  al.,	  2010).	  	  
Animal	   models	   of	   FUS	   related	   ALS,	   that	   overexpress	   mutant	   FUS	   proteins,	   exhibit	  
pathological	  phenotype	  like	  ALS,	  but	  also	  wt	  FUS	  over-­‐expression	  results	  in	  progressive	  
motor	  neuron	  degeneration	  (Iguchi	  et	  al.,	  2013).	  
	  
OPTN	  
OPTN	  gene	  mutations	  correlates	  with	  fALS	  in	  1-­‐4%	  of	  cases.	  OPTN	  was	  first	  observed	  
mutated	   in	   Japanese	   families;	   other	   dominant	   and	   recessive	   mutations	   were	   later	  
identified.	   Optineurin	   encoded	   by	   OPTN	   gene	   negatively	   regulates	   TNFα-­‐induced	  
nuclear	   factor	  kappa	  B	   (NF-­‐κB)	  activation.	  OPTN	  ALS-­‐causative	  mutations	  abolish	   the	  
inhibition	  of	  activation	  of	  NF-­‐κB	  (Maruyama	  et	  al.,	  2010).	  Other	  functions	  of	  optineurin	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are	  correlated	  with	  autophagy,	  since	  it	  may	  act	  as	  an	  autophagic	  receptor	  and	  because	  
it	   is	   involved	   in	   the	   maintenance	   of	   Golgi	   morphology	   (Sahlender	   et	   al.,	   2005).	  
Optineurin	   is	   also	   present	   in	   ubiquitinated	   neuronal	   cytoplasmic	   inclusions	   of	   sALS	  
(Osawa	  et	  al.,	  2011).	  
	  
VCP	  
Mutations	   in	   Valosin-­‐containing	   protein	   (VCP)	   gene	   were	   first	   described	   in	   patients	  
suffering	  of	  inclusion	  body	  myopathy	  (IBM)	  correlated	  with	  FTD	  (Badadani	  et	  al.,	  2010;	  
Watts	  et	  al.,	  2004).	  Recently,	   in	  2010,	  VCP	  mutations	  have	  been	  identified	  in	  1-­‐2%	  of	  
autosomal	   dominant	   fALS	   cases	   (Johnson	   et	   al.,	   2010).	   VCP	   is	   involved	   in	   several	  
cellular	   pathways	   responsible	   for	   protein	  degradation,	   such	   as	   ubiquitin	   proteasome	  
system	  (UPS),	  autophagy	  and	  endosomal	  sorting	  (Meyer	  et	  al.,	  2012).	  ALS	  related	  VCP	  
mutations	  disrupt	  autophagosome	  maturation	  and	  block	   the	  autophagic	  pathway	   (Ju	  
et	  al.,	  2009).	  VCP	  mutation	  carriers	  exhibit	  heterogeneous	  phenotypes	  with	  the	  same	  
mutations.	   VCP-­‐ALS	   patients	   present	   ubiquitinated	   TDP-­‐43	   inclusions	   in	   the	   affected	  
motor	  neurons.	  This	  is	  confirmed	  also	  in	  mutant	  VCP	  knock-­‐in	  mice,	  that	  develop	  age	  
related	  motor	  dysfunction	  characterized	  by	  abnormal	  TDP-­‐43	   inclusions	   in	   the	  brain,	  
spinal	  cord	  and	  muscles	  (Badadani	  et	  al.,	  2010).	  
	  
C9ORF72	  
In	  2009,	  the	  major	  ALS	  locus	  was	  identified	  on	  chromosome	  9p21	  (van	  Es	  et	  al.,	  2009).	  
The	   C9ORF72	   gene	  was	   then	   associated	   to	   ALS	   thanks	   to	   the	   identification	   of	   large	  
GGGGCC	  exanucleotide	  repeat	  expansion	  (from	  700	  to	  1,600	  copies)	  within	  a	  C9ORF72	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non	   coding	   region	   (DeJesus-­‐Hernandez	   et	   al.,	   2011;	   Renton	   et	   al.,	   2011).	   C9ORF72	  
expansion	  was	  observed	   in	  up	  to	  80%	  of	   fALS/FTD	  cases,	  20%-­‐50%	  of	   fALS	  cases	  and	  
5%-­‐20%	  of	  sALS	  and	  it	  is	  considered	  the	  most	  common	  cause	  of	  ALS	  and	  FTD	  (Ling	  et	  
al.,	   2013).	   Clinically,	   C9ORF72	   ALS	   patients	   have	   a	   higher	   incidence	   of	   earlier	   and	  
bulbar	  onset	  with	  rapid	  disease	  progression	  compared	  to	  patients	  without	  expansion	  
(Chiò	   et	   al.,	   2012).	   The	   pathogenic	   mechanism	   of	   C9ORF72	   expansion	   seems	   to	   be	  
related	   to	   three	   different	   possible	   mechanisms:	   a)	   the	   loss	   of	   function	   of	   C9ORF72	  
gene	  (haploinsufficiency),	  b)	  the	  gain	  of	  toxic	  function	  of	  new	  mutated	  proteins,	  c)	  the	  
gain	  of	  new	  RNA	   toxicity	   caused	  by	  mutated	  RNA	   (Fig.	  7)	   (La	  Spada	  &	  Taylor,	  2010).	  
Moreover,	   bi-­‐directional	   transcription	   and	   ATG	   independent	   translation	   (RAN	  
translation),	   directly	   correlated	   with	   RNA	   secondary	   structure	   of	   long	   repeated	  
sequence,	  lead	  to	  two	  different	  possible	  toxic	  RNAs	  and	  five	  different	  long	  di-­‐peptides:	  
poly-­‐(glycine-­‐proline,	  GP),	  poly-­‐(glycine-­‐alanine,	  GA),	  poly-­‐(glycine-­‐arginine,	  GR),	  poly-­‐
(proline-­‐alanine,	   PA),	   poly-­‐(proline-­‐arginine,	   PR)	   (Fig.	   8).	   Differently	   from	   other	   ALS-­‐
related	  proteins,	  the	  long	  DPRs	  produced	  by	  GGGGCC	  expansion	  in	  C9ORF72	  gene	  do	  
not	  have	  specific	  functions	  (Mori	  et	  al.,	  2013).	  In	  addition,	  the	  alternative	  combination	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Figure	  8	  -­‐	  Schematic	  rappresentation	  of	  protein	  generated	  by	  RAN	  translation	  of	  expanded	  GGGGCC	  and	  CCCCGG.	  
From	  (Gendron	  et	  al.,	  2015)	  	  
	  
	   	  
expansion in C9ORF72 (Al-Sarraj et al., 2011;Murray et al., 2011;
Troakes et al., 2012), suggesting that additional component(s)
other than TDP-43 are present in the inclusions. Cytoplasmic
ubiquilin-2-containing inclusions have also been reported in
the cerebellar granular and hippocampal molecular layers
(Brettschneider et al., 2012).
Pathogenic Mechanisms for the Repeat Expansion in
C9ORF72 Gene
The expanded hexanucleotide repeat in the C9ORF72 gene is
reminiscent ofmultiple prior repeat expansion diseases for which
three different prototypes of pathogenic mechanisms have been
demonstrated: loss of function of the gene containing the repeat
(haploinsufficiency), gain of protein toxicity due to the expression
of protein containing the repeat expansion (mutant protein), and
gain of RNA toxicity due to the production of RNA containing the
repeat (mutant RNA) (La Spada and Taylor, 2010). Additional
toxic mechanisms can result from complementary repeat-con-
taining RNA produced by bidirectional transcription (Moseley
et al., 2006) or repeat associated non-ATG (RAN) translation
(Zu et al., 2011), leading to production, respectively, of potentially
toxic RNA and protein species. For C9ORF72, because the
GGGGCC repeat expansion is located within an alternative non-
coding intron 1, the underlying disease pathogenesis may be
driven by RNA-mediated or RAN translation-dependent toxicity
or haploinsufficiency or any combination of these (Figure 4).
Loss of Function and Gain of Toxicity: Lessons from the
Fragile X Locus and Myotonic Dystrophy
The location of the repeat expansion in intron 1 of C9ORF72
resembles the CGG repeats of the FMR1 (fragile X mental retar-
dation 1) gene, which, depending on the size of the repeats,
yields three different syndromes: fragile X syndrome (>200
repeats), fragile X-associated tremor/ataxia syndrome (50–200
repeats), and premature ovarian insufficiency (50–200 repeats)










































































Figure 4. Potential Pathogenic Mechanisms for GGGGCC Repeat Expansion within the C9ORF72 Gene
Top: schematic representation of the human C9ORF72 gene (yellow, UTRs; blue, coding exons). Hexanucleotide (GGGGCC) repeat expansion is located
between alternative exons 1a and 1b. At least three mechanisms may contribute to disease pathogenesis: (A) GGGGCC repeat expansions may lead to reduced
expression of the allele containing the repeat expansion (haploinsufficiency); (B) RNA foci containing transcribed GGGGCC repeats may sequester RNA-binding
protein(s); or (C) repeat associated non-AUG (RAN) translation of GGGGCC repeat-containing RNA produces toxic polydipeptides in each of three reading
frames. Data and images reproduced with permission from (A) Gijselinck et al. (2012), (B) DeJesus-Hernandez et al. (2011), and (C) Mori et al. (2013b).
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The	  protein	  quality	  control	  system	  
In	  healthy	  cells,	  the	  misfolded	  proteins	  are	  managed	  by	  protein	  quality	  control	  (PQC).	  
Unfortunately,	   in	   some	   pathological	   conditions,	   PQC	  may	   be	   overwhelmed	   and	   this	  
would	  result	  in	  misfolded	  protein	  accumulation.	  This	  occurs	  in	  ALS	  and	  in	  SBMA,	  where	  
mutant	   ALS-­‐related	   proteins	   and	   inactive	   mutant	   AR	   are	   rapidly	   cleared	   by	  
proteasome,	   that	   consequently	   reduces	   its	   ability	   to	  process	  proteasome	  substrates.	  
Indeed,	   we	   already	   proved	   that	   over-­‐expression	   of	   mutant	   ALS-­‐related	   proteins	   in	  
motor	  neuronal	  cells	  reduces	  the	  proteasome	  degradation	  of	  GFPu	  proteins.	  Similarly,	  
we	   showed	   that	   only	   the	   soluble	   and	   cytoplasmic	   inactive	   mutant	   AR	   reduces	   the	  
proteasome	   activity	   analysed	   by	   GFPu	   reporter	   protein.	   In	   fact,	   testosterone	  
treatment	   activates	   AR	   nuclear	   translocation	   and	   aggregation	   that	   leads	   to	   the	  
reduction	  of	  GFPu	  levels.	  This	  is	  because	  AR	  is	  now	  partially	  localized	  in	  the	  nucleus	  to	  
play	   its	   functions,	   and	   partially	   sequestered	   in	   aggregates,	   which	   may	   prevent	  
proteasome	  saturation.	  
Next,	   SBMA	   will	   be	   used	   to	   describe	   the	   PQC	   mechanisms	   and	   functions	   in	   the	  




Several	   families	   of	   HSPs	   represent	   the	   first	   defence	   of	   PQC.	   HSPs	   recognize	   and	  
stabilize	   misfolded	   proteins	   with	   their	   chaperone	   activity.	   It	   has	   been	   proven	   that	  
different	  chaperones	  increase	  the	  ARpolyQ	  clearance,	  accumulation	  and	  aggregation	  in	  
SBMA	   cell	   models	   (Adachi	   et	   al.,	   2009).	   In	   fact,	   enhancing	   the	   HSPs	   levels	   by	   heat	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shock	   response	   mediated	   by	   heat	   shock	   factor	   1	   (HSF-­‐1),	   ARpolyQ	   aggregation	   is	  
reduced	   (Kondo	   et	   al.,	   2013).	   Several	   HSPs	   prevent	   ARpolyQ	   aggregation,	   such	   as	  
HSP70,	   HSP40	   and	  HSP90.	   The	   complex	   interaction	   between	  HSPs	   and	   ARpolyQ	   has	  
been	   well	   reviewed	   in	   Pratt	   et	   al.,	   2014	   (Pratt	   et	   al.,	   2014),	   where	   the	   authors	  
described	   the	   interaction	   between	   ARpolyQ	   and	   HSP90,	   possibly,	   as	   a	   start	   of	  
aggregation.	   Moreover,	   the	   ability	   of	   molecular	   chaperons	   to	   prevent	   ARpolyQ	  
aggregation	  changes	  based	  in	  the	  types	  and	  interactions	  between	  HSPs	  involved.	  	  
HSP70	   interacts	   with	   the	   C-­‐terminus	   of	   Heat	   shock	   cognate	   (HSC)	   protein	   70-­‐
interacting	   protein	   (CHIP),	   that	   ubiquitinates	   misfolded	   protein	   by	   its	   E3	   ubiquitin	  
ligase	  activity	  and	  subtracts	  ARpolyQ	  from	  folding	  machinery	  to	  PQC	  degradation.	  CHIP	  
over-­‐expression	   in	   SBMA	   neuronal	   models	   show	   a	   great	   reduction	   of	   ARpolyQ	  
accumulation.	  In	  parallel,	  CHIP	  over-­‐expression	  in	  SBMA	  transgenic	  mice	  shows	  a	  clear	  
reduction	  of	  SBMA	  symptoms	  and	  AR	  nuclear	  accumulation	  (Adachi	  et	  al.,	  2007).	  	  
We	   also	   proved	   that	   the	   chaperone	   HSPB8,	   a	   small	   ATP-­‐independent	   HSPs,	   is	   an	  
inhibitor	  of	  ARpolyQ	  aggregation	  (Rusmini	  et	  al.,	  2013).	  HSPB8	  acts	  in	  a	  complex	  with	  
BCL2-­‐associated	   athanogene	   3	   (BAG3),	   HSC70	   and	   CHIP	   to	   route	  misfolded	   proteins	  
resistant	  to	  HSPs-­‐dependent	  refolding	  toward	  autophagic	  degradation	  (Rusmini	  et	  al.,	  
2013;	  Gamerdinger	  et	  al.,	  2011;	  Crippa	  et	  al.,	  2010b).	  	  
	  
The	  proteasome	  
If	   chaperones	   fail	   to	   refold,	   specific	   proteins	   target	   toxic	   species	   to	   degradative	  
pathway:	  the	  ubiquitin	  proteasome	  system	  (UPS)	  (Fig.	  9)	  and	  the	  autophagy.	  Regarding	  
UPS	   degradation,	   misfolding	   proteins	   recognized	   by	   HSP70/HSP40	   complex	   are	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ubiquitinated	   by	   CHIP	   and	   directed	   to	   the	   20S	   proteasome	   subunit.	   Then,	   wt	   and	  
mutant	   AR	   are	   efficiently	   degraded	   by	   UPS	   and	   accumulate	   in	   neuronal	   and	   non-­‐
neuronal	  cells	  after	  UPS	  inhibition	  (Dossena	  et	  al.,	  2014;	  Rusmini	  et	  al.,	  2013;	  Rusmini	  
et	  al.,	  2010).	  Different	  equilibrium	  between	  UPS	  and	  autophagy	  power	  is	  observed	  in	  
different	   cells	   and	   may	   imply	   the	   differences	   in	   ARpolyQ	   processing	   (Crippa	   et	   al.,	  
2013b;	  Onesto	  et	  al.,	  2011).	  Recently,	  it	  has	  been	  proven	  that	  ARpolyQ	  tends	  to	  form	  
insoluble	   species	   prevalently	   in	   neuronal	   cells	   compared	   to	   other	   types.	   In	   fact,	   in	  
iPSCs	   derived	   from	   SBMA	   patients,	   ligand	   induced	   ARpolyQ	   aggregates	   can	   be	  
detected	   in	   filter	   retardation	  assay	   (FRA)	  only	  when	  cells	  are	  differentiated	  to	  motor	  
neurons	   and	  not	   in	   undifferentiated	   iPSCs	   or	   fibroblast	   (Nihei	   et	   al.,	   2013).	   Previous	  
studies,	   with	   the	   proteasome	   reporter	   YFPu,	   investigated	   the	   role	   of	   the	   UPS	   after	  
ligand-­‐induced	   ARpolyQ	   aggregation.	   These	   studies	   clearly	   showed	   that	   the	   UPS	  
pathway	  is	  impaired	  in	  absence	  of	  ARpolyQ	  aggregates	  (untreated	  ARpolyQ	  is	  cleared	  
by	   UPS),	   but	   ARpolyQ	   aggregate	   formation	   is	   correlated	   with	   normal	   UPS	   activity.	  
These	   observations	   confirm	   that	   aggregates	   protect	   UPS	   from	   an	   overwhelming	   of	  
misfolded	   protein	   excess.	   In	   parallel,	   aggregates	   may	   be	   massively	   handled	   by	  
autophagy	  for	  degradation.	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Autophagy	  
Autophagy	   (meaning	   “self-­‐eating”),	   in	   particular	   macroautophagy	   (normally	   named	  
autophagy),	   is	   a	   degradative	   pathway	   responsible	   for	   the	   digestion	   and	   recycling	   of	  
nutrients	   via	   autophagosome.	   Autophagosome	   engulfs	   proteins	   and	   organelles	   and	  
delivers	   them	  to	   lysosome	   for	  degradation.	  Other	  autophagy	  pathways	  contribute	  at	  
protein	  homeostasis:	  i)	  microautophagy	  is	  an	  unspecific	  degradative	  process	  similar	  to	  
macroautophagy,	  but	  the	  lysosomal	  membrane	  encases	  directly	  cytosolic	  components	  
(Li	   et	   al.,	   2012).	   ii)	   chaperone	   mediated	   autophagy	   (CMA)	   is	   a	   form	   of	   lysosome	  
degradation	   in	   which	   the	   substrates	   are	   delivered	   directly	   to	   the	   lysosome	   without	  
autophagosome	   formation.	   CMA	   recognizes	   a	   pentapeptide	   sequence	   KFERQ	   and	  
HSC70	   and	   lysosome-­‐associated	  membrane	   protein	   type	   2	   (LAMP-­‐2A)	   is	   involved	   in	  
recognition	  and	  lysosome	  internalization	  (Fig.	  10)	  (Kaushik	  &	  Cuervo,	  2012).	  	  
Autophagy	  was	   found	   to	   be	   altered	   in	   different	  MNDs,	   including	   SBMA	   and	   ALS.	   In	  
addition,	  mutations	   in	   proteins	   involved	   in	   autophagy	   pathway	   have	   been	   linked	   to	  
diseases	  (Menzies	  et	  al.,	  2015).	  Autophagy	  (Fig.	  11)	  is	  a	  multi-­‐step	  process	  that	  starts	  
with	   initiation,	  when	  the	  fusion	  of	  different	  membrane	  sources	   forms	  a	  phagophore.	  
This	  structure	  surrounds	  portions	  of	  cytoplasm	  until	  the	  two	  edges	  are	  fused	  together	  
to	  form	  an	  autophagosome.	  In	  this	  step	  various	  autophagy	  (ATG)	  proteins	  are	  involved.	  
In	  particular,	  ATG5	  –ATG12	  –	  ATG	  16L1,	  ATG7,	  ATG9,	  ATG	  10	  and	  ATG	  14	  contribute	  to	  
phagophore	  expansion	  and	  closure.	  Moreover,	  the	  cleavage	  of	  microtubule-­‐associated	  
protein	  1	  light	  chain	  3	  (LC3)	  by	  ATG4B	  to	  form	  LC3-­‐I	  and	  the	  following	  conjugation	  with	  
phosphatidyletanolamine	   by	   ATG7	   and	   ATG3	   to	   form	   LC3-­‐II	   are	   necessary	   steps	   to	  
complete	  the	  autophagosome	  biogenesis	  (see	  Menzies	  et	  al.,	  2015	  for	  review).	  Then,	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autophagosomes	  are	  trafficked	  by	  dynein	  to	  the	  perinuclear	  region,	  where	  the	  fusion	  
with	  lysosome	  occurs.	  This	  step	  is	  regulated	  by	  VAMP7,	  VAMP8	  and	  VT11B	  belonging	  
to	   the	   family	   of	   SNARE	   proteins.	   Overall,	   correct	   acid	   lysosomal	   pH	   and	   functional	  
degrading	  enzymes	  are	  necessary	  conditions	  for	  efficient	  autophagy.	  Moreover,	  there	  
must	   be	   sufficient	   lysosomes	   available,	   because	   the	   autophagy	   process	   consumes	  
lysosomes.	  Recently,	   lysosome	  biogenesis	  has	  been	  observed	   to	  be	   regulated	  by	   the	  
transcription	  factor	  EB	  (TFEB),	  the	  master	  regulator	  for	  lysosomal	  biogenesis.	  For	  this	  
reason,	  TFEB	  plays	  an	  important	  role	  in	  autophagy	  regulation.	  	  
ARpolyQ	  is	  recognized	  by	  p62/SQSTM1,	  which	  interact	  with	  LC3-­‐II	  to	  target	  AR	  toward	  
autophagy.	   Misfolded	   proteins	   are	   directed	   to	   the	   microtubule	   organization	   centre	  
(MTOC),	   where	   misfolded	   proteins	   can	   interact	   and	   form	   aggresomes,	   in	   order	   to	  
facilitate	  the	  insertion	  into	  nascent	  autophagosomes	  (Johnston	  et	  al.,	  2002).	  While	  UPS	  
is	  responsible	  for	  wt	  and	  mutant	  ARpolyQ	  degradation	  in	  basal	  condition,	  autophagy	  is	  
essential	  when	  UPS	   is	   overwhelmed.	   In	   fact,	   the	   accumulation	   of	   ARpolyQ	   insoluble	  
species	  may	  be	   linked	   to	  a	  defect	   in	  autophagy.	   In	   support	  of	   this	   hypothesis	   it	  was	  
proven	   that	  depletion	  of	  p62/SQSTM1	   results	   in	  an	   increase	  of	   insoluble	  ARpolyQ	   in	  
affected	  cells	  and	  an	  earlier	  disease	  onset	   in	  SBMA	  mice	  models	  (Doi	  et	  al.,	  2013).	   In	  
parallel,	   p62/SQSTM1	  over-­‐expression	   reduces	   the	   soluble	   and	   insoluble	   fractions	  of	  
ARpolyQ	   (Doi	   et	   al.,	   2013).	   In	   this	   condition,	   autophagy	   is	   essential	   for	   PQC	   system	  
functions	  (Rusmini	  et	  al.,	  2013;	  Carra	  et	  al.,	  2012;	  Rusmini	  et	  al.,	  2010).	  
Autophagy	  is	  controlled	  by	  specific	  chaperones,	  such	  as	  the	  HSPB8,	  which	  responds	  to	  
proteasome	   inhibition	   (Crippa	   et	   al.,	   2010a;	   Crippa	   et	   al.,	   2010b).	   In	   addition,	   re-­‐
routing	   from	  proteasome	   to	  autophagy	   is	   also	  mediated	  by	   the	   co-­‐chaperone	  BAG3,	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that	   interacts	   with	   HSPB8	   and	   BAG1,	   respectively	   responsible	   for	   autophagy	   or	  
proteasome	   clearance	   (Gamerdinger	   et	   al.,	   2011).	   Then,	   the	   increasing	   HSPB8	   level,	  
promoted	  by	  transcriptional	  activation	  of	  HSPB8	  promoter,	  results	  in	  a	  higher	  number	  
of	   HSPB8-­‐BAG3	   complex	   (2:1	   ratio)	   that	   interacts	   with	   HSC70-­‐CHIP	   and	   misfolded	  
proteins.	  We	  have	  already	  proven	  that	  HSPB8	  decreases	  ARpolyQ	  aggregation	  via	  the	  
increase	   of	   the	   ARpolyQ	   solubility	   (Rusmini	   et	   al.,	   2013).	   In	   motor	   neurons,	   HSPB8	  
prevents	   ARpolyQ	   aggregation	   without	   modifying	   p62-­‐SQSTM1	   and	   LC3	   expression,	  
but	   it	   is	   able	   to	   reduce	  p62	  bodies	   formation	   and	   restore	   a	   normal	   autophagic	   flux,	  
which	   is	   impaired	   in	   SBMA	   cell	  models	   after	   testosterone	   treatment	   (Rusmini	   et	   al.,	  
2013).	  Because	  of	  this,	  HSPB8-­‐BAG3	  interaction	  and	  their	  relative	  levels	  are	  important	  
in	   the	   removal	   of	   misfolded	   proteins	   and	   for	   a	   normal	   viability	   of	   motor	   neurons.	  
HSPB8	  levels	  decrease	  with	  age	  in	  mice,	  but	  the	  protective	  effects	  of	  HSPB8	  on	  motor	  
neuron	  are	  confirmed	  by	  the	  high	  HSPB8	   levels	  observed	   in	  ALS	  mice	  motor	  neurons	  
that	  survive	  at	  the	  end-­‐stage	  of	  the	  disease	  (Crippa	  et	  al.,	  2010b).	  Notably,	  the	  K141N	  
and	   K141E	   missense	   mutations	   in	   HSPB8	   α-­‐crystalline	   domain	   have	   been	   linked	   to	  
Charcot-­‐Marie-­‐Tooth	  type	  2L	  disease	  and	  in	  hereditary	  distal	  motor	  neuropathy	  type	  II.	  
The	   expression	   of	   these	  mutant	  HSPB8	   proteins	   shows	   neurite	   degeneration	   only	   in	  
primary	  motor	   neuronal	   cells	   culture	   (reduction	   in	   number	   and	   in	   average	   length	  of	  
the	   neurites).	   Although	   the	   mechanism	   through	   which	   mutant	   HSPB8	   leads	   to	   a	  
specific	  motor	  neuron	  disease	   is	   currently	  unknown,	   these	  data	   show	   the	   important	  
role	   of	   HSPB8	   in	   the	   maintenance	   of	   efficient	   motor	   neurons	   (Irobi	   et	   al.,	   2010;	  
Fontaine	  et	  al.,	  2006).	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PQC	   and	   autophagy	   are	   important	   targets	   to	   modulate	   in	   order	   to	   counteract	  
misfolded	  protein	  toxicity.	   In	  our	   laboratory,	  we	  observed	  that	  autophagy	  facilitation	  
by	  HSPB8	   induction	   or	   by	   trehalose	   treatment	   drastically	   reduced	  misfolded	   protein	  
aggregation	   also	   in	   ALS	   models.	   Autophagy	   modulation	   seems	   to	   be	   a	   target	   to	  
counteract	   misfolded	   protein	   toxicity	   in	   MNDs	   (Rusmini	   et	   al.,	   2013;	   Crippa	   et	   al.,	  
2013a;	  Onesto	  et	  al.,	  2011;	  Rusmini	  et	  al.,	  2010;	  Crippa	  et	  al.,	  2010b).	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Figure	  9	  -­‐	  Schematic	  Diagram	  of	  ubiquitin	  proteasome	  pathway.	  
	  From	  Huang	  Laboratori	  at	  University	  of	  California	  Irvine	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Figure	  10	  -­‐	  Steps	  and	  regulation	  of	  CMA.	  Steps:	  (a)	  Recognition	  of	  substrate	  proteins	  by	  hsc70/	  cochaperones;	  (b)	  
binding	  of	  substrate-­‐chaperone	  complex	  to	  LAMP-­‐2A;	  (c)	  unfolding	  of	  the	  substrate;	  (d)	  LAMP-­‐2A	  multimerization,	  
substrate	  translocation	  and	  subsequent	  degradation;	  (e)	  disassembly	  of	  LAMP-­‐2A	  multimer/translocon.	  Regulation	  
of	  levels	  of	  LAMP-­‐2A	  at	  the	  lysosomal	  membrane	  is	  attained	  through	  (1)	  de	  novo	  synthesis	  and	  (2)	  degradation	  in	  
specialized	  microdomains	  at	  the	  lysosomal	  membrane	  (from	  Kaushik	  et	  al.,	  2012).	  
Figure 1.
Steps and regulation of CMA. Steps: (a) Recognition of substrate proteins by hsc70/
cochaperones; (b) binding of substrate-chaperone complex to LAMP-2A; (c) unfolding of
the substrate; (d) LAMP-2A multimerization, substrate translocation and subsequent
degradation; (e) disassembly of LAMP-2A multimer/translocon. Regulation of levels of
LAMP-2A at the lysosomal membrane is attained through (1) de novo synthesis and (2)
degradation in specialized microdomains at the lysosomal membrane.
Kaushik and Cuervo Page 17

































Figure	  11	  -­‐	  Overviewoftheautophagypathwayandthesitesofactionofdisease-­‐associatedproteins.	  This	  diagram	  shows	  
a	  simplified	  version	  of	  autophagy	  (from	  Menzies	  et	  al.,	  2015).	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Misfolded	  proteins	  transport	  
To	  efficiently	  remove	  misfolded	  proteins,	  autophagy	  requires	  the	  functions	  of	  dynein	  
motor	  protein.	   In	  fact,	  cytoplasmic	  dynein	  binds	  directly	  or	   indirectly	  to	  Rab	  GTPases	  
and	  drives:	  i)	  autophagy	  substrates	  at	  autophagosome	  nucleation	  site	  (Gamerdinger	  et	  
al.,	   2011);	   and	   ii)	   autophagosome	   to	   lysosome	   fusion	   (Jahreiss	   et	   al.,	   2008).	  
Cytoplasmic	   dynein	   binds	   the	   BAG3	   that	   interacts	   with	   HSPB8-­‐HSC70-­‐CHIP	   and	  
recognizes	  misfolded	  proteins	  to	  concentrate	  them	  at	  the	  MTOC	  (Crippa	  et	  al.,	  2010b;	  
Johnston	  et	  al.,	  2002).	  These	  observations	  support	  the	  key	  role	  of	  cytoplasmic	  dynein	  
to	   enable	   autophagy	   in	   the	   clearance	   of	   MND-­‐related	   misfolded	   proteins.	  
Furthermore,	  also	  BAG3	  plays	  an	  essential	  role	  in	  the	  delivery	  of	  misfolded	  proteins	  to	  
MTOC	   and	   autophagosomes.	   In	   fact,	   BAG3	   contains	   the	   proline-­‐rich	   (PXXP)	   repeat	  
motif	   that	   specifically	   interacts	  with	   the	  14-­‐3-­‐3	  proteins,	   acting	  as	  a	  bridge	  between	  
HSC70	   substrate	   and	   the	   dynein	   complex.	   Subsequently,	   dynein	   and	   the	   associated	  
factors	  move	   on	   the	  microtubule	   toward	   the	  MTOC,	  where	   aggresomes	   are	   formed	  
(Dul	  et	  al.,	  2001).	  Thus,	  BAG3/HSC70	  complex	  recognizes	  HSPB8,	  CHIP	  and	  misfolded	  
proteins	   and	   by	   BAG3	   PXXP	   domain	   are	   specifically	   routed	   by	   dynein	   to	   form	   the	  
aggresome	   (Gamerdinger	   et	   al.,	   2011).	   The	   BAG3-­‐mediated	   routing	   via	   HSC70	   is	  
involved	  in	  a	  selective	  autophagy,	  in	  which	  ubiquitination	  might	  occur	  at	  later	  stages,	  
mediated	   by	   CHIP.	   Interestingly,	   in	   aggresomes,	   several	   misfolded	   proteins	   are	   not	  
ubiquitinated	   (García-­‐Mata	   et	   al.,	   1999),	   and	   BAG3-­‐assisted	   aggresome	   targeting	   of	  
misfolded	   proteins	   can	   also	   be	   independent	   from	   their	   ubiquitination	   status	  
(Gamerdinger	  et	  al.,	  2011).	  It	  has	  been	  proposed	  that	  BAG3	  mediates	  the	  recruitment	  
of	   misfolded	   proteins	   to	   be	   ubiquitinated	   by	   CHIP,	   while	   an	   alternative	   pathways	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involved	  in	  aggresome	  formation	  is	  controlled	  by	  histone	  deacetylase	  6	  (HDAC6),	  that	  
it	  is	  also	  an	  interactor	  of	  the	  dynein	  motor	  complex	  (through	  the	  dynactin/p150Glued).	  
This	  apparently	  occurs	  only	  after	  CHIP-­‐mediated	  ubiquitination	  of	  substrates	  escaping	  
UPS	   degradation	   (Muñoz-­‐Moreno	   et	   al.,	   2015;	   Kraft	   et	   al.,	   2010;	   Sha	   et	   al.,	   2009;	  
Dompierre	   et	   al.,	   2007).	   Thus,	   both	   aggresome	   pathways	   require	   dynein	   to	  
concentrate	  misfolded	  proteins	  at	  MTOC	  (Johnston	  et	  al.,	  2002).	  Notably,	  mutations	  in	  
the	   gene	   DYNC1H1	   coding	   for	   dynein	   (cytoplasmic	   1,	   heavy	   chain	   1),	   the	   essential	  
subunit	   of	   the	   cytoplasmic	   dynein	   complex,	   have	   been	   found	   in	   several	   neuronal	  
diseases	   (e.g.:	   spinal	   muscular	   atrophy	   with	   lower	   extremity	   dominance	   (SMA-­‐LED),	  
intellectual	   disability	   with	   neuronal	   migration	   defects,	   malformations	   of	   cortical	  
development,	   and	   Charcot-­‐Marie-­‐Tooth	   disease,	   type	   2O)	   (Strickland	   et	   al.,	   2015;	  
Scoto	   et	   al.,	   2015;	   Sau	   et	   al.,	   2011;	   Moore	   et	   al.,	   2009;	   Ravikumar	   et	   al.,	   2005;	  
Hafezparast	  et	  al.,	  2003;	  LaMonte	  et	  al.,	  2002).	  At	  the	  same	  time,	   in	  transgenic	  mice	  
models	   of	   fALS	   (SOD1	   G93A	   mice)	   characterized	   by	   anterograde	   and	   retrograde	  
transport	   alterations	   (Bilsland	   et	   al.,	   2010;	   Williamson	   &	   Cleveland,	   1999),	  
dysfunctional	  dynein	  was	  able	   to	   improve	  motor	   function	  and	   to	  extend	  survival	   (El-­‐
kadi	  et	  al.,	  2010;	  Teuchert	  et	  al.,	  2006;	  Kieran	  et	  al.,	  2005).	  
Even	   though	   the	   axonal	   transport	   deficit	   occurs	   in	   other	   MNDs,	   like	   Huntington’s	  
disease	  (HD)	  and	  Alzheimer’s	  disease,	  altered	  axonal	  transport	  does	  not	  seem	  to	  play	  a	  
role	  in	  SBMA	  disease	  initiation	  or	  progression	  (Malik	  et	  al.,	  2011).	  	  
Collectively,	   all	   these	   observations	   indicate	   that	  misfolded	   protein	   transport	   plays	   a	  
central	   role	   in	   MNDs.	   Several	   questions	   on	   the	   role	   of	   dynein	   in	   the	   clearance	   of	  
misfolded	  proteins	   remain	  open.	   In	  particular,	   it	   remains	   to	  be	  determined	  at	  which	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stage	  monomeric	  misfolded	   species	   collapses	   into	   oligomeric	   and	   aggregated	   forms	  
that	   initially	   produce	   aggresomes	   and	   later	   mature	   to	   insoluble	   inclusions	   not	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The	  aims	  of	  this	  work	  was	  to	  investigate	  the	  implications	  of	  protein	  misfolding	  in	  SBMA	  
and	   in	   ALS.	   In	   the	   first	   part	   of	   the	   thesis,	   I	   characterized	   the	   response	   to	  misfolded	  
ARpolyQ	  protein	  in	  skeletal	  muscle	  and	  spinal	  cord	  tissues	  during	  disease	  progression	  
in	  SBMA,	  by	  analysing	  both	  AR	  expression	  levels	  and	  selected	  genes	  involved	  in	  the	  of	  
PQC	   degradative	   pathways	   in	   quadriceps	   muscle	   and	   in	   spinal	   cords	   of	   SBMA	  
transgenic	  mice	  model.	  By	  RT-­‐qPCR	  and	  western	  blot	  analysis,	  I	  studied	  the	  expression	  
of	   proteins	   responsible	   for	   autophagic	   recognition	   of	   misfolded	   proteins.	   I	   also	  
evaluated	  the	  existence	  of	  differences	  in	  the	  response	  of	  the	  two	  tissues	  to	  misfolded	  
proteins.	  
In	   the	   second	   part	   of	   the	   thesis,	   I	   focused	   my	   attention	   on	   the	   role	   of	   dynein	   in	  
autophagic	   removal	   of	   misfolded	   proteins	   responsible	   for	   MNDs.	   First	   of	   all,	   I	  
confirmed	   that	   HSPB8	   exterts	   a	   pro-­‐degradative	   activity	   on	   ARpolyQ	   aggregates.	   By	  
using	  dynein	  modulators,	   I	  deeply	   investigated	   the	   role	  of	  dynein	  on	  autophagic	   flux	  
and	   on	   the	   levels	   of	   ARpolyQ,	   G93A	   SOD1	   and	   TDP-­‐43	   ΔC	   misfolded	   proteins	  
responsible	  for	  SBMA	  or	  fALS.	  Moreover,	   I	  analysed	  the	  levels	  of	  chaperones	  and	  co-­‐
chaperones	   involved	   in	   misfolded	   proteins	   degradation	   in	   order	   to	   measure	   the	  
equilibrium	  between	  different	  PQC	  degradative	  pathways	  (UPS,	  Autophagy	  and	  CMA)	  
after	   the	   inhibition	   of	   dynein-­‐mediated	   transport.	   Finally,	   I	   evaluated	   the	   pro-­‐
degradative	   effect	   of	   HSPB8	   and	   the	   role	   of	   dynein	   mediated	   transport	   in	   motor	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Chemicals	  
Erythro-­‐9-­‐(2-­‐Hydroxy-­‐3-­‐nonyl)	   adenine	   hydrochloride	   (EHNA),	   Z-­‐Leu-­‐Leu-­‐Leu-­‐al	   (MG-­‐
132)	   and	   trehalose	   have	   been	   obtained	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	  MO,	   USA),	   3-­‐
Methyladenine	  (3-­‐MA)	  have	  been	  obtained	  from	  Selleckchem	  (Houston,	  TX,	  USA).	  
	  
Generation	  and	  maintenance	  of	  AR113Q	  knock-­‐in	  mice	  
Animal	   care	   and	   experimental	   procedures	   were	   conducted	   in	   accordance	   with	   the	  
Italian	   Institute	   of	   Technology	   and	   the	   University	   of	   Trento	   ethical	   committees	   and	  
were	  approved	  by	   the	   Italian	  Ministry	  of	  Health.	  Generation	  and	  genotyping	  of	  mice	  
containing	   androgen	   receptor	   with	   113	   CAG	   repeats	   in	   exon	   1	   was	   described	  
previously	  (Yu	  et	  al.,	  2006a;	  Yu	  et	  al.,	  2006b).	  Mice	  genetic	  background	  was	  C57Bl/6J.	  
Females	   carrying	   one	   copy	   of	   AR113Q	   in	   the	   X	   chromosome	   were	   crossed	   with	  
C57Bl/6J	  mice	  to	  maintain	  the	  colony.	  Mice	  were	  genotyped	  by	  PCR	  on	  tail	  DNA,	  using	  
REDExtract-­‐N-­‐Amp	   Tissue	   PCR	   kit	   (Sigma-­‐Aldrich,	   St	   Louis,	   MO,	   USA)	   according	   to	  
manufacturer’s	  instructions.	  The	  mice	  were	  housed	  in	  filtered	  cages	  in	  a	  temperature-­‐
controlled	   room	   with	   a	   12-­‐hour	   light/12-­‐hour	   dark	   cycle	   with	   ad	   libitum	   access	   to	  
water	  and	  food.	  Quadriceps	  muscles	  and	  spinal	  cord	  were	  rapidly	  collected	  after	   the	  
sacrifice,	  snap	  frozen	  in	  liquid	  nitrogen,	  and	  conserved	  at	  −80°C	  until	  RNA	  and	  protein	  
extraction.	  
	  
Plasmids	  &	  siRNA	  
The	  plasmid	  coding	  for	  AR.Q46,	  GFP-­‐AR.Q48,	  and	  pCI-­‐HSPB8	  are	  routinely	  used	  in	  our	  
laboratory	  and	  they	  have	  been	  previously	  described	  (Giorgetti	  et	  al.,	  2015;	  Rusmini	  et	  
Materials	  and	  methods	  
	  
	   	  
51	  
al.,	   2013;	   Carra	   et	   al.,	   2005;	   Simeoni,	   2000).	   pcDNA/HA-­‐Bag1	   coding	   for	   the	   protein	  
Bag1	  was	  obtained	  from	  prof.	  Harm	  H.	  Kampinga,	  University	  of	  Groningen,	  Groningen,	  
The	  Netherlands	  (Nollen	  et	  al.,	  2001;	  Nollen	  et	  al.,	  2000).	  The	  plasmid	  expressing	  the	  
proteasome	   function	   reporter	   GFPu	   was	   obtained	   from	   prof.	   Ron	   Kopito,	   Stanford	  
University,	  Stanford,	  CA,	  USA	  (Bence	  et	  al.,	  2001).	  The	  pCMV-­‐β	  plasmid,	  encoding	  for	  
β-­‐galactosidase	   (Clontech	   Lab.,	  Mountain	   View,	   CA,	   USA),	   was	   used	   to	   evaluate	   the	  
protein	  expression	  levels	  after	  EHNA	  treatment.	  pcDNA3-­‐wtSOD1	  and	  pcDNA3-­‐G93A-­‐
SOD1	   expressing	   human	   wtSOD1	   or	   mutant	   G93A-­‐SOD1	   were	   obtained	   from	   Dr.	  
Caterina	  Bendotti,	  Mario	  Negri	  Institue,	  Milano,	  Italy	  (Tortarolo	  et	  al.,	  2004).	  pFLAG-­‐FL	  
TDP-­‐43,	  and	  pFLAG-­‐ΔC	  TDP-­‐43,	  expressing	  FLAG-­‐tagged	  wt	   full-­‐length	  human	  TDP-­‐43	  
and	   a	   C-­‐terminus	   truncated	   form,	   respectively,	   were	   obtained	   from	   Dr.	   Emanuele	  
Buratti,	   International	  Centre	  for	  Genetic	  Engineering	  and	  Biotechnology,	  Trieste,	   Italy	  
(Ayala	  et	  al.,	  2008a;	  Ayala	  et	  al.,	  2008b).	  pAG3	  C9orf72	  Nested	  2	  Rpt	  and	  pAG3	  C9orf72	  
Nested	  66	  Rpt	  encoding	  for	  2	  or	  66	  GGGGCC	  repeats	  without	  ATG,	  without	  stop	  codon	  
and	   tagged	  with	   one	   peptide-­‐tag	   per	   frame	   (polyGA-­‐HA;	   polyGP-­‐Myc;	   polyGR-­‐FLAG)	  
was	   obtained	   from	   Prof.	   Leonard	   Petrucelli,	   Mayo	   Clinic,	   Jacksonville,	   Florida,	   USA.	  
pCMV-­‐Flag-­‐polyGP-­‐V5-­‐His	   encoding	   for	   polyGP	   di-­‐peptide	   was	   obtained	   from	   Prof.	  
Daisuke	  Ito,	  Keio	  University	  School	  of	  Medicine,	  Tokio,	  Japan	  (Yamakawa	  et	  al.,	  2015).	  
pcDNA3	  was	  used	  to	  normalize	  for	  transfected	  plasmid	  DNA	  amount.	  	  
pcDNA5/TO-­‐GFPAR.Q39	  was	  used	  to	  obtain	  stable	  and	  inducible	  SBMA	  cell	  model	  and	  
was	   constructed	   by	   cloning	   the	   sequence	   coding	   for	   GFPARQ.39	   into	  NheI	   and	   XbaI	  
sites	   of	   pcDNA5/TO	   (Life	   Technologies	   Corporation,	   Carlsbad,	   CA,	   USA)	   previously	  
modified	  with	  insertion	  of	  BamHI	  and	  NheI	  sites.	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To	  silence	  endogenous	  proteins,	  we	  have	  used:	  a)	  cytoplasmic	  dynein	  1	  heavy	  chain	  1	  
custom	   siRNA	   duplex	   (5’-­‐GGG	  UAA	   AGC	  UAG	   AGA	  GAA	  UUU-­‐3’	   (sense)	   5’-­‐AUU	   CUC	  
UCU	  AGC	  UUU	  ACC	  CUU-­‐3’	  (antisense));	  b)	  HSPB8	  custom	  siRNA	  duplex	  (5’-­‐	  CGG	  AAG	  
AGC	   UGA	   UGG	   UAA	   AUU-­‐3’	   (sense)	   5’-­‐	   UUU	   ACC	   AUC	   AGC	   UCU	   UUC	   CGU	   U-­‐3’	  
(antisense))	   (Dharmacon,	   Thermo	   Scientific	   Life	   Sciences	   Research,	   Waltham,	   MA,	  
USA).	  
	  
Cell	  culture	  and	  transfection	  	  
The	  immortalized	  motoneuronal	  cell	  line	  NSC34	  (Durham	  et	  al.,	  1993;	  Cashman	  et	  al.,	  
1992)	  is	  routinely	  used	  in	  our	  laboratory	  and	  has	  been	  transfected	  with	  Lipofectamine	  
(Life	   Technologies	   Corporation,	   Carlsbad,	   CA,	   USA)/transferrin	   (Sigma-­‐Aldrich),	   as	  
previously	  described	  (Marron	  et	  al.,	  2005;	  Piccioni	  et	  al.,	  2002;	  Simeoni,	  2000),	  using	  
0.6	  µg	  of	  plasmid	  DNA,	  4	  µL	  of	  transferrin	  solution	  and	  2	  µL	  of	  Lipofectamine	  (amount	  
for	   one	   well	   of	   12-­‐wells	   multiwell	   plate).	   siRNA	   transfection	   was	   performed	   with	  
Lipofectamine	   2000	   (Life	   Technologies),	   using	   40	   pmol	   of	   target	   RNA	   and	   following	  
manufacturer’s	  instructions.	  
Inducible	   stably	   transfected	  NSC34-­‐GFPAR.Q39	  cell	   line	  was	  obtained	  by	   transfecting	  
pcDNA5/TO-­‐GFPAR.Q39	   into	   TR4	  NSC34	   cell	   line	   stably	   transfected	  with	   pcDNA6/TR	  
encoding	   for	   tetracycline	   repressor,	   kindly	   provided	   from	  Dr.	   Enrico	  Garattini,	  Mario	  
Negri	  institute,	  Milan,	  Italy	  (Locatelli	  et	  al.,	  2012).	  	  
Rat	   adrenal	   pheochromocytoma	   (PC12)	   cells	   stably	   transfected	   with	   the	   plasmid	  
encoding	  AR.Q112	  express	  AR	  under	  the	  control	  of	  a	  Tet-­‐On	  promoter	  responsive	  to	  1	  
µg/mL	  of	  doxycycline.	  PC12-­‐AR.Q112	  have	  been	  produced	  and	  kindly	  provided	  by	  prof.	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Diane	  Merry,	  TJU,	  Philadelphia,	  PA,	  USA	  (Walcott	  &	  Merry,	  2002).	  	  
iPS	   cells	   from	   fibroblast	   of	   SBMA	   patients	   (SB6MP2	   clone)	   generated	   by	   Oct4,	   Klf4,	  
Sox2	  and	  c.Myc	   transfection	  were	  kindly	  provided	  by	  dr.	  Christopher	  Gruniseich	  and	  
dr.	  Kennet	  Fischbeck,	  NIH,	  Betesta,	  USA.	  iPS	  cells	  were	  cultured	  in	  Essential	  8	  medium	  
(Life	  Technologies)	  and	  differentiated	  into	  motor	  neurons	  as	  described	  by	  Grunseich	  et	  
al,	  2014	  (Grunseich	  et	  al.,	  2014b).	  Briefly,	   iPSCs	  were	  grown	  to	  80%	  confluency,	  then	  
digested	  with	  collagenase	  IV	  (Life	  Technologies),	  scraped	  off	  of	  the	  dish,	  and	  cells	  were	  
re-­‐plated	   into	   low	  adherence	  dishes	  (Corning,	  Corning,	  NY)	   in	  KSR	  (Life	  Technologies)	  
based	  media	   with	   20	   ng/ml	   FGF	   (ORF	   genetics,	   Kopavogur,	   Iceland),	   20	   μM	   ROCK-­‐I	  
(Selleckchem),	   10	   μMSB431542	   (Stemgent,	   Lexington,	   MA,	   USA),	   and	   0.2	   μM	  
LDN193189	   (Stemgent),	   to	   allow	   embryo	   bodies	   (EBs)	   formation.	   EBs	   were	  
transitioned	  to	  a	  KSR	  free	  medium	  at	  day	  3.	  1	  μM	  retinoic	  acid	  (Sigma)	  was	  added	  at	  
day	   5	   to	   direct	   cells	   differentiation	   into	   rostral	   spinal	   cord	   phenotype.	   1	   μM	  
smoothened	   agonist	   (Merck	   Millipore,	   Darmstadt,	   Germania).	   and	   0.5	   μM	  
purmorphamine	   (Ann	   Arbor,	   MI,	   USA)	   were	   added	   at	   day	   7	   to	   ventralize	   the	  
differentiating	  population.	  The	  EBs	  were	  dissociated	  at	  day	  14	  and	  plated	  at	  150.000	  
cells/well	  on	  12-­‐well	  multiwell	  plates	  coated	  with	  poly-­‐D-­‐lysine	  (Life	  Technologies)	  and	  
laminin	   (Sigma).	   Differentiated-­‐motor	   neurons	   were	   allowed	   to	   growth	   for	   an	  
additional	   14	   days	   in	   neurobasal	   media	   (Life	   Technologies)	   with	   25	   μM	   glutamate	  
(Euroclone),	   0.4	  μg/ml	   ascorbic	   acid	   (Sigma),	   10	  ng/ml	  GDNF	   (PeproTech,	  Rocky	  Hill,	  
NJ,	   USA),	   10	   ng/ml	   CNTF	   (PeproTech),	   1	   μg/ml	   laminin	   (Sigma),	   B-­‐27	   (Life	  
Technologies),	   N2	   (Life	   Technologies),	   non-­‐essential	   amino	   acids	   (Euroclone),	   and	  
pen/strep/glutamine	   (Euroclone).	   Motoneuronal	   cells	   were	   treated	   with	   10nM	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testosterone	  and/or	  100µM	  EHNA	  for	  last	  48	  hours.	  
Stably	   transfected	   NSC34-­‐wtSOD1	   and	   NSC34-­‐G93A-­‐SOD1	   cell	   lines	   have	   been	  
produced	   and	   kindly	   provided	   by	   Prof.	   Maria	   Teresa	   Carrı`,	   Università	   Roma	   Tor	  
Vergata,	   Roma,	   Italy.	   	   These	   cell	   lines	   express	  myc-­‐tagged	   human	  wtSOD1	  or	  G93A-­‐
SOD1	  and	  were	  routinely	  maintained	  as	  described	  by	  Ferri	  et	  al.	  (Ferri	  et	  al.,	  2006).	  
In	   the	   experiments	   involving	   steroid	   hormone	   treatments,	   the	   serum	   was	   replaced	  
with	   charcoal-­‐stripped	   serum,	   to	   eliminate	   endogenous	   steroids	   (Pozzi	   et	   al.,	   2003;	  
Piccioni	  et	  al.,	  2002;	  Poletti	  et	  al.,	  2001).	  	  
	  
RNA	  and	  protein	  extraction	  
NSC34	  cells	  were	  plated	  at	  180.000	  cells/well	   in	  six-­‐well	  multiwell	  plates	  and	  treated	  
with	  100	  µM	  EHNA.	  After	  48	  hours,	  cells	  were	  harvested	  and	  centrifuged	  5	  min	  at	  100	  
x	   g	   at	   4°C;	   the	  pellets	  were	   lysate	  by	  10	  passages	   through	  a	   21-­‐gauge	  needle	   in	   TRI	  
Reagent	   (Sigma-­‐Aldrich).	   Frozen	   spinal	   cord	   and	   muscle	   were	   suspended	   in	   TRI-­‐
Reagent	   (Sigma-­‐Aldrich)	   and	   homogenized	   with	   Tissue-­‐Lyser	   (QIAGEN,	   Valencia,	   CA,	  
USA).	   Then,	  RNA	  was	  extracted	   following	   the	  TRI-­‐REAGENT	  Manufacturer’s	  protocol.	  
After	   homogenization,	   1-­‐bromo-­‐3-­‐chloropropane	   was	   added	   to	   ensure	   complete	  
dissociation	   of	   nucleoprotein	   complexes	   and	   then	   the	   samples	   were	   centrifuged	   to	  
obtain	   the	   phase	   separation.	   The	   aqueous	   phase,	   containing	   RNA	   was	   isolated	   and	  
purified.	  Briefly,	   aqueous	  phase	  was	  washed	  with	  2-­‐propanol	   and	   subsequently	  with	  
ethanol	  both	  to	  remove	  the	  residual	  phenol	  and	  to	  precipitate	  RNA,	  respectively.	  The	  
RNA	  pellet	  was	  dis-­‐	  solved	  in	  RNase-­‐free	  water	  (30μL).	  RNA	  quantification	  was	  carried	  
out	  by	  absorbance	  at	  260	  nm.	  The	  proteins	  were	  precipitated	  from	  the	  organic	  phase	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with	   propanol	   and	   then	   the	   pellets	   were	   washed	   with	   0.3M	   guanidine	  
hydrochloride/95%	   ethanol	   solution	   (3	   times).	   After	   the	   three	   washes,	   ethanol	   was	  
added	   and	   the	   pellets	  were	   re-­‐suspended	   using	   1%	   SDS-­‐	   8M	  Urea	   in	   Tris	   HCl	   pH8.0	  
solution	  (100μL).	  
	  
mRNA	  expression	  analysis	  
Total	  RNA	  (1	  µg)	  was	  treated	  with	  DNAse	  (Sigma-­‐Aldrich),	  and	  reverse	  transcribed	  into	  
cDNA	   using	   the	  High-­‐Capacity	   cDNA	  Archive	   Kit	   (Life	   Technologies)	   according	   to	   the	  
manufacturer’s	   protocol.	   All	   primers	   for	   real-­‐time	   PCR	   were	   designed	   using	   the	  
program	   Primer	   3.	   The	   primers	   were	   synthesized	   by	   MWG	   Biotech	   (Ebersberg,	  
Germany)	   with	   the	   following	   sequence:	   mAR:	   5’-­‐ATC	   CCA	   GTC	   CCA	   CTT	   GTG	   TC-­‐
3’(forward),	  5’-­‐GGT	  CTT	  CTG	  GGG	  TGG	  AAA	  GT-­‐3’	  (reverse);	  mouse	  ATG10:	  5ʹ′-­‐TTC	  ACA	  
GCA	  GAT	  AGG	  CGA	   TG	   -­‐3ʹ′	   (forward),	   5ʹ′-­‐TGC	  AGG	   TCT	   CGT	   CAC	   TTC	   AG-­‐3ʹ′	   (reverse);	  
mouse	  Beclin1:	  5ʹ′-­‐TGA	  AAT	  CAA	  TGC	  TGC	  CTG	  GG-­‐3ʹ′	  (for-­‐	  ward),	  5ʹ′-­‐CCA	  GAA	  CAG	  TAT	  
AAC	  GGC	  AAC	  TCC	  -­‐3ʹ′	   (reverse);	  mouse	  HSPB2:	  5ʹ′-­‐GCT	  CAG	  TGA	  AGG	  CAA	  GTT	  CC	  -­‐3ʹ′	  
(forward),	  5ʹ′-­‐CAG	  GAC	  ATA	  GGT	  GCG	  ACA	  GA-­‐3ʹ′(reverse);	  mouse	  HSPB2:	  5ʹ′-­‐GCT	  CAG	  
TGA	   AGG	   CAA	   GTT	   CC	   -­‐3ʹ′	   (forward),	   5ʹ′-­‐CAG	   GAC	   ATA	   GGT	   GCG	   ACA	   GA-­‐3ʹ′(reverse)	  
mouse	  HSPB3:	  5ʹ′-­‐CAT	  CAT	  CAT	  CCA	  GAC	  CTT	  CG	  -­‐3ʹ′	  (forward),	  5ʹ′-­‐ACT	  TCC	  ACC	  ACC	  AAG	  
ATT	   CC-­‐3ʹ′	   (reverse)	  mMAP-­‐LC3-­‐B:	   5’-­‐CGT	  CCT	  GGA	  CAA	  GAC	  CA-­‐3’	   (forward),	   5’-­‐CCA	  
TTC	  ACC	  AGG	  AGG	  AA-­‐3’	   (reverse);	  mP62/SQSTM1:	  5’-­‐AGG	  GAA	  CAC	  AGC	  AAG	  CT-­‐3’	  
(forward),	   5’-­‐GCC	  AAA	  GTG	  TCC	  ATG	  TTT	  CA-­‐3’	   (reverse);	  mGAPDH:	  5’-­‐CCA	  GAA	  CAT	  
CAT	  CCC	  TGC	  AT-­‐3’	  (forward),	  5’-­‐CAG	  TGA	  GCT	  TCC	  CGT	  TCA-­‐3’	  (reverse);	  mRplPO:	  5’-­‐
GGT	  GCC	  ACA	  CTC	  CAT	  CAT	  CA-­‐3’	  (forward),	  5’-­‐AGG	  CCT	  TGA	  CCT	  TTT	  CAG	  TAA	  GT-­‐3’	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(reverse);	  mHSPB8:	   5’-­‐ATA	  CGT	  GGA	  AGT	  TTC	  AGG	  CA-­‐3’	   (forward),	   5’-­‐TCT	  CCA	  AAG	  
GGT	  GAG	  TAC	  GG-­‐3’	  (reverse);	  mBAG3:	  5’-­‐ATG	  GAC	  CTG	  AGC	  GAT	  CTC	  A-­‐3’	  (forward),	  
5’-­‐CAC	  GGG	  GAT	  GGG	  GAT	  GTA-­‐3’(reverse);	  mBAG1:	  5’-­‐GAA	  ACA	  CCG	  TTG	  TCA	  GCA	  CT-­‐
3’	  (forward),	  5’-­‐GCT	  CCA	  CTG	  TGT	  CAC	  ACT	  C-­‐3’(reverse);	  mLamp2A:	  5’-­‐GCA	  GTG	  CAG	  
ATG	   AAG	   ACA	   AC-­‐3’	   (forward),	   5’-­‐AGT	   ATG	   ATG	   GCG	   CTT	   GAG	   AC-­‐3’	   (reverse);	  
mHSC70:	  5’-­‐CCT	  CGG	  AAA	  GAC	  CGT	  TAC	  CA-­‐3’	  (forward),	  5’-­‐TTT	  GTT	  GCC	  TGT	  CGC	  TGA	  
GA-­‐3’	  (reverse);	  mβ-­‐actin:	  5’-­‐GTC	  GAG	  TCG	  CGT	  CCA	  CC-­‐3’	  (forward),	  5’-­‐GTC	  ATC	  CAT	  
GGC	   GAA	   CTG	   GT-­‐3’	   (reverse);	   hHSPB8:	   5’-­‐	   AGA	   GGA	   GTT	   GAT	   GGT	   GAA	   GAC	   C-­‐3’	  
(forward),	  5’-­‐CTG	  CAG	  GAA	  GCT	  GGA	  TTT	  TC-­‐3’	  (reverse);	  hBAG1:	  5’-­‐TTT	  AGA	  GCA	  GCC	  
CGA	  GTG	  AT-­‐3’	  (forward),	  5’-­‐	  GAC	  AGC	  AGA	  CAG	  CCA	  ACA	  AA-­‐3’	  (reverse);	  hBAG3:	  5’-­‐	  
GGG	   TGG	  AGG	  CAA	  AAC	  ACT	  AA-­‐3’	   (forward),	   5’-­‐AGA	   CAG	   TGC	  ACA	  ACC	  ACA	  GC-­‐3’	  
(reverse);	  hP0:	  5’-­‐GTG	  GGA	  GCA	  GAC	  AAT	  GTG	  GG-­‐3’	  (forward),	  5’	  -­‐TGC	  GCA	  TCA	  TGG	  
TGT	  TCT	  TG-­‐3’	  (reverse).	  
The	  evaluated	  efficiency	  of	  each	  set	  of	  primers	  was	  close	  to	  100%	  for	  both	  target	  and	  
reference	   genes.	   Real-­‐time	   PCR	   was	   performed	   using	   the	   CFX	   96	   Real-­‐Time	   System	  
(Bio-­‐Rad,	   Hercules,	   CA,	   USA)	   in	   a	   10	   µL	   total	   volume,	   using	   the	   iTaq	   SYBR	   Green	  
Supermix	  (Bio-­‐Rad),	  and	  with	  500	  nM	  primers.	  PCR	  cycling	  conditions	  were	  as	  follows:	  
94°C	  for	  10	  min,	  40	  cycles	  at	  94°C	  for	  15	  s	  and	  60°C	  for	  1	  min.	  Melting	  curve	  analysis	  
was	   performed	   at	   the	   end	   of	   each	   PCR	   assay	   as	   a	   control	   for	   specificity.	   Data	  were	  
expressed	  as	  Ct	  values	  and	  used	  for	  the	  relative	  quantification	  of	  targets	  with	  the	  ∆∆Ct	  
calculation	  (Rusmini	  et	  al.,	  2015;	  Crippa	  et	  al.,	  2013a).	  To	  exclude	  potential	  bias	  due	  to	  
averaging	   data	   transformed	   through	   the	   equation	   2−∆∆Ct	   to	   give	   N-­‐fold	   changes	   in	  
gene	  expression,	  all	   statistics	  were	  performed	  with	  ∆Ct	  values.	  Each	  experiment	  was	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carried	  out	  with	  four	  independent	  samples.	  	  
	  
Western	  blot	  (WB)	  analysis	  and	  filter	  retardation	  assay	  (FRA)	  	  
NSC34	  or	  PC12	  cells	  were	  plated	   in	  12-­‐well	  plates	  at	  80.000	  cell/well,	   transfected	  as	  
previously	  described	  or	  induced	  with	  1	  µg/mL	  doxycycline.	  AR	  activation	  is	  induced	  by	  
10	   nM	   testosterone	   treatment	   for	   48	   hours.	   Inhibition	   of	   dynein	   ATPase	   activity	   is	  
performed	   by	   100	   µM	   EHNA	   for	   48	   hours.	   In	   experiments	   involving	   autophagy	  
blockage	  or	  induction,	  10	  mM	  3-­‐MA	  or	  100	  mM	  trehalose	  were	  added	  to	  the	  cells	  for	  
the	  last	  48	  hours.	  Proteasome	  inhibition	  was	  performed	  by	  10	  µM	  MG132	  treatment	  
for	  the	  last	  16	  hours	  (overnight	  treatment).	  48	  hours	  after	  plating,	  cells	  were	  harvested	  
and	   centrifuged	   5	  min	   at	   100	   x	   g	   at	   4°C;	   the	   cell	   pellets	   were	   re-­‐suspended	   in	   PBS	  
(added	  of	  the	  protease	  inhibitor	  cocktail,	  Sigma-­‐Aldrich)	  and	  homogenized	  using	  slight	  
sonication	   as	   previously	   described	   (Rusmini	   et	   al.,	   2007;	   Poletti	   et	   al.,	   2001).	   Total	  
proteins	  were	  determined	  with	  the	  bicinchoninic	  acid	  method	  (BCA	  assay,	  Euroclone).	  	  
Protein	  concentration,	  of	   spinal	   cord	  and	  quadriceps	   samples,	  was	  determined	  using	  
Pierce	  660nM	  protein	  assay	  reagent	  with	  Ionic	  Detergent	  Compatibility	  Reagent	  (IDCR)	  
(Thermo-­‐Fisher	   Scientific).	   WB	   analysis	   were	   performed	   using	   10	   and	   15%	   SDS-­‐
polyacrylamide	   gel	   electrophoresis.	  WB	  was	   performed	   on	   10%,	   12%	   or	   15%	   SDS	   –	  
polyacrylamide	  gel	  electrophoresis	   loading	  15	  µg	  or	  20	  µg	  of	   total	  proteins.	  Samples	  
were	  then	  electro-­‐transferred	  to	  nitrocellulose	  (Bio-­‐Rad)	  or	  PVDF	  (polyscreen	  transfer	  
membrane,	   Amersham,	   GE	   Healthcare	  Wauwatosa,	  WI,	   USA,	   USA)	   using	   a	   semi-­‐dry	  
transfer	  apparatus	  (Trans-­‐Blotw	  TurboTM	  Transfer	  System,	  Bio-­‐Rad).	  The	  membranes	  
were	   treated	   with	   a	   blocking	   solution	   containing	   5%	   nonfat	   dried	   milk	   powder	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(EuroClone,	  MI,	  Italy)	  in	  Tris	  buffered	  saline	  with	  Tween	  20	  (0,01%)	  for	  1	  hour	  and	  then	  
incubated	  with	  one	  of	  the	  following	  primary	  antibodies:	  (a)	  rabbit	  polyclonal	  AR-­‐H280	  
(dilution	  1:3.000)	  to	  detect	  wtAR	  and	  ARpolyQ	  (Santa	  Cruz	  Biotchnology,	  Texas,	  USA);	  
(b)	   rabbit	   polyclonal	   anti-­‐LC3	   (dilution	   1:4.000,	   Sigma-­‐Aldrich);	   (c)	   rabbit	   polyclonal	  
anti-­‐P62/SQSTM1	   (dilution	   1:4.000,	   Abcam,	   UK);	   (d)	   rabbit	   polyclonal	   anti-­‐dynein	  
heavy	   chain	   (dilution	   1:1.000,	   Santa	   Cruz);	   (e)	   rabbit	   polyclonal	   anti-­‐GFP	   HRP	  
conjugated	   (dilution	   1:15.000	   Vector	   Laboratories,	   Burlingame,	   CA,	   USA);	   (f)	   rabbit	  
polyclonal	   anti-­‐HA	   (dilution	   1:1.000,	   Santa	   Cruz);	   (g)	   rabbit	   polyclonal	   anti-­‐LAMP2A	  
(dilution	  1:1.000,	  Abcam);	  (h)	  mouse	  monoclonal	  Anti-­‐Hsc70	  antibody	  [13D3]	  (dilution	  
1:3.000,	  Abcam);	  (i)	  home-­‐made	  rabbit	  polyclonal	  anti-­‐BAG3	  (kindly	  provided	  by	  Prof.	  
Serena	  Carra,	  Università	  degli	  studi	  di	  Modena	  e	  Reggio	  Emilia,	  Italy;	  1:6000);	  (l)	  rabbit	  
polyclonal	   anti-­‐BAG1	   (Santa	   Cruz,	   Dallas,	   TX,	   USA,	   1:500);	   (m)	   home-­‐made	   rabbit	  
polyclonal	  anti-­‐HSPB8	  (provided	  by	  Dr.	  J.	  Landry,	  Quebec,	  Canada;	  1:1000);	  (n)	  mouse	  
monoclonal	   anti-­‐FLAG	   (Sigma,	   1:1000);	   (o)	   rabbit	   polyclonal	   anti-­‐MYC	   (Santa	   Cruz,	  
1:1000);	   (p)	   monoclonal	   anti-­‐α-­‐tubulin	   (Sigma-­‐Aldrich,	   1:4.000);	   (q)	   anti-­‐β-­‐actin	  
(Sigma-­‐Aldrich,	   1:2.000);	   (r)	   rabbit	   polyclonal	   anti-­‐GAPDH	   (1:4.000,	   Santa	   Cruz).	  
Immunoreactivity	  was	  detected	  using	  the	  following	  secondary	  peroxidase-­‐conjugated	  
antibodies:	  goat	  anti-­‐rabbit	   (dilution	  1:20.000,	  Santa	  Cruz);	  goat	  anti-­‐mouse	   (dilution	  
1:20.000,	   Santa	   Cruz).	   Signals	   were	   revealed	   by	   chemiluminescence	   detection	   kit	  
reagents	   (Clarity™	  Western	   ECL	   Blotting	   Substrate,	   Bio-­‐Rad).	   The	   same	   membranes	  
were	  subsequently	  processed	  with	  different	  antibodies	  to	  detect	  the	  levels	  of	  different	  
proteins	   in	   the	   same	   sample,	   after	   stripping	   for	   20	   min	   at	   room	   temperature	  
(StripABlot,	  EuroClone).	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FRA	  was	  performed	  using	  a	  Bio-­‐Dot	  SF	  Microfiltration	  Apparatus	  (Bio-­‐Rad).	  6	  µg	  of	  the	  
total	  proteins	  were	  filtered	  through	  a	  0.2	  µm	  cellulose	  acetate	  membrane	  (Whatman,	  
GE	  Healthcare).	   Slot-­‐blots	  were	  probed	   as	   described	   for	  WB	   to	   detect	  AR.Q46,	  GFP-­‐
AR.Q39,	   AR.Q112,	   and	   with	   (a)	   rabbit	   polyclonal	   ADI-­‐SOD-­‐100-­‐F	   (1:1000,	   Enzo	   Life	  
Science,	   NY,	   USA)	   to	   detect	   SOD1;	   (b)	   mouse	   polyclonal	   anti-­‐flag	   (dilution	   1:1000,	  
Sigma-­‐Aldrich)	  to	  detect	  FL,	  ∆C-­‐TDP-­‐43	  and	  polyGP.	  
A	  ChemiDoc	  XRS	  System	  (Bio-­‐Rad)	  was	  used	  for	  the	  image	  acquisition	  of	  WB	  and	  FRA.	  
Optical	  intensity	  of	  samples	  assayed	  with	  WB	  or	  FRA	  was	  detected	  and	  analyzed	  using	  
the	  Image	  Lab	  software	  (Bio-­‐Rad).	  	  
	  
Protein	  Fractionation	  
Protein	  fractionation	  of	  NSC34	  transfected	  with	  AR.Q46	  was	  modified	  from	  Koyama	  et	  
al.	  (Koyama	  et	  al.,	  2006).	  The	  cells	  were	  harvested	  and	  centrifuged	  5	  min	  at	  1.200	  rpm	  
at	   4°C,	   re-­‐suspended	   in	   PBS	   (containing	   protease	   inhibitor	   cocktail,	   Sigma)	   and	  
homogenized	  using	  slight	  sonication.	  The	  homogenates	  were	  centrifuged	  at	  16.000	  g	  
for	   10	   min	   at	   4°C.	   The	   resultant	   supernatants	   were	   collected	   as	   the	   PBS-­‐soluble	  
fraction.	  The	  pellets	  were	  extracted	  by	  slight	  sonication	   in	  1%	  Triton	  X-­‐100	   (TX)/PBS.	  
After	  centrifugation	  at	  16.000	  g	  for	  10	  min	  at	  4°C,	  the	  supernatants	  were	  considered	  
the	  TX-­‐soluble	  fraction.	  The	  pellets	  were	  extracted	  by	  slight	  sonication	  in	  5%	  SDS/PBS.	  
After	  centrifugation	  at	  16.000	  g	  for	  10	  min	  at	  4°C,	  the	  supernatants	  were	  considered	  
the	  SDS-­‐soluble	  fraction.	  Protein	  concentrations	  of	  PBS	  and	  TX	  fraction	  were	  measured	  
by	  a	  BCA	  protein	  assay	  (Pierce)	  and	  analysed	  in	  Western	  blot	  as	  described	  above.	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Microscopy	  analyses	  on	  NSC34	  cells	  	  
NSC34	   cells	   were	   plated	   in	   12-­‐well	   multiwell	   plates	   containing	   coverslips	   at	   70.000	  
cells/well	  density,	   transiently	   transfected	  with	   the	  plasmid	  coding	   for	  GFP-­‐ARQ.48	  or	  
hHSPB8	  or	  with	  DYNC1H1	  siRNA	  as	  previously	  described.	  AR	  activation	  is	  induced	  by	  10	  
nM	   testosterone	   treatment	   for	   48	   hours,	   inhibition	   of	   dynein	   ATPase	   activity	   is	  
performed	   by	   treatment	  with	   100	  µM	  EHNA	   for	   48	   hours.	   In	   experiments	   involving	  
autophagy	   induction,	  100mM	  trehalose	  was	  added	  to	   the	  cells	   for	   the	   last	  48	  hours.	  
Then,	  the	  cells	  were	  fixed	  and	  processed	  as	  previously	  described	  (Sau	  et	  al.,	  2007).	  The	  
following	   primary	   antibodies	   were	   used	   to	   analyze	   LC3	   and	   p62/SQSTM1	   protein	  
distributions:	  rabbit	  polyclonal	  anti-­‐LC3-­‐B	  antibody	  (1:500,	  Sigma-­‐Aldrich)	  in	  5%	  nonfat	  
milk,	   and	   rabbit	   polyclonal	   anti-­‐P62/SQSTM1	   antibody	   (1:500,	   Abcam)	   in	   5%	   nonfat	  
milk.	   Secondary	   antibodies	   were:	   Alexa	   488	   anti-­‐rabbit	   and	   Alexa	   594	   anti-­‐rabbit	  
(1:1000,	  Life	  Technologies)	  in	  5%	  nonfat	  milk.	  Cells	  were	  stained	  with	  DAPI	  to	  visualize	  
the	  nuclei.	  An	  Axiovert	  200	  microscope	  (Zeiss	  Instr.,	  Oberkochen,	  Germany)	  equipped	  
with	   FITC/TRITC/DAPI	   and	   combined	   with	   a	   Photometric	   Cool-­‐Snap	   CCD	   camera	  
(Ropper	   Scientific,	   Trenton,	   NJ,	   USA)	   was	   used.	   Phase	   contrast	   image	   was	   used	   to	  
evaluate	   the	   morphology.	   Images	   were	   processed	   using	   the	   Metamorph	   software	  
(Universal	  Imaging,	  Downing-­‐	  town,	  PA,	  USA).	  
	  
Proteasome	  activity	  
Proteasome	  chymotryptic	  assay	  was	  performed	  as	  described	  by	  Allen	  et	  al.	   (Allen	  et	  
al.,	  2003).	  NSC34	  cells	  were	  plated	  in	  6-­‐well	  multiwell	  plates	  at	  180.000	  cells/well.	  Cells	  
were	  washed	  with	   ice-­‐cold	  PBS	  and	   then	  harvested	  and	  centrifuged	  at	  100	  x	  g	   for	  5	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min,	  at	  4°C.	  Pellets	  re-­‐suspended	  in	  0.3	  mL	  of	  proteasome	  extract	  buffer	  (20	  mM	  Tris/	  
HCl,	  pH	  7.4,	  containing	  0.1	  mM	  EDTA,	  1	  mM	  2-­‐mercaptoethanol,	  5	  mM	  ATP,	  20%	  v/v	  
glycerol,	  and	  0.04%	  v/v	  Nonidet	  P-­‐40)	  were	  homogenized	  by	  10	  passages	  through	  a	  21-­‐
gauge	   needle,	   and	   then	   centrifuged	   at	   12.000	   x	   g	   for	   15	   min	   at	   4°C,	   saving	   the	  
supernatant.	   Total	   proteins	   were	   determined	   with	   BCA	   protein	   assay	   (Pierce).	  
Proteasome	   assay	   reaction	   mixtures	   consisted	   of	   50	   mM	   HEPES/KOH,	   pH	   8.0,	  
containing	   5	   mM	   EGTA,	   100	   µg	   of	   cell	   protein	   extract	   per	   mL	   of	   assay	   reaction.	  
Chymotryptic	   proteasome	   substrate	   conjugated	   with	   amidomethylcoumarin	   (AMC),	  
the	  peptide	  Suc-­‐LLVY-­‐AMC,	  was	  added	  to	  the	  mix	  at	  50	  µM	  and	  incubated	  at	  37°C	  for	  
45	  min.	   The	   resulting	   fluorescence	  was	  measured	   at	   340	  nm	  excitation	   and	   460	  nm	  
emission	  using	  a	  plate	  spectrofluorimeter	  (Enspire,	  Perkin	  Elmer,	  MA,	  USA).	  
	  
Cell	  viability	  assay	  
The	  3-­‐(4,5-­‐dimethyl-­‐2-­‐thiazolyl)-­‐2,5	  diphenyl-­‐2H-­‐tetrazolium	  bromide	  (MTT)-­‐based	  cell	  
proliferation	   assay	   (MTT	   assay)	  was	   carried	   out	   on	  NSC34	   cells	   24	   or	   48	   hours	   after	  
treatment	  with	  EHNA	  100	  μM,	   and	  performed,	   in	   24-­‐well	  multiwell	   plates	   at	   45.000	  
cells/well.	  MTT	  solution	  was	  prepared	  at	  1.5	  mg/mL	  in	  DMEM	  without	  phenol	  red	  and	  
was	  filtered	  through	  a	  0.2	  μm	  filter.	  Then,	  the	  culture	  medium	  was	  removed	  from	  the	  
plate	  and	  300	  μL	  of	  MTT	  solution	  was	  added	  into	  each	  well.	  Cells	  were	  incubated	  for	  
30	  min	  at	  37°C	  with	  5%	  CO2,	  95%	  air	  and	  complete	  humidity.	  After	  30	  min,	  500	  μL	  of	  2-­‐
propanol	  was	  added	  into	  each	  well	  and	  the	  precipitates	  were	  suspended.	  The	  optical	  
density	  (OD)	  of	  the	  wells	  was	  determined	  using	  a	  plate	  reader	  at	  a	  wavelength	  of	  550	  
nm.	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NSC34	  cells	  were	  plated	  in	  24-­‐well	  multiwell	  plates	  at	  density	  of	  40.000	  cells/well	  and	  
transfected	  with	   0.4	   μg	   of	   pCMV-­‐βgal	   plasmid.	   24	   hours	   after	   transfection	   the	   cells	  
were	  lysated	  in	  250	  μL	  of	  lysis	  buffer	  (Promega)	  and	  	  100	  μL	  of	  samples	  were	  added	  to	  
750	   μL	   of	   assay	   buffer	   (Na2HPO4∗7H2O	   60	  mM,	   NaH2PO4∗H2O	   40	  mM,	   KCl	   10	  mM,	  
MgSO4	   1mM,	   β-­‐mercaptoethanol	   50	   mM,	   pH	   7.0),	   in	   presence	   of	   4	   mg/mL	   of	   β-­‐
galactosidase	   substrate	   o-­‐nitrophenyl-­‐β-­‐D-­‐galactopyraniside	   (ONPG,	   Sigma)	   and	  
incubated	   at	   37°C	   until	   yellow	   color	   appearance.	   Then,	   500	   μL	   of	   1M	   Na2CO3	   were	  
added	  and	  200	  μL	  of	  the	  final	  solution	  were	  transferred	   into	  a	  96-­‐well	  plate	  and	  420	  
nm	  absorbance	  was	  evaluated	  using	  Enspire	  plate	  spectrofluorimeter	  (PerkinElmer).	  
	  
Statistical	  analysis	  	  
Statistical	  analysis	  has	  been	  performed	  using	  Student’s	  t-­‐test	  for	  two	  group	  
comparisons	  and	  two-­‐way	  ANOVA	  for	  more	  group	  comparisons	  using	  the	  PRISM	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AR	  expression	  in	  quadriceps	  muscle	  and	  spinal	  cords	  of	  SBMA	  mouse	  model	  
Muscle	  tissue	  was	  recently	  considered	  as	  a	  possible	  primary	  target	  of	  ARpolyQ	  toxicity	  
in	  SBMA	  pathogenesis.	  In	  order	  to	  understand	  the	  role	  of	  ARpolyQ	  in	  muscle	  tissue	  we	  
first	  analysed	  the	  expression	  of	  AR	  in	  muscle	  and	  in	  spinal	  cord	  of	  SBMA	  male	  mice	  and	  
age-­‐matched	  controls.	  We	  collected	  quadriceps	  muscle	  from	  male	  non-­‐transgenic	  (Wt)	  
mice	   and	   from	   male	   ARQ113	   transgenic	   (SBMA)	   mice	   at	   9	   (corresponding	   to	   pre-­‐
symptomatic	  stage)	  or	  24	  (corresponding	  to	  symptomatic	  stage)	  weeks	  of	  age.	  We	  also	  
used	  24	  week-­‐old	  female	  mice	  as	  negative	  control.	  As	  it	  is	  clearly	  shown	  in	  the	  graph	  in	  
Fig.	   12A,	   AR	   expression	   levels	   are	   comparable	   in	   control	   and	   SBMA	   mice.	   Also,	   no	  
differences	   are	   observed	   between	   pre-­‐symptomatic	   and	   symptomatic	   SBMA	   male	  
mice.	  Moreover,	   female	   control	   mice	   show	   the	   same	   expression	   levels	   observed	   in	  
SBMA	   mice.	   This	   indicates	   no	   apparent	   negative	   selective	   pressure	   associated	   to	  
atrophy	  of	  muscle	  fibers	  expressing	  high	  levels	  of	  ARpolyQ,	  suggesting	  that	  the	  loss	  of	  
muscle	   cells	   induced	   by	   ARpolyQ	   toxicity	   does	   not	   cause	  modification	   in	   the	   overall	  
levels	  of	  AR	  expression	  in	  muscles.	  In	  parallel,	  we	  analysed	  the	  AR	  expression	  levels	  in	  
spinal	   cord	   because	   in	   this	   tissue	   AR	   expression	   is	   confined	   to	   anterior	   horn	  motor	  
neuron	   (affected	   in	   SBMA	   patients)	   (Marron	   et	   al.,	   2005;	   Poletti,	   2004;	   Pozzi	   et	   al.,	  
2003).	   Interneuron	  and	  glial	   cells	  expresses	   very	   low	   levels	  of	  AR	   (Matsumoto	  et	  al.,	  
2013;	  Matsumoto,	  1997;	  Matsumoto	  et	  al.,	  1988).	  The	  graph	  in	  Fig.	  12B	  demonstrates	  	  
that	   AR	   expression	   remains	   unchanged	   in	   spinal	   cord	   in	   all	   conditions	   analysed,	  
possibly	  supporting	  the	  notion	  that	  in	  the	  mouse	  model	  selected	  for	  this	  study	  there	  is	  
no	  relevant	   loss	  on	  motor	  neuron	   in	  the	  spinal	  cord,	   the	  exclusive	  target	  of	  ARpolyQ	  
neurotoxicity	   in	   this	   structure.	   Collectively,	   these	  data	   also	   show	   that	  AR	   expression	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levels	  in	  SBMA	  mice	  are	  very	  similar	  to	  those	  found	  in	  control	  mice	  both	  in	  muscle	  and	  
spinal	  cord,	  at	  all	  age	  tested.	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Figure	  12	  -­‐	  Expression	  of	  AR	  in	  quadriceps	  muscle	  and	  spinal	  cords	  of	  SBMA	  mouse	  model.	  RT-­‐qPCRs	  
were	  performed	  on	  total	  RNA	  extracted	  from	  quadricep	  muscles	  (A)	  or	  whole	  spinal	  cords	  (B)	  of	  male	  
non-­‐transgenic	   (Wt)	  mice,	   and	   of	   AR113Q	  mice	   at	   9	   (corresponding	   to	   presymptomatic	   stage)	   or	   24	  
(corresponding	  to	  symptomatic	  stage)	  weeks	  of	  age.	  As	  additional	  control,	  quadriceps	  muscles	  of	  female	  
AR113Q	  mice	   at	   24	  weeks	   were	   used	   (n	   =	   5).	   Data	   have	   been	   normalized	   to	   the	   amount	   of	   GAPDH	  
mRNA,	  expressed	  relative	  to	  the	  levels	  determined	  in	  Wt	  mice	  at	  9	  weeks	  taken	  as	   internal	  reference,	  
and	  expressed	  as	  fold	  changes.	  Data	  are	  means	  ±	  SD	  of	  three	  independent	  replicates	  for	  Wt	  and	  AR113Q	  
mice	  at	  9	  weeks,	  and	  of	  five	  independent	  replicates	  for	  Wt	  and	  AR113Q	  mice	  at	  24	  weeks.	  (A)	  RT-­‐qPCR	  
on	   AR	   mRNA	   expression	   levels	   in	   quadricep	   muscles.	   (B)	   RT-­‐qPCR	   on	   AR	   mRNA	   expression	   levels	   in	  
spinal	  cords.	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motoneurons28,69,70 (affected in SBMA patients), while interneurons and glial cells express very low levels 
of AR71–73. Thus, it is conceivable that AR mRNA variations in spinal cord correlate with the motoneu-
ronal cell modification, and are representative of motoneuron loss. The data reported in Fig. 3(b) show 
a mild, but not significant decrease in AR expression in AR113Q male mice at 24 wks. From these data 
we conclude that expression of AR in AR113Q is similar to that of control mice both in muscle and 
spinal cord.
Modification of autophagic markers in muscle of symptomatic AR113Q male mice. To better 
understand whether symptom onset correlates with an activation of gene expression of proteins involved 
in PQC system in muscle cells, we measured changes in the expression of autophagic markers in the 
skeletal muscle of symptomatic AR113Q male mice. It has already been reported that the autophagy 
master regulator gene product TFEB is up-regulated in these mice when symptoms appear10. TFEB 
increase is paralleled by the increase of some specific TFEB target genes10. Here, we analysed the expres-
sion of four genes encoding proteins which are essential for autophagy initiation and are critical markers 
for the autophagic process. Two of these genes are critical for autophagosome assembly: Beclin-1 (the 
ATG6 ortholog, which regulates and associates to Vps34 to induce autophagy) and ATG10 (an E2-like 
enzyme involved in LC3 activation and modification essential for autophagosome formation); the other 
two, are TFEB regulated and considered typical autophagy markers: p62/SQSTM1 (which recognizes 
Figure 3. Expression of AR in quadriceps muscle and spinal cords of SBMA mouse model. RT-qPCRs 
were performed on total RNA extracted from quadricep muscles (A) or whole spinal cords (B) of male 
non-transgenic (Wt) mice, and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 
(corresponding to symptomatic stage) weeks of age. As additional control, quadriceps muscles of female 
AR113Q mice at 24 weeks were used (n = 5). Data have been normalized to the amount of GAPDH mRNA, 
expressed relative to the levels determined in Wt mice at 9 weeks taken as internal reference, and expressed 
as fold changes. Data are means ± SD of three i dependent eplicates for Wt and AR113Q mice at 9 weeks, 
and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on AR mRNA 
expression levels in quadricep muscles. (B) RT-qPCR on AR mRNA expression levels in spinal cords.
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Autophagic	  markers	  in	  muscle	  of	  SBMA	  male	  mice	  
Next,	  we	  analysed	  the	  gene	  expression	  of	  selected	  mRNA	  coding	  for	  proteins	  involved	  
in	   PQC	   system	   in	   skeletal	   muscle	   of	   symptomatic	   SBMA	   male	   mice.	   To	   better	  
understand	  the	  possible	  correlation	  between	  PQC	  regulation	  and	  symptoms	  onset	  we	  
analysed	   the	   expression	   of	   autophagic	   markers	   in	   quadriceps	   because	   it	   has	   been	  
proven	   that	   the	   autophagic	   master	   regulator	   gene	   product	   TFEB	   is	   up-­‐regulated	   in	  
these	   mice	   at	   symptoms	   onset	   (Chua	   et	   al.,	   2014).	   We	   analysed,	   by	   RT-­‐qPCR,	   the	  
expression	  of	  four	  genes	  that	  encode	  for	  essential	  autophagic	  proteins:	  	  
i)	  Bleclin	  1	   (ATG6	  ortholog)	  and	   ii)	  ATG10	  which	  are	  both	  critical	   for	  autophagosome	  
assembly;	  iii)	  p62/SQSTM1	  and	  LC3	  which	  are	  both	  regulated	  by	  TFEB	  and	  are	  typically	  
considered	   autophagy	  markers.	   As	   it	   shows	   in	   Fig.	   13,	  we	   found	   that	   all	   autophagic	  
markers	   analysed	   are	   clearly	   and	   specifically	   up-­‐regulated	   in	  muscle	   of	   symptomatic	  
SBMA	  male	  mice;	  no	  differences	  were	  found	  between	  all	  other	  mice	  groups	  studied.	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Figure	  13	  -­‐	  Expression	  of	  autophagic	  markers	  in	  quadriceps	  muscle	  of	  SBMA	  mouse	  model.	  RT-­‐qPCRs	  
were	  performed	  on	  total	  RNA	  extracted	  from	  quadricep	  muscles	  of	  male	  non-­‐transgenic	  (Wt)	  mice,	  and	  
of	   AR113Q	  mice	   at	   9	   (corresponding	   to	   presymptomatic	   stage)	   or	   24	   (corresponding	   to	   symptomatic	  
stage)	  weeks	  of	  age.	  As	  additional	  control,	  quadriceps	  of	  female	  AR113Q	  mice	  at	  24	  weeks	  were	  used	  (n	  
=	   5).	   All	   animals	   were	   age-­‐matched.	   Data	   have	   been	   normalized	   to	   the	   amount	   of	   GAPDH	   mRNA,	  
expressed	   relative	   to	   the	   levels	   determined	   in	  Wt	  mice	   at	   9	   weeks	   taken	   as	   internal	   reference,	   and	  
expressed	  as	   fold	   changes.	  Data	  are	  means	  ±	   SD	  of	   three	   independent	   replicates	   for	  Wt	  and	  AR113Q	  
mice	  at	  9	  weeks,	  and	  of	  five	  independent	  replicates	  for	  Wt	  and	  AR113Q	  mice	  at	  24	  weeks.	  (A)	  RT-­‐qPCR	  
on	  Beclin1	  mRNA	  expression	  levels	  in	  quadricep	  muscles.	  *p<0.05	  vs.	  24	  weeks	  Wt	  mice;	  °°p<0.001	  vs.	  9	  
weeks	  AR113Q	  mice.	  
(B)	  RT-­‐qPCR	  on	  ATG10	  mRNA	  expression	  levels	  in	  quadricep	  muscles.	  **p	  <	  0.001	  vs.	  24	  weeks	  Wt	  mice;	  
°°p	  <	  0.001	  vs.	  9	  weeks	  AR113Q	  mice.	  (C)	  RT-­‐qPCR	  on	  P62/SQSTM1	  mRNA	  expression	  levels	  in	  quadricep	  
muscles.	  **p<0.001	  vs.	  24	  weeks	  Wt	  mice;	  °p<0.05	  vs.	  9	  weeks	  AR113Q	  mice.	  (D)	  RT-­‐qPCR	  on	  LC3	  mRNA	  
expression	  levels	  in	  quadricep	  muscles.	  **p<0.001	  vs.	  24	  weeks	  Wt	  mice;	  °p<0.05	  vs.	  9	  weeks	  AR113Q	  
mice.	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ubiquitinated protein for their insertion into autophagosomes), and LC3 (which after its lipidation to 
LC3-II associates to the autophagosome membrane)43,44. We found that all autophagic markers analysed 
were robustly and specifically induced in skeletal muscle of symptomatic AR113Q male mice (Beclin-1 
in Fig. 4(a); ATG10 in Fig. 4(b); p62/SQSTM1 in Fig. 4(c); LC3 in Fig. 4(d)) over controls; no changes 
were present by comparing muscles of all other mice groups included in the study.
Induction of pro-autophagic chaperones in muscle of symptomatic AR113Q male mice. We 
already demonstrated that one of the key protein involved in the autophagic removal of misfolded pro-
teins (such as ARpolyQ associated to SBMA or mutant SOD1 and TDP-43 associated to ALS, etc) is the 
HSPB8. Expression of HSPB8 is robustly increased by UPS blockage to facilitate autophagy53,54. HSPB8 
expression is also enhanced when PQC is altered in ALS especially in motoneuron and muscle cells57,58. 
Therefore, we investigated whether, also in the case of SBMA, HSPB8 may be involved in the response 
to protein toxicity in muscle. When we analysed HSPB8 expression in SBMA mice (Fig. 5(a)) we found 
that this gene was transcriptionally up-regulated specifically in symptomatic AR113Q male mice, while 
it remained unchanged in all other mice tested, and at all time points considered. HSPB8 interacts with 
another member of its same family, namely the chaperone HSPB2. Interestingly, HSPB2 usually con-
jugates with a third member of the family, the chaperone HSPB3, found mutated in an axonal type of 
motor neuropathy74; HSPB2 and HSPB3 are capable to form hetero-oligomers in a 3:1 subunit ratio75 
Figure 4. Expression of autophagic markers in quadriceps muscle of SBMA mouse model. RT-qPCRs 
were performed on total RNA extracted from quadricep muscles of male non-transgenic (Wt) mice, and of 
AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to symptomatic stage) 
weeks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks were used (n = 5). All 
animals were age-matched. Data have been normalized to the amount of GAPDH mRNA, expressed relative 
to the levels determined in Wt mice at 9 weeks taken as internal reference, and expressed as fold changes. 
Data are means ± SD of three independent replicates for Wt and AR113Q mice at 9 weeks, and of five 
independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on Beclin1 mRNA expression 
levels in quadric p muscles. *p < 0.05 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q mice.  
(B) RT-qPCR on ATG10 mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 weeks Wt mice; 
°°p < 0.001 vs. 9 weeks AR113Q mice. (C) RT-qPCR on P62/SQSTM1 mRNA expression levels in quadricep 
muscles . **p < 0.001 vs. 24 weeks Wt mice; °p < 0.05 vs. 9 weeks AR113Q mice. (D) RT-qPCR on LC3 
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Pro-­‐autophagic	  chaperone	  and	  co-­‐chaperone	  levels	  in	  muscle	  of	  SBMA	  male	  mice	  
We	   had	   already	   proven	   that	   autophagy	   promotion	   by	   HSPB8	   over-­‐expression	   (also	  
confirmed	  in	  this	  study	  in	  Fig.	  18;	  see	  above)	  or	  by	  the	  HSPB8	  inducer-­‐trehalose	  result	  
in	   a	   clear	   reduction	   of	   testosterone	   induced	   misfolded	   and	   insoluble	   species	   of	  
ARpolyQ	  in	  motoneuronal	  cells.	  Thus,	  here	  we	  investigated	  the	  levels	  of	  expression	  of	  
HSPB8,	  a	  pro-­‐degradative	  chaperone	  involved	  in	  autophagic	  degradation	  of	  SBMA	  and	  
ALS	   related	   proteins.	   Indeed,	   HSPB8	   expression	   is	   increased	   by	   UPS	   blockage	   to	  
facilitate	   autophagy	   like	   in	   ALS	   affected	   motor	   neuron	   and	   muscle	   cells.	   RT-­‐qPCR	  
analysis	  of	  SBMA	  muscle	   tissue	   (Fig.	  14A)	   shows	   that	  HSPB8	  gene	   is	   transcriptionally	  
up-­‐regulated	  only	  in	  symptomatic	  SBMA	  male	  mice,	  while	  it	   is	  unchanged	  in	  all	  other	  
conditions	  analysed.	  This	  suggests	  that	  HSPB8	  may	  contribute	  to	  counteract	  ARpolyQ	  
toxicity	   in	  muscle	   tissue.	  We	   also	   tested	   the	   levels	   of	   HSPB2,	   that	   directly	   interacts	  
with	  HSPB8,	  and	   the	   levels	  of	  HSPB3	   that	   interacts	  with	  HSPB2.	   Interestingly,	  HSPB3	  
was	   found	  to	  be	  mutated	   in	  an	  axonal	   type	  of	  motor	  neurophaty	   (Kolb	  et	  al.,	  2010).	  
HSPB2	   and	   HSPB3	   are	   both	   highly	   expressed	   in	   skeletal	   muscle	   (Carra	   et	   al.,	   2012)	  
where	   they	   are	   involved	   in	   myogenic	   differentiation	   (den	   Engelsman	   et	   al.,	   2009;	  
Sugiyama	  et	  al.,	  2000).	  RT-­‐qPCR	  analysis	  of	  SBMA	  muscle	  tissue	  (fig.	  14B,C)	  shows	  that	  
HSPB2	  and	  HSPB3	  genes	  are	  transcriptionally	  up-­‐regulated	  only	  in	  symptomatic	  SBMA	  
male	  mice,	  while	  they	  remained	  unchanged	  in	  all	  other	  conditions	  analysed.	  Moreover,	  
to	   efficiently	   exert	   its	   pro-­‐degradative	   activity,	   HSPB8	   must	   associate	   to	   the	   co-­‐
chaperone	   BAG3;	   once	   the	   complex	   is	   formed	   and	   the	  misfolded	   protein	   recruited,	  
these	   proteins	   interact	   with	   HSC70	   and	   CHIP.	   Now	   misfolded	   proteins	   become	  
ubiquitinated	  by	  CHIP	  and	  they	  are	  recognized	  by	  p62/SQSTM1	  for	  their	  	  insertion	  into	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autophagosomes.	  Alternately,	  when	  the	  co-­‐chaperone	  BAG1	   is	  up-­‐regulated	  or	  when	  
low	  levels	  of	  BAG3	  are	  present,	  the	  HSC70-­‐CHIP	  complex	  can	  interact	  with	  BAG1	  which	  
re-­‐route	  misfolded	  proteins	   to	  UPS,	   rather	   than	   to	   autophagy.	   In	   this	   context,	   BAG3	  
levels,	   BAG1	   levels	   and	   their	   ratio	   are	   essential	   to	   understand	   which	   pathway	   is	  
preferred	   to	   clear	  misfolded	   proteins	   in	   a	   given	   cell	   type.	   Expression	   levels	   of	   BAG1	  
and	  BAG3	   in	  SBMA	  muscle	  male	  mice	  were	  analysed	  by	  RT-­‐qPCR.	  Fig.	  15	  shows	   that	  
both	   co-­‐chaperones	   are	   induced	   only	   in	   muscle	   of	   symptomatic	   SBMA	   male	   mice.	  
However,	   the	   ratio	   measured	   is	   dramatically	   increased	   only	   in	   favour	   of	   BAG3	   in	  
symptomatic	  SBMA	  male	  mice.	  Collectively,	  these	  data	  clearly	  show	  that	  autophagy	  is	  
preferentially	  activated	  in	  response	  to	  mutant	  ARpolyQ	  in	  muscle	  tissue	  of	  SBMA	  male	  
mice.	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Figure	  14	  -­‐	  Expression	  of	  pro-­‐autophagic	  chaperones	  in	  quadriceps	  muscle	  of	  SBMA	  mouse	  model.	  RT-­‐	  
qPCRs	  were	   performed	   on	   total	   RNA	   extracted	   from	   quadricep	  muscles	   of	  male	   non-­‐transgenic	   (Wt)	  
mice,	   and	   of	   AR113Q	   mice	   at	   9	   (corresponding	   to	   presymptomatic	   stage)	   or	   24	   (corresponding	   to	  
symptomatic	  stage)	  weeks	  of	  age.	  As	  additional	  control,	  quadriceps	  of	  female	  AR113Q	  mice	  at	  24	  weeks	  
were	  used	  (n	  =	  5).	  All	  animals	  were	  age-­‐matched.	  Data	  have	  been	  normalized	  to	  the	  amount	  of	  GAPDH	  
mRNA,	  expressed	  relative	  to	  the	  levels	  determined	  in	  Wt	  mice	  at	  9	  weeks	  taken	  as	   internal	  reference,	  
and	  expressed	  as	  fold	  changes.	  Data	  are	  means	  ±	  SD	  of	  three	  independent	  replicates	  for	  Wt	  and	  AR113Q	  
mice	  at	  9	  weeks,	  and	  of	  five	  independent	  replicates	  for	  Wt	  and	  AR113Q	  mice	  at	  24	  weeks.	  (A)	  RT-­‐qPCR	  
on	  HSPB8	  mRNA	  expression	  levels	  in	  quadricep	  muscles.	  *p<0.05	  vs.	  24	  weeks	  Wt	  mice;	  °°p<0.001	  vs.	  9	  
weeks	  AR113Q	  mice.	  (B)	  RT-­‐qPCR	  on	  HSPB2	  mRNA	  expression	  levels	  in	  quadricep	  muscles.	  **p	  <	  0.001	  
vs.	  24	  weeks	  Wt	  mice;	  °°p	  <	  0.001	  vs.	  9	  weeks	  AR113Q	  mice.	  (C)	  RT-­‐qPCR	  on	  HSPB3	  mRNA	  expression	  
levels	  in	  quadricep	  muscles.	  **p<0.001	  vs.	  24	  weeks	  Wt	  mice;	  °°p<0.001	  vs.	  9	  weeks	  AR113Q	  mice.	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Figure 5. Expression of pro-autophagic chaperones in quadriceps muscle of SBMA mouse model. RT-
qPCRs were performed on total RNA extracted from quadricep muscles of male non-transgenic (Wt) mice, 
and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to symptomatic 
stage) weeks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks were used 
(n = 5). All animals were age-matched. Data have been n rmalized to the amount of GAPDH mRNA, 
expressed relative to the levels determined in Wt mice at 9 weeks taken as internal reference, and expressed 
as fold changes. Data are means ± SD of three independent replicates for Wt and AR113Q mice at 9 weeks, 
and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on HSPB8 mRNA 
expression levels i  quadricep muscles. *p < 0.05 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q 
mice. (B) RT-qPCR on HSPB2 mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 weeks Wt 
mice; °°p < 0.001 vs. 9 weeks AR113Q mice. (C) RT-qPCR on HSPB3 mRNA expression levels in quadricep 
muscles. **p < 0.001 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q mice.
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Figure 5. Expression of pro-autophagic chaperones in quadriceps muscle of SBMA mouse model. RT-
qPCRs were performed on total RNA extracted from quadricep muscles of male non-transgenic (Wt) mice, 
and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to symptomatic 
stage) weeks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks were used 
(n = 5). All animals were age-matched. Data have been normalized to the amount of GAPDH mRNA, 
expressed relative to the levels determined in Wt mice at 9 weeks taken as internal reference, and expressed 
as fold changes. Data are means ± SD of three independent replicates for Wt and AR113Q mice at 9 weeks, 
and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on HSPB8 mRNA 
expression levels in quadricep muscles. *p < 0.05 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q 
mice. (B) RT-qPCR on HSPB2 mRNA expression levels  quadricep muscles. **p < 0.001 vs. 24 weeks Wt 
mice; °°p < 0.001 vs. 9 weeks AR113Q mice. (C) RT-qPCR on HSPB3 mRNA expression levels in quadricep 
muscles. **p < 0.001 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q mice.
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Figure 5. Expression of pro-autophagic chap rones in quadriceps muscle of SBMA mouse model. RT-
qPCRs were performed on total RNA extracted from quadric p muscles of male non-transgenic (Wt) mice, 
and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to symptomatic 
stage) weeks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks were used 
(n = 5). All animals were age-matched. Data have been normalized to the amount of GAPDH mRNA, 
expressed relative to the levels determined in Wt mice at 9 weeks taken as internal reference, and expressed 
as fold changes. Data are means ± SD of three independent replicates for Wt and AR113Q mice at 9 weeks, 
and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on HSPB8 mRNA 
expression levels in quadricep muscles. *p < 0.05 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q 
mice. (B) RT-qPCR on HSPB2 mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 weeks Wt 
mice; °°p < 0.001 vs. 9 weeks AR113Q mice. (C) RT-qPCR on HSPB3 mRNA expression levels in quadricep 
muscles. **p < 0.001 vs. 24 weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q mice.
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Figure	  15	  -­‐	  Expression	  of	  BAG1	  and	  BAG3	  co-­‐chaperones	  in	  quadriceps	  muscle	  of	  SBMA	  mouse	  model.	  
RT-­‐qPCRs	  were	  performed	  on	  total	  RNA	  extracted	  from	  quadricep	  muscles	  of	  male	  non-­‐transgenic	  
(Wt)	  mice,	  and	  of	  AR113Q	  mice	  at	  9	  (corresponding	  to	  presymptomatic	  stage)	  or	  24	  (corresponding	  to	  
symptomatic	  stage)	  weeks	  of	  age.	  As	  additional	  control,	  quadriceps	  of	  female	  AR113Q	  mice	  at	  24	  weeks	  
were	  used	  (n	  =	  5).	  All	  animals	  were	  age-­‐matched.	  Data	  have	  been	  normalized	  to	  the	  amount	  of	  GAPDH	  
mRNA,	  expressed	  relative	  to	  the	  levels	  determined	  in	  Wt	  mice	  at	  9	  weeks	  taken	  as	   internal	  reference,	  
and	  expressed	  as	  fold	  changes.	  Data	  are	  means	  ±	  SD	  of	  three	  independent	  replicates	  for	  Wt	  and	  AR113Q	  
mice	  at	  9	  weeks,	  and	  of	  five	  independent	  replicates	  for	  Wt	  and	  AR113Q	  mice	  at	  24	  weeks.	  (A)	  RT-­‐qPCR	  
on	  BAG1	  mRNA	  expression	  levels	  in	  quadricep	  muscles.	  **p<0.001	  vs.	  24	  weeks	  Wt	  mice;	  °p<0.05	  vs.	  9	  
weeks	  AR113Q	  mice.	  (B)	  RT-­‐qPCR	  on	  BAG3	  mRNA	  expression	   levels	   in	  quadricep	  muscles.	  **p	  <	  0.001	  
vs.	   24	  weeks	  Wt	  mice;	   °°p	   <	   0.001	   vs.	   9	  weeks	  AR113Q	  mice.	   (C)	   BAG3:BAG1	   relative	   ratio	   of	  mRNA	  
expression	   levels	   in	   quadricep	  muscles.	   Data	   represent	   variations	   of	   the	   relative	   levels	   of	   BAG3	   and	  
BAG1	  normalized	  over	  the	  relative	  BAG3	  and	  BAG1	  levels	  of	  age-­‐matched	  9	  weeks	  Wt	  mice.	  **p	  <	  0.001	  
vs.	  24	  weeks	  Wt	  mice;	  °°p<0.001	  vs.	  9	  weeks	  AR113Q	  mice.	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Figure 6. Expression of BAG1 and BAG3 co-chaperones in quadriceps muscle of SBMA mouse model. 
RT-qPCRs were performed on total RNA extracted from quadricep muscles of male non-transgenic 
(Wt) mice, and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to 
symptomatic stage) weeks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks 
were used (n = 5). All animals were age-matched. Data have been normalized to the amount of GAPDH 
mRNA, expressed relative to the levels determined in Wt mice at 9 weeks taken as internal reference, and 
expressed as fold changes. Data are means ± SD of three independent replicates for Wt and AR113Q mice at 
9 weeks, and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on BAG1 
mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 weeks Wt mice; °p < 0.05 vs. 9 weeks 
AR113Q mice. (B) RT-qPCR on BAG3 mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 
weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q mice. (C) BAG3:BAG1 relative ratio of mRNA expression 
levels in quadricep muscles. Data represent variations of the relative levels of BAG3 and BAG1 normalized 
over the relative BAG3 and BAG1 levels of age-matched 9 weeks Wt mice. **p < 0.001 vs. 24 weeks Wt mice; 
°°p < 0.001 vs. 9 weeks AR113Q mice.
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Figure 6. Expression of BAG1 and BAG3 co-chaperones in quadriceps muscle of SBMA mouse model. 
RT-qPCRs were performed on total RNA extracted from quadricep muscles of male non-transgenic 
(Wt) mice, and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to 
symptomatic stage) weeks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks 
were used (n = 5). All ani als were age-matched. Data have been normalized to the amount of GAPDH 
mRNA, expressed rela ive to the levels determi ed in Wt mice at 9 weeks taken as internal reference, and 
expressed as fold changes. Data are means ± SD of three independent replicates for Wt and AR113Q mice at 
9 weeks, and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on BAG1 
mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 weeks Wt mice; °p < 0.05 vs. 9 weeks 
AR113Q mice. (B) RT-qPCR on BAG3 mRNA expression levels in quadricep muscles. **p < 0.001 vs. 24 
weeks Wt mice; °°p < 0.001 vs. 9 weeks AR113Q mice. (C) BAG3:BAG1 relative ratio of mRNA expression 
levels in quadricep muscles. Data represent variations of the relative levels of BAG3 and BAG1 normalized 
over the relative BAG3 and BAG1 levels of age-matched 9 weeks Wt mice. **p < 0.001 vs. 24 weeks Wt mice; 
°°p < 0.001 vs. 9 weeks AR113Q mice.
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Figure 6. Expression of BAG1 and BAG3 co-chaperones in quadriceps muscle of SBMA mouse model. 
RT-qPCRs were performed on total RNA extracted from quadricep muscles of male non-transgenic 
(Wt) mice, and of AR113Q mice at 9 (corresponding to presymptomatic stage) or 24 (corresponding to 
symp matic stage) we ks of age. As additional control, quadriceps of female AR113Q mice at 24 weeks 
were used (n = 5). All animals were age-matched. Data have been normalized to the a ount of GAPDH 
mRNA, expressed relative to the levels determined in Wt mice at 9 weeks taken as internal reference, and 
expressed as fold changes. Data are means ± SD of three independent replicates for Wt and AR113Q mice at 
9 weeks, and of five independent replicates for Wt and AR113Q mice at 24 weeks. (A) RT-qPCR on BAG1 
mRNA expression levels in quadricep uscles. **p < 0.001 vs. 24 weeks Wt mice; °p < 0.05 vs. 9 weeks 
AR113Q mice. (B) RT-qPCR on BAG3 mRNA expression levels in qua ricep uscles. **p < 0.001 vs. 24 
weeks Wt mic ; °°p < 0.001 vs. 9 weeks A 3  i . (C) BAG3:BAG1 relative ratio of mRNA expression 
levels in quadricep muscles. Data represent variations of the relative levels of BAG3 and BAG1 normalized 
over the relative BAG3 and BAG1 levels of age-matched 9 weeks Wt mice. **p < 0.001 vs. 24 weeks Wt mice; 
°°p < 0.001 vs. 9 weeks AR113Q mice.
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Analysis	   of	   expression	   of	   proteins	   regulating	   autophagy	   in	   muscle	   of	   SBMA	   male	  
mice	  
Next,	   we	   evaluated	   whether	   the	   expression	   modulation	   observed	   in	   HSPB8	   related	  
autophagic	   genes	   is	   reflected	   in	   variations	   of	   proteins	   levels.	   Western	   blot	   (WB)	  
analysis	  showed	  that	  LC3-­‐I	  drastically	  decrease	  in	  symptomatic	  SBMA	  male	  mice	  (Fig.	  
16	  A,C)	  and	  that	  p62/SQSTM1	  does	  not	  change	  between	  the	  analysed	  groups	  (Fig.	  16	  
A,B),	   indicating	  that	  autophagy	   is	  activated	   in	  SBMA	  muscle	  tissue	  and	  that	  although	  
p62/SQSTM1	  mRNA	   is	   induced,	   p62/SQSTM1	   is	  well	   cleared	   by	   autophagy.	   Also	  WB	  
analysis	   (Fig.	   16	   A,D-­‐G)	   showed	   that	   the	   levels	   of	   HSPB8,	   BAG3	   are	   increased	   in	  
symptomatic	  SBMA	  male	  mice	  while	  BAG1	  levels	  are	  equal	   in	  all	  the	  groups	  analysed	  
as	   observed	   in	   mRNA	   analysis.	   In	   addition,	   the	   BAG3:BAG1	   ratio	   (Fig.	   16	   H)	   is	  
confirmed	  as	  increased	  also	  in	  protein	  levels.	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  Figure	  16	  -­‐	  	  Evaluation	  of	  the	  levels	  of	  proteins	  regulating	  autophagy	  and	  HSPB8-­‐mediated	  response	  
in	   skeletal	   muscle	   of	   symptomatic	   AR113Q	   male	   mice.	   (A)	   Western	   blot	   analysis	   perfomed	   on	  
quadriceps	  of	  male	  wt	  and	  AR113Q	  mice	  at	  9	  and	  24	  weeks.	  As	  additional	  control,	  quadriceps	  of	  female	  
AR113Q	  mice	  at	  24	  weeks	  were	  used.	  (B)	  Quantification	  of	  p62/SQSTM1	  protein	  expression	  levels	  in	  in	  
wt	  (n	  =	  3)	  and	  AR113Q	  (n	  =	  3)	  male	  mice	  at	  24	  weeks.	  The	  p62/SQSTM1	  protein	  levels	  were	  normalized	  
using	  tubulin	  as	  control.	  (C)	  Quantification	  of	  LC3-­‐I	  protein	  expression	  levels	  in	  in	  wt	  (n=3)	  and	  AR113Q	  
(n=3)	  male	  mice	  at	  24	  weeks.	   The	   LC3-­‐I	  protein	   levels	  were	  normalized	  using	   tubulin	  as	   control.	   *p	  <	  
0.05	   vs.	   24	  weeks	  Wt	  mice.	   (D)	  Quantification	  of	   the	   LC3-­‐II/LC3-­‐I	   ratio	   in	  wt	   (n=3)	   and	  AR113Q	   (n=3)	  
male	  mice	  at	  24	  weeks.	  (E)	  Quantification	  of	  HSPB8	  protein	  expression	  levels	  in	  in	  wt	  (n=3)	  and	  AR113Q	  
(n=3)	  male	  mice	  at	  24	  weeks.	  The	  HSPB8	  protein	  levels	  were	  normalized	  using	  tubulin	  as	  control;	  *p	  <	  
0.05	   vs.	   24	   weeks	  Wt	   mice.	   (F)	   Quantification	   of	   BAG3	   protein	   expression	   levels	   in	   in	   wt	   (n=3)	   and	  
AR113Q	  (n=3)	  male	  mice	  at	  24	  weeks.	  The	  BAG3	  protein	  levels	  were	  normalized	  using	  tubulin	  as	  control;	  
*p	  <	  0.05	  vs.	  24	  weeks	  Wt	  mice.	  (G)	  Quantification	  of	  BAG1	  protein	  expression	  levels	  in	  in	  wt	  (n=3)	  and	  
AR113Q	  (n=3)	  male	  mice	  at	  24	  weeks.	  The	  BAG1	  protein	  levels	  were	  normalized	  using	  tubulin	  as	  control.	  
(H)	  Quantification	  of	   the	   ratio	  between	  BAG3	  and	  BAG1	  protein	   levels	   in	  wt	   (n=3)	   and	  AR113Q	   (n=3)	  
male	  mice	  at	  24	  weeks;	  **p<0.001	  vs.	  24	  weeks	  Wt	  mice.	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Figure 7. For legend see next page.
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Autophagic	  response	  in	  spinal	  cord	  of	  SBMA	  male	  mice	  
We	   then	   evaluated	  whether	   changes	   in	   PQC	  markers	   are	   also	   present	   in	   the	   spinal	  
cords	  of	  the	  AR113Q	  mice	  at	  the	  pre-­‐symptomatic	  and	  at	  the	  symptomatic	  stages.	  As	  is	  
shown	  in	  Fig.	  17	  the	  expression	  analysis	  of	  Beclin-­‐1,	  p62/SQSTM1,	  LC3,	  HSPB8,	  HSPB2,	  
HSPB3,	  BAG1	  and	  BAG3	  (Fig.	  17	  (A–H),	  respectively)	  did	  not	  show	  detectable	  variation	  
in	  the	  different	  groups	  tested,	  including	  symptomatic	  (24wks)	  AR113Q	  male	  mice.	  We	  
only	   observed	   variation	   in	   the	   relative	   BAG3:BAG1	   ratio	   (Fig.	   8(i)),	   which	   in	  
symptomatic	  AR113Q	  male	  mice	   is	   in	   favour	  of	   the	  BAG3	  expression,	   suggesting	   the	  
preferred	   activation	   of	   the	   autophagic	   pathway	   over	   the	   UPS	   pathway	   also	   in	   the	  
spinal	  cord.	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Figure	  17	  -­‐	  Expression	  of	  autophagic	  markers,	  chaperones,	  and	  co-­‐chaperones	  in	  spinal	  cords	  of	  SBMA	  
mouse	  model.	  RT-­‐qPCRs	  were	  performed	  on	  total	  RNA	  extracted	  from	  whole	  spinal	  cord	  of	  male	  non-­‐	  
transgenic	  (Wt)	  mice,	  and	  of	  AR113Q	  mice	  at	  9	  weeks	  (corresponding	  to	  presymptomatic	  stage)	  or	  24	  
weeks	  (corresponding	  to	  symptomatic	  stage).	  As	  additional	  control,	  spinal	  cord	  of	  female	  AR113Q	  mice	  
at	   24	   weeks	   were	   used	   (n	   =	   5).	   All	   animals	   were	   age-­‐matched.	   Data	   have	   been	   normalized	   to	   the	  
amount	  of	  GAPDH	  mRNA,	  expressed	  relative	  to	  the	   levels	  determined	  in	  Wt	  mice	  at	  9	  weeks	  taken	  as	  
internal	  reference,	  and	  expressed	  as	  fold	  changes.	  Data	  are	  means	  ±	  SD	  of	  three	  independent	  replicates	  
for	  Wt	  and	  AR113Q	  mice	  at	  9	  weeks,	  and	  of	  five	  independent	  replicates	  for	  Wt	  and	  AR113Q	  mice	  at	  24	  
weeks.	   (A)	   RT-­‐	   qPCR	   on	   Beclin1	  mRNA	   expression	   levels	   in	   spinal	   cord.	   (B)	   RT-­‐qPCR	   on	   P62/SQSTM1	  
mRNA	  expression	  levels	  in	  spinal	  cord.	  (C)	  RT-­‐qPCR	  on	  LC3	  mRNA	  expression	  levels	  in	  spinal	  cord.	  (D)	  RT-­‐
qPCR	  on	  HSPB8	  mRNA	  expression	  levels	  in	  spinal	  cord.	  (E)	  RT-­‐qPCR	  on	  HSPB2	  mRNA	  expression	  levels	  in	  
spinal	  cord.	  (F)	  RT-­‐qPCR	  on	  HSPB3	  mRNA	  expression	  levels	   in	  spinal	  cord.	  (G)	  RT-­‐qPCR	  on	  BAG1	  mRNA	  
expression	   levels	   in	   spinal	   cord.	   (H)	   RT-­‐qPCR	   on	   BAG3	   mRNA	   expression	   levels	   in	   spinal	   cord.	   (I)	  
BAG3:BAG1	  relative	  ratio	  of	  mRNA	  expression	  levels	   in	  whole	  spinal	  cord.	  Data	  represent	  variations	  of	  
the	   relative	   levels	   of	   BAG3	   and	   BAG1	   normalized	   over	   the	   relative	   BAG3	   and	   BAG1	   levels	   of	   age-­‐
matched	  9	  weeks	  Wt	  mice.	  *p<0.05	  vs.	  24	  weeks	  Wt	  mice.	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HSPB8	  prodegradative	  effect	  on	  ARpolyQ	  
We	  next	  confirmed	  that	  HSPB8	  has	  a	  potent	  prodegradative	  effect	  on	  ARpolyQ	  soluble	  
and	   insoluble	   species	   promoted	   by	   testosterone	   activation	   in	   NSC34	   motoneuronal	  
cells.	   As	   clearly	   show	   in	   high	   resolution	   immunofluorescence	   microscopy	   (HRFM)	  
analysis	   (Fig.	   18),	   the	  mutant	   ARpolyQ	   is	   localized	   in	   the	   cytoplasm	   of	   cells	  without	  
testosterone.	   Subsequently,	   testosterone	   treatment	   induces	   ARpolyQ	   translocation	  
into	  the	  nucleus.	  In	  addition,	  incomplete	  translocation	  resulted	  in	  aggregate	  formation	  
in	   the	  perinuclear	   zone	  of	  30-­‐35%	  cells.	   These	  are	  visible	  as	   inclusions	   in	   IF	  analysis.	  
The	   Heat	   Shock	   Protein	   (HSP)	   B8	   over-­‐expression,	   by	   facilitating	   autophagy,	  
counteracts	   the	  misfolded	  ARpolyQ	  aggregation.	   In	   immunofluorescence	   (IF)	   analysis	  
we	   showed	   that	   HSPB8	   drastically	   reduces	   ARpolyQ	   inclusions	   induced	   by	   10nM	  
testosterone.	  We	  also	  evaluated	  the	  PBS-­‐insoluble	  fraction	  of	  mutant	  ARpolyQ	  in	  filter	  
retardation	  assay	   (FRA)	  with	  the	  cellulose	  acetate	  membrane	  that	  hold	  only	  proteins	  
bigger	   than	  0,2µm.	  FRA	  analysis	   (Fig.	   18)	   revealed	   that	   testosterone	   induces	  mutant	  
ARpolyQ	   retention	   on	   cellulose	   acetate	   confirming	   the	   presence	   of	   aggregates	   and	  
PBS-­‐insoluble	  mutant	   ARpolyQ	   species.	   Also,	   as	   is	   shown	   in	   IF	   analysis	   HSPB8	   over-­‐
expression	  completely	  removes	  mutant	  ARpolyQ	  aggregates.	  Moreover,	  the	  evaluation	  
of	   HSPB8	   effect	   by	   western	   blot	   (WB)	   analysis	   showed	   the	   reduction	   of	   the	   total	  
soluble	  ARpolyQ	  protein	  (Fig.	  18).	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Figure	   18	   -­‐	   Autophagic	   clearance	   of	   ARpolyQ.	   NSC34	   cells	   transfected	   with	   AR.Q46	   alone	   or	   with	  
hHSPB8	   treated	  with	   veichle	   (ethanol,	   EtOH)	   or	   10	   nM	   testosterone	   (T),	   for	   48h.	   (A)	   High	   resolution	  
immunofluorescence	  microscopy	   (HRFM)	   analysis	   (63x	  magnification)	   of	   AR	   (green);	  Nuclei	   stain	  with	  
DAPI	  (blue).	   (B)	  Filter	  retardation	  assay	  (FRA)	  showed	  AR.Q46	   insoluble	  fraction	  accumulation	  after	  10	  
nM	   T	   treatment	   and	   reduction	   after	   HSPB8	   over-­‐expression.	   Histograms	   represent	   the	   densitometric	  
analysis	   of	   three	   replicates	   for	   each	   sample	   ($=P<0,05	   vs.	   EtOH;	   *=p<0,05	   vs.	   T).	   (C)	  WB	   analysis	   of	  
AR.Q46	  soluble	  fraction,	  β-­‐tubulin	  was	  used	  as	  loading	  control.	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Dynein	   silencing	   effect	   on	   NSC34	   cells	   morphology,	   ARpolyQ	   aggregates	   and	  
autophagy	  
HSPB8	   recognizes	  misfolded	   proteins	   and	   target	   them	   to	   autophagy.	   This	   process	   is	  
mediated	  by	  misfolded	  proteins	  and	  HSPB8-­‐BAG3-­‐HSC70-­‐CHIP	  complex	  formation	  that	  
may	   transport	   misfolded	   proteins	   at	   MTOC	   for	   the	   subsequent	   insertion	   into	  
autophagosome.	  The	  transport	  is	  mediated	  by	  dynein	  motor	  proteins	  that	  with	  14-­‐3-­‐3	  
proteins	   interacts	   with	   BAG3	   and	   indirectly	   with	   misfolded	   proteins.	   Thus,	   dynein	  
mediated	   this	   retrograde	   transport	   and	   it	   is	   essential	   for	   autophagic	   degradation	   of	  
misfolded	  proteins.	  However,	  if	  autophagy	  is	  overwhelmed,	  dynein	  may	  contribute	  to	  
concentrate	  misfolded	   proteins	   to	  MTOC	  where	   they	   can	   normally	   interact	   to	   form	  
aggregates.	   To	   test	   the	   role	   of	   dynein	  we	   designed	   a	   specific	   siRNA	   recognizing	   the	  
heavy	   chain	   1	   of	   cytoplasmic	   dynein1	   (DYNC1H1	   siRNA)	   in	   order	   to	   worsen	   the	  
autophagy	  and	  the	  overall	  ARpolyQ	  clearance.	  
As	   is	  shown	  in	  the	  phase	  contrast	  microscopy	  and	  in	  the	  HRFM	  (Fig.	  19	  A),	  DYNC1H1	  
siRNA	   reduces	   the	   dynein	   cytoplasmic	   levels	   and	   induces	   a	   mild	   change	   in	   cell	  
morphology.	   After	   DYNC1H1	   siRNA	   transfection,	   the	   dynein	   level	   reduction	   is	   also	  
confirmed	   in	   WB	   analysis	   (Fig.	   19	   B)	   where	   dynein	   protein	   almost	   disappears.	   The	  
densitometric	   analysis	   clearly	   shows	   a	   reduction	   of	   approximately	   80%.	   Next,	   we	  
analysed	  the	  effect	  of	  dynein	  silencing	  on	  aberrant	  biochemical	  properties	  of	  mutant	  
ARpolyQ.	   	  We	   silenced	   dynein	   in	   immortalized	  motoneuronal	   cell	   line	   (NSC34	   cells)	  
stably	   transfected	  with	   inducible	  GFP-­‐tagged	  AR.Q39.	  Unexpectedly,	  dynein	   silencing	  
reduces	  the	  levels	  of	  PBS	  insoluble	  species	  of	  mutant	  ARpolyQ	  evaluated	  by	  FRA	  (Fig.	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19	   C).	   Densitometric	   analysis	   clearly	   shows	   the	   reduction	   of	   testosterone	   induced	  
mutant	  ARpolyQ	  retained	  on	  the	  cellulose	  acetate	  membrane.	  	  
We	   then	   analysed	   the	   consequence	   of	   dynein	   perturbation	   on	   autophagy	   by	   the	  
localization	   of	   LC3	   and	   p62/SQSTM1	   proteins	   responsible	   for	   autophagosome	  
formation.	   As	   expected,	   the	   dynein	   silencing	   resulted	   in	   an	   impaired	   autophagy	   as	  
showed	  by	  the	  HRFM	  of	  LC3	  and	  p62/SQSTM1	  autophagic	  markers	  that	  clearly	  shows	  
the	   accumulation	   on	   LC3	   and	   p62/SQSTM1	   into	   large	   autophagosome	   and	  
p62/SQSTM1	   bodies	   (Fig.	   19	   D)	   confirming	   perturbed	   autophagy	   without	   functional	  
dynein	  transport.	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Fig.	  19	  -­‐	  Effect	  of	  dynein	  silencing	  on	  autophagy	  and	  ARpolyQ	  clearance.	  	  
(A)	   Phase	   contrast	   and	   HRFM	   performed	   on	   NSC34	   cells	   transfected	   with	   dynein	   1	   heavy	   chain	   1	  
(DYNC1H1)	   siRNA	   shows	   cell	   morphology	   and	   dynein	   distribution.	   (B)	   WB	   analysis	   of	   NSC34	   cells	  
transfected	  with	  DYNC1H1	  siRNA	  shows	  the	  levels	  of	  dynein	  heavy	  chain;	  β-­‐tubulin	  was	  used	  as	  loading	  
control.	  Histogram	  represents	  the	  densitometric	  analysis	  of	  three	  replicates	  for	  each	  sample	  (**=p<0,01	  
vs.	  control)	  (C)	  FRA	  of	  NSC34	  stably	  expressing	  GFP-­‐AR.Q39	  and	  transfected	  with	  DYNC1H1	  siRNA	  shows	  
AR.Q39	   PBS	   insoluble	   fraction	   accumulation	   after	   10	   nM	   T	   treatment	   and	   reduction	   after	   dynein	  
silencing.	  Histogram	  represents	  the	  densitometric	  analysis	  of	  three	  replicates	  for	  each	  sample	  ($=p<0,05	  
vs.	  relative	  EtOH;	  *=p<0,05	  vs.	  T);	  (D)	  HRFM	  performed	  on	  NSC34	  cells	  transfected	  with	  DYNC1H1	  siRNA	  
shows	   sequestosome	   1	   (p62/SQSTM1)	   or	  Microtubule-­‐associated	   proteins	   1A/1B	   light	   chain	   3A	   (LC3)	  
distribution	  (green);	  nuclei	  were	  stained	  with	  DAPI	  (blue)	  (63x	  magnification).	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Effects	  of	  dynein	  inhibition	  with	  EHNA	  on	  ARpolyQ	  clearance	  
Dynein	  silencing	  efficiency	   is	  mediated	  by	  the	  number	  of	  cells	  that	  receive	  the	  siRNA	  
during	  transfection.	  Although	  we	  have	  obtained	  a	  great	  silencing	  efficiency	  (Fig.	  19	  B)	  
not	  all	  cells	  picked	  up	  siRNA	  at	  the	  same	  amount.	  	  
In	  order	   to	  avoid	   this	  and	   to	  more	  deeply	  analyse	   the	   role	  of	  dynein	  motor	   function	  
impairments	   in	   the	   clearance	   of	   mutant	   ARpolyQ	   we	   also	   used	   pharmacologic	  
inhibitors	  of	  dynein	  activity.	  This	  approach	  allowed	  us	   to	   inhibit	  dynein	  activity	   in	  all	  
treated	   cells.	   Among	   the	   two	   small	   molecules	   generally	   used	   as	   dynein	   inhibitors,	  
vanadate	  and	  erythro-­‐9-­‐[3-­‐2-­‐(hydrosynonyl)]adenine	   (EHNA),	   only	   the	   latter	   is	   highly	  
specific	   for	   the	   ATP	   binding	   site	   of	   dynein.	   EHNA	   inhibits	   the	   ATPase	   and	   motor	  
activities	  of	  cytoplasmic	  dynein	  thus	  blocking	  the	  microtubule-­‐based	  transport	  toward	  
the	  MTOC.	  We	  treated	  the	  cell	  with	  100	  µM	  of	  EHNA.	  	  
Thus,	   we	   confirmed	   our	   previously	   data	   obtained	   in	   dynein-­‐silenced	   cells.	   In	   FRA,	  
EHNA	   greatly	   reduced	   the	   accumulation	   of	   testosterone-­‐induced	   PBS	   insoluble	  
misfolded	  ARpolyQ	  (AR.Q46;	  Fig.	  20	  A)	  in	  transiently	  transfected	  NSC34	  cells.	  
In	  parallel,	  we	  demonstrated	  that	  in	  WB	  analysis	  (Fig	  20	  B)	  the	  effect	  of	  EHNA	  was	  not	  
mediated	  by	  a	  reduction	  of	  the	  overall	  content	  of	  soluble	  ARpolyQ,	  but	  EHNA	  clearly	  
shows	  a	   shift	  between	   the	  PBS	  and/or	  Triton	   insoluble	   fraction	   (possibly	   responsible	  
for	   inclusion	  appearance	   in	   IF	  and	  aggregation	   in	  FRA)	   to	   the	  PBS	  soluble	   fraction	  of	  
ARpolyQ	  (Fig.	  20	  C).	   In	  addition,	  EHNA	  treatment	   lead	  to	  a	  dramatic	  reduction	  of	  the	  
overall	  amount	  of	  SDS-­‐insoluble	  ARpolyQ	  species,	  normally	  present	  in	  large	  amounts	  in	  
the	  stacking	  gels	  of	  EHNA-­‐untreated	  ARpolyQ	  samples	  (Fig.	  20	  C).	  Next,	  we	  examined	  
the	  effects	  of	  dynein	  inhibition	  on	  the	  formation	  of	  inclusion	  of	  misfolded	  ARpolyQ	  in	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NSC34	  cells	  expressing	  mutant	  AR.Q46.	  The	  immunofluorescence	  microscopy	  analysis	  
shows	  that	  EHNA	  treatment	  lead	  to	  the	  complete	  clearance	  of	  cytoplasmic	  aggregates	  
of	  ARpolyQ	  induced	  by	  testosterone	  (Fig.	  20	  D).	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Effect	  of	  dynein	  ATPase	  activity	  inhibition	  on	  AR.Q46	  clearance.	  	  
NSC34	  cells	  transfected	  with	  ARQ.46	  and	  treated	  with	  ethanol	  (EtOH)	  or	  10	  nM	  testosterone	  (T)	  and/or	  
EHNA	   100	   M	   for	   48	   hours.	   (A)	   Filter	   retardation	   assay	   (FRA)	   shows	   ARpolyQ	   PBS	   insoluble	   fraction	  
($=p<0.05	  vs.	  EtOH;	  *=p<0.05	  vs.	  T);	  (B)	  WB	  analysis	  on	  NSC34	  cells	  transfected	  with	  AR.Q46	  and	  treated	  
with	   10	   nM	   T	   or	   EtOH	   and	   100	  µM	   EHNA	   or	   DMSO	   for	   48	   hours	   shows	   AR.Q46	   soluble	   fraction,	  α-­‐
tubulin	  was	   used	   as	   loading	   control;	   (C)	  WB	   analysis	   on	   PBS,	   Triton	   X100	   and	   SDS	   lysates	   fraction	   of	  
NSC34	  cells	  transfected	  with	  AR.Q46	  and	  treated	  with	  10nM	  T	  or	  EtOH	  and	  100	  µM	  EHNA	  or	  DMSO	  for	  
48	   hours,	   GAPDH	  was	   used	   as	   loading	   control	   (D)	   HRFM	   performed	   on	   NSC34	   cells	   transfected	  with	  
AR.Q46	  and	  treated	  with	  10	  mM	  T	  or	  EtOH	  and	  100	  µM	  EHNA	  or	  DMSO	  for	  48	  hours,	  AR	  was	  stained	  
with	  AR	  H280	  antibody	  (green),	  nuclei	  were	  stained	  with	  DAPI	  (blue)	  (63x	  magnification).	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In	   order	   to	   validate	   the	   prodegradative	   effect	   of	   EHNA	   treatment	   observed	   in	  
overexpressed	  ARpolyQ	  SBMA	  cell	  model,	  we	  extended	  our	  analysis	  to	  two	  alternative	  
inducible	  and	  stable	  models	  of	  SBMA:	  i)	  the	  NSC34	  motoneuronal	  cells	  expressing	  the	  
GFP-­‐AR.Q39	   and	   ii)	   the	   PC12	  neuronal-­‐like	   expressing	   the	  AR.Q112.	   The	  NSC34	   cells	  
were	  developed	  to	  normalized	  the	  ARpolyQ	  levels	  in	  every	  cells.	  FRA	  in	  Fig.	  21	  A	  shows	  
that	   the	   PBS	   insoluble	   mutant	   ARpolyQ	   levels	   observed	   in	   NSC34	   expressing	   GFP-­‐
AR.Q39	   are	   testosterone	   dependent	   and	   also	   increase	   when	   PQC	   degradative	  
pathways	   are	   inhibited	   with	   3-­‐MA	   and	   MG132	   compound	   to	   block	   autophagy	   and	  
proteasome	   chimotryptic	   activity	   respectively.	   Notably,	   also	   in	   this	   case,	   EHNA	  
treatment	  reverted	  the	  accumulation	  of	  most	  of	  the	  misfolded	  PBS	  insoluble	  species	  of	  
ARpolyQ.	   In	   parallel,	   in	   PC12/AR.Q112	   SBMA	   (developed	   by	   Dr.	   Diane	   Merry	   (TJU,	  
Philadelphia,	   PA,	   USA))	   inducible	   model	   characterized	   by	   an	   extremely	   long	   polyQ	  
highly	  prone	   to	   intra-­‐nuclear	   aggregates,	  we	   similarly	  observed	   the	  effects	   shown	   in	  
Fig.	  21	  B.	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Figure	  21	  	  -­‐	  Effect	  of	  dynein	  ATPase	  activity	  inhibition	  on	  ARpolyQ	  (Q.39	  and	  Q.112)	  clearance.	  	  
Filter	   retardation	   assay	   (FRA)	   shows	  ARpolyQ	   insoluble	   fraction	   of:	   (A)	  NSC34	   cells	   stably	   transfected	  
with	  GFP-­‐ARQ.39	  induced	  with	  1	  µg/mL	  doxycycline	  for	  72	  hours	  and	  treated	  with	  10	  nM	  testosterone	  
and/or	   100	  µM	  EHNA	  and/or	   10	  mM	  3-­‐MA	   for	   last	   48	  hours	   and/or	   10	  µM	  MG132	   for	   last	   16	  hours	  
($=p<0.05	  vs.	  relative	  EtOH;	  *=p<0.05	  vs.	  T);	  (C)	  PC12	  cells	  stably	  transfected	  with	  AR.Q112	  induced	  with	  
1	  µg/mL	  doxycycline	  for	  72	  hours	  and	  treated	  with	  10	  nM	  testosterone	  and/or	  100	  µM	  EHNA	  for	  last	  48	  
hours	   ($=p<0.05	  vs.	   relative	  EtOH**=p<0.01	  vs.	  T).	  Histograms	  represent	  the	  densitometric	  analysis	  of	  
three	  replicates	  for	  each	  sample.	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Analysis	  of	  viability	  of	  NSC34	  cells	  treated	  with	  EHNA	  	  
In	   order	   to	   confirm	   the	   specific	   pro-­‐degradative	   effect	   of	   dynein	   ATPase	   activity	  
inhibition,	  we	  tested	  EHNA	  possible	  interference	  with	  cells	  viability	  and/or	  transfected	  
protein	   over-­‐expression.	   First,	   to	   exclude	   toxic	   effect	   of	   EHNA	   treatment	   we	  
performed	  a	  MTT	  assay	  to	  measure	  the	  viability	  of	  NSC34	  cells	  after	  EHNA	  treatment.	  
MTT	  assay	   is	   a	   colorimetric	   assay	   that	  measures	   the	   cell	  metabolic	   activity	   and,	   in	   a	  
certain	  condition,	  evaluates	  the	  number	  of	  viable	  cells	  in	  the	  sample.	  Thanks	  to	  NADPH	  
dependent	   oxidoreductase	   enzymes,	   that	   catalyse	   the	   reduction	   of	   the	   tetrazolium	  
dye	  MTT	  to	  its	  insoluble	  and	  purple	  coloured	  formazan,	  we	  can	  evaluate	  the	  enzymatic	  
activity	   and	   then	   the	   viability	   of	   the	   cells.	   Fig.	   22	   shows	   the	   spectrophotometric	  
quantification	  of	  formazan	  of	  six	  independent	  replicates	  for	  each	  condition	  analysed.	  It	  
is	  clear	  that	  EHNA	  treatment	  does	  not	  influences	  the	  viability	  of	  used	  cell	  model.	  Next	  
to	   exclude	   the	   interference	  with	   transfected	   protein	   over-­‐expression,	  we	   performed	  
the	   classical	  β-­‐galactosidase	  assay.	  The	   result	   is	   shown	   in	  Fig.	  22	  and	   represents	   the	  
colorimetric	  analysis	  of	  6	  independent	  replicates	  for	  each	  condition	  analysed.	  Even	  in	  
this	  case,	  EHNA	  treatment	  does	  not	  alter	  the	  expression	  of	  transfected	  β-­‐galactosidase	  
protein.	   Collectively,	   these	   experiments	   exclude	   that	   EHNA	   effect	   on	   misfolded	  
ARpolyQ	  is	  not	  caused	  by	  toxic	  unspecified	  effect	  or	  by	  interference	  with	  disease	  cell	  
models.	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Figure	  22	  -­‐	  Viability	  of	  NSC34	  cells	  EHNA	  treated.	  (A)	  MTT	  assay	  performed	  on	  NSC34	  cell	  treated	  with	  
DMSO	   or	   100	   µM	   EHNA	   for	   24	   or	   48	   hours.	   (B)	   β-­‐galactosidase	   assay	   performed	   on	   NSC34	   cells	  
transfected	  with	  pCMV-­‐β	  and	  treated	  with	  DMSO	  or	  100	  µM	  EHNA	  for	  24	  or	  48	  hours	  after	  transfection;	  	  
Histograms	  represent	  the	  analysis	  of	  six	  replicates	  for	  each	  samples.	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Pro-­‐degradative	  effect	  of	  EHNA	  on	  ARpolyQ	  
To	   evaluate	   which	   pathway	   is	   mainly	   involved	   in	   the	   enhanced	   solubility	   of	  
testosterone-­‐induced	   misfolded	   ARpolyQ	   species	   after	   inhibition	   of	   the	   dynein-­‐
mediated	   transport	   to	   MTOC,	   we	   selectively	   blocked	   the	   two	   major	   pathways	   of	  
degradation.	  As	  is	  shown	  in	  Fig.	  23,	  both	  the	  inhibition	  of	  autophagy	  with	  3-­‐MA	  and	  of	  
the	  proteasome	  with	  MG132	  resulted	   in	  a	   significant	   increase	  of	   insoluble	  misfolded	  
ARpolyQ	   species	   in	   FRA.	   These	   species	   are	   considerably	  more	   abundant	   after	   3-­‐MA	  
than	  MG132	   treatment.	  However,	  dynein	   inhibition	  with	  EHNA	   is	   still	   able	   to	   reduce	  
insoluble	  misfolded	  ARpolyQ	  species	  when	  autophagy	   is	  blocked	  with	  3-­‐MA,	  but	  not	  
when	   proteasome	   is	   inhibited	   by	   MG132.	   These	   data	   strongly	   indicate	   that	  
proteasome	   and	   not	   autophagy,	   is	   required	   to	   clear	   insoluble	   misfolded	   ARpolyQ	  
species	   that	   cannot	   be	   transported	   and	   concentrated	   at	   MTOC	   to	   form	   the	  
aggresomes.	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Figure	  23	  -­‐	  Dynein	  ATPase	  activity	  inhibition	  promotes	  ARpolyQ	  clearance	  via	  UPS.	  	  
NSC34	  stably	  transfected	  with	  GFP-­‐AR.Q39	  treated	  with	  10	  nM	  testosterone,	  10	  mM	  3-­‐MA	  and/or	  100	  
 M	   EHNA	   for	   last	   48	   hours	   and/or	   10	   M	  MG132	   for	   last	   16	   hours.	   FRA	   shows	   ARpolyQ	   insoluble	  
fraction	   (**=p<0.01	   vs.	   EtOH;	   §§=p<0.01	   vs.	   T;	   ##=p<0.01	   vs.	   T/3MA);	   Histograms	   represent	   the	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Treatment	  with	  EHNA	  enhances	  UPS	  mediated	  degradation	  of	  misfolded	  proteins	  
To	   test	   whether	   UPS	   degradation	   is	   promoted	   by	   EHNA,	   we	   used	   the	   proteasome	  
reporter	   GFPu,	   which	   consists	   of	   the	   GFP	   protein	   tagged	  with	   a	   short	   degron	   (CL1)	  
capable	  to	  target	  the	  protein	  to	  proteasome	  for	  degradation	  (Rusmini	  et	  al.,	  2007;	  Sau	  
et	  al.,	  2007;	  Bence	  et	  al.,	  2001).	  Any	  condition	  which	  perturb	  the	  proteasome	  activity	  
will	   result	   in	  GFPu	   accumulation	   into	   the	   cells	   (Giorgetti	   et	   al.,	   2015;	   Rusmini	   et	   al.,	  
2013;	  Rusmini	  et	  al.,	  2011;	  Rusmini	  et	  al.,	  2010).	  With	  this	  system,	  we	  confirmed	  our	  
previous	   data	   showing	   that	   the	   formation	   of	   testosterone-­‐inducible	   insoluble	  
misfolded	   ARpolyQ	   species	   correlates	   with	   proteasome	   desaturation.	   Indeed,	   as	   is	  
shown	  in	  Fig.	  24	  A,	  GFPu	  accumulates	  in	  NSC34	  cells	  expressing	  the	  mutant	  AR	  (in	  its	  
soluble	   form)	   in	   absence	   of	   testosterone,	   but	   it	   is	   rapidly	   cleared	   by	   the	   same	   cells	  
after	   testosterone	   treatment	   (which	   induces	   ARpolyQ	   aggregation).	   Interestingly,	  
dynein	   inhibition	   with	   EHNA	   resulted	   in	   a	   better	   clearance	   of	   GFPu	   when	   UPS	   was	  
partially	   impaired,	   suggesting	   that	   the	   blockage	   of	  misfolded	   protein	   transport	   does	  
not	   impair	   the	   proteasome	   activity	   even	   if	   the	   proteasome	   has	   to	   deal	   with	   larger	  
fraction	   of	   proteins	   to	   be	   processed.	   We	   also	   confirmed	   that,	   in	   immortalized	  
motoneuronal	  NSC34	  cells,	  EHNA	  treatment	  has	  no	  direct	  effects	  (neither	  positive,	  nor	  
negative)	  on	  the	  chimotryptic	  activity	  of	  the	  proteasome	  (Fig.	  24	  B).	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Figure	  24	  -­‐	  Proteasome	  response	  in	  EHNA	  treated	  NSC34	  cells.	  
(A)	  NSC34	  cells	   transfected	  with	  GFPu	   reporter	  and/or	  ARpolyQ	  and	   treated	  with	  10nM	  T	  and/or	  100	  
µM	   EHNA.	  WB	   shows	   ARpolyQ	   and	   GFPu	   bands	   (*=p<0.05	   vs.	   EtOH).	   β-­‐tubulin	   was	   used	   as	   loading	  
control;	  (B)	  Proteasome	  chimotryptic	  activity	  was	  performed	  on	  NSC34	  treated	  with	  DMSO	  or	  100	  µM	  
EHNA	  and	  10	  µM	  MG132	  as	  negative	  control	  (**=p<0.01	  vs.	  ctrl).	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The	  autophagic	  response	  in	  EHNA	  treated	  NSC34	  cells	  
In	  cells	  treated	  with	  EHNA,	  mutant	  ARpolyQ	  may	  be	  degraded	  more	  efficiently	  via	  the	  
proteasome	  as	  a	  consequence	  of	  impaired	  autophagy.	  We	  then	  studied	  whether	  EHNA	  
affected	   autophagy	   flux	   in	   basal	   conditions	   and	   upon	   stimulation	   with	   trehalose,	   a	  
well-­‐known	  mTOR-­‐independent	   autophagy	   activator	   (Giorgetti	   et	   al.,	   2015;	   Zhang	   et	  
al.,	   2014;	   Rusmini	   et	   al.,	   2013;	   Sarkar	   et	   al.,	   2007;	   Tanaka	   et	   al.,	   2004).	   First	   of	   all,	  
EHNA	  alone	  has	   no	   effects	   on	  p62/SQSTM1	  or	   on	   LC3	  protein	   (Fig.	   25	  A,	   upper	   and	  
middle	  insets,	  respectively;	  quantification	  in	  Fig.	  25	  B	  and	  Fig.	  25	  C,	  respectively)	  and	  
mRNA	  (Fig.	  25	  D	  and	  25	  E,	  respectively)	  even	  if	  a	  mild,	  but	  not	  significant,	  increase	  of	  
the	  levels	  of	  these	  transcripts	  can	  be	  detected	  in	  RT-­‐qPCR	  analysis.	  In	  addition,	  EHNA	  
does	  not	  significantly	  alter	  the	  LC3-­‐II/LC3-­‐I	  ratio	  measured	  by	  western	  blot	  (Fig.	  25	  C).	  
We	  observed	  only	  subtle	  changes	   in	  the	  LC3	  distribution	  (from	  LC3-­‐I	  diffuse	  to	  LC3-­‐II	  
punctate	   distribution)	   and	   a	   mild	   increase	   of	   p62/SQSTM1	   levels,	   with	   few	  
p62/SQSTM1	   bodies	   after	   EHNA	   treatment	   (Fig.	   25	   F).	   	   Thus,	   dynein	   inhibition	  with	  
EHNA	  does	  not	  significantly	  affects	  autophagy	  in	  basal	  conditions.	  As	  expected,	  3-­‐MA	  
treatment	  increased	  the	  LC3-­‐II/LC3-­‐I	  ratio,	  but	  this	  effect	  was	  partially	  counteracted	  by	  
EHNA.	   Trehalose	   was	   able	   to	   significantly	   increase	   the	   LC3-­‐II/LC3-­‐I	   ratio	   (Fig.	   25	   C),	  
which	   suggests	   an	   enhanced	   conversion	   of	   LC3	   from	   its	   diffuse	   to	   its	   lipidated,	  
authophagosome	  associated	   form	  (as	  also	  clearly	  evidenced	  and	  confirmed	  by	   the	   IF	  
analysis	   in	   Fig.	   25	  F),	   a	   conversion	   required	   to	   start	   the	   initial	   autophagic	   steps.	   The	  
effect	  of	   trehalose	  on	   the	  LC3-­‐II/LC3-­‐I	   ratio	  was	   significantly,	  even	   if	  not	   completely,	  
inhibited	  by	  EHNA,	  and	  this	  was	  accompanied	  by	  a	  significant	  increase	  in	  the	  number	  
and	  size	  of	  p62/SQSTM1	  bodies	  (Fig.	  25	  F).	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Collectively,	  these	  observations	  strongly	  suggest	  that	  EHNA	  prevents	  the	  lipidation	  of	  
LC3	   (to	   LC3-­‐II)	   induced	  by	   trehalose	  and	   its	   association	   to	  nascent	   autophagosomes,	  
and	  further	  suggests	  that,	  under	  our	  experimental	  conditions,	  the	  decreased	  levels	  of	  
aggregated	  misfolded	  ARpolyQ	  is	  not	  due	  to	  increased	  degradation	  via	  autophagy	   	  
Results	  
	  









Figure	  25	  -­‐	  Autophagy	  modulation	  by	  EHNA	  treatment.	  	  
NSC34	  cells	   treated	  with	  DMSO,	  100	   M	  EHNA,	  10	  mM	  3-­‐MA,	   trehalose	  and/or	  10	   M	  MG132	   for	  48	  
hours;	   (A)	   WB	   analysis	   show	   p62-­‐SQSTM1,	   LC3	   levels;	   -­‐tubulin	   was	   used	   as	   loading	   control;	   the	  
histograms	  represent	  densitometric	  quantification	  of	   three	  replicates	   for	  each	  sample	  of	  p62-­‐SQSTM1	  
(B)	   and	   LC3II/LC3I	   ratio	   (C)	   (*=p<0.05	   vs.	   3-­‐MA	   or	   trehalose);	   (D,E)	   the	   histogram	   represents	   p62-­‐
SQSTM1	   and	   LC3	  mRNA	   levels	   normalized	   with	   RplP0	  mRNA	   levels.	   Analysis	   was	   conducted	   on	   four	  
samples	  (F)	  HRFM	  shows	  p62-­‐SQSTM1	  and	  LC3	  localization	  (63x	  magnification).	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The	  effect	  of	  EHNA	  on	  chaperone	  and	  co-­‐chaperones	  levels	  
As	   previous	   results	   describe,	   chaperone	   and	   co-­‐chaperone	   levels	   are	   essential	   to	  
control	  the	  PQC	  removal	  of	  misfolded	  ARpolyQ	  and	  misfolded	  proteins	  in	  general.	  Here	  
HSPB8	   and	   BAG3	   are	   necessary	   to	   target	   autophagic	   substrates	   to	   autophagy	   and	  
BAG1	  is	  necessary	  to	  target	  proteasome	  substrates	  to	  UPS.	  Here	  the	  BAG3:BAG1	  ratio	  
is	   an	   indicator	  of	   preponderant	   degradative	  pathway.	  Here	  we	  analysed	  by	  RT-­‐qPCR	  
the	   HSPB8,	   BAG3	   and	   BAG1	  mRNA	   levels	   in	   NSC34	   cells	   treated	  with	   EHNA.	   Fig.	   26	  
shows	   the	   analysis	   results	   where	   EHNA	   increased	   only	   BAG1	   mRNA	   levels	   without	  
alteration	  in	  HSPB8	  and	  BAG3	  levels.	  
We	  also	  extended	  our	  analysis	  on	  human	  SBMA	  iPSCs	  differentiated	  to	  motor	  neuron.	  
After	   14	   days	   to	   obtain	   embryo	   bodies	   and	   12	   days	   in	   motoneuronal	   medium	   we	  
treated	  our	  culture	  with	  testosterone	  and/or	  EHNA.	  Then,	  by	  RT-­‐qPCR	  we	  analysed	  the	  
mRNA	  levels	  of	  HSPB8,	  BAG3	  and	  BAG1.	  As	  is	  shown	  in	  Fig.	  27:	  i)	  HSPB8	  level	  is	  equal	  
in	   all	   conditions	   analysed	   (Fig.	   27	   A),	   ii)	   BAG3	   is	   significantly	   increased	  when	  motor	  
neuron	  culture	  is	  treated	  with	  testosterone	  and	  EHNA,	  but	  it	  slightly	  increased	  also	  in	  
absence	  of	  EHNA	  (Fig.	  27	  B).	  Interestingly,	  EHNA	  drastically	  increases	  BAG1	  mRNA	  level	  
of	  motor	  neuron	  culture	  treated	  with	  testosterone	  and	  in	  their	  controls	  (Fig.	  27	  C).	  In	  
conclusion,	   BAG1	   expression	   analysis,	   in	   NSC34	   cells	   and	   testosterone-­‐treated	   MN	  
iPSCs,	  strongly	  support	  our	  working	  hypothesis.	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Figure	  26	  -­‐	  Chaperones	  levels	  of	  EHNA	  treated	  NSC34	  cells	  
NSC34	  cells	  treated	  with	  DMSO	  or	  100	  µM	  EHNA	  for	  48	  hours.	  The	  histograms	  represent	  HSPB8,	  BAG3	  
and	   BAG1	   mRNA	   levels	   normalized	   with	   RplP0	   mRNA	   levels,	   four	   samples	   for	   each	   condition	   were	  
analysed	  (*=p<0.05	  vs.	  DMSO).	   	  
Results	  
	  






Figure	  27	  -­‐	  Chaperones	  levels	  of	  EHNA	  treated	  motoneuronal	  differentiated	  iPS	  cells	  
MNs	  obtained	   from	  Kennedy’s	   patients	   iPS	   cells	   treated	  with	   10	  nM	   testosterone	   (T)	   and/or	   100	  µM	  
EHNA	   for	   48	   hours.	   The	   histograms	   represent	   HSPB8,	   BAG3	   and	   BAG1	  mRNA	   levels	   normalized	  with	  
RplP0	  mRNA	  levels,	  four	  samples	  for	  each	  condition	  were	  analysed	  (*=p<0.05	  vs.	  T;	  $=p<0.05	  vs.	  EtOH;	  
°°=p<0.01	  vs.	  T);	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BAG1	  mediates	  ARpolyQ	  UPS	  degradation	  	  
We	   then	   tested	   the	   functional	   significance	   of	   BAG1	   up-­‐regulation	   on	   misfolded	  
ARpolyQ	   clearance	   upon	   inhibition	   of	   dynein-­‐mediated	   transport.	   As	   expected,	   the	  
FRA	   analysis	   (Fig.	   28	   A)	   shows	   that	   BAG1	   over-­‐expression	   completely	   prevents	   the	  
accumulation	   of	   ARpolyQ	   retained	   on	   the	   cellulose	   acetate	   membrane.	   We	   also	  
checked	   the	   BAG1	   over-­‐expression	   by	   WB	   analysis	   (panel	   28	   A	   lower	   inset).	   The	  
reduction	  of	  misfolded	  ARpolyQ	  confirms	  the	  pro-­‐degradative	  effect	  of	  BAG1.	  
	  Next,	  we	  wondered	  whether	  the	  pro-­‐degradative	  function	  of	  BAG1	  was	  dependent	  on	  
a	   functional	   proteasome.	   FRA	   in	   Fig.	   28	   B	   shows	   that	   the	   proteasome	   inhibition,	   by	  
MG132	   o/n	   treatment,	   fully	   prevents	   the	   pro-­‐degradative	   activity	   of	   BAG1	   on	  
testosterone-­‐inducible	  insoluble	  misfolded	  ARpolyQ	  species	  in	  NSC34	  cells.	  These	  data	  
confirm	  that	  by	  preventing	  the	  HSPB8/BAG3(14-­‐3-­‐3)	  dynein-­‐directed	  accumulation	  of	  
misfolded	  ARpolyQ	  at	   the	  MTOC,	   the	  cells	  allow	  an	  optimized	  BAG1	   recognition	  and	  
proteasome	  degradation	  of	  the	  monomeric	  misfolded	  ARpolyQ	  species.	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Figure	  28	  -­‐	  BAG1	  up-­‐regulation	  reduces	  ARpolyQ	  accumulation.	  
(A)	  NSC34	   cells	   expressing	  AR.Q46	  and	  or	  BAG1	  and	   treated	  with	   testosterone	   for	   last	   48	  hours;	   FRA	  
shows	  PBS	  insoluble	  AR-­‐polyQ	  levels	  (upper	  panel),	  histograms	  represent	  the	  densitometric	  analysis	  of	  
three	   replicates	   for	   each	   sample	   ($=p<0.05	   vs	   EtOH;	   *=p<0.05	   vs.	   T),	  WB	   (lower	   panel)	   shows	   BAG1	  
protein	  level;	  (B)	  NSC34	  cells	  expressing	  AR.Q46	  and	  or	  BAG1	  and	  treated	  with	  10	  nM	  testosterone	  for	  
last	   48	   hours	   and/or	   10	   µM	   MG132	   for	   last	   16	   hours;	   FRA	   shows	   PBS	   insoluble	   AR-­‐polyQ	   levels,	  
histogram	   represents	   densitometry	   analysis	   of	   three	   replicates	   for	   each	   sample	   (*=p<0.05	   vs.	   EtOH;	  
°=p<0.05	  vs.	  T).	   	  
Results	  
	  
	   	  
101	  
EHNA	  effects	  on	  CMA	  markers	  
BAG1	   in	   association	  with	  HSC70	   can	   also	   route	  misfolded	  proteins	   to	  CMA,	  which	   is	  
however	   restricted	   to	   proteins	   bearing	   the	   KFERQ	  motif.	   Therefore,	   in	   collaboration	  
with	   Prof.	   Carlo	   Ferrarese,	   Università	   degli	   Studi	   -­‐	  Milano	   Bicocca,	  Milano,	   Italy,	   we	  
analysed	  whether	  EHNA	  dynein	  inhibition	  may	  modulate	  the	  expression	  of	  key	  player	  
required	   for	   CMA,	   such	   as	   HSC70	   and	   lysosomal-­‐associated	   membrane	   protein	   2A	  
(Lamp2A),	  a	  membrane	  glycoprotein	  required	  to	  protect	  and	  maintain	  lysosomes,	  and	  
that	  serves	  as	  specific	  receptor	  for	  CMA.	  We	  performed	  a	  WB	  analysis	  (Fig.	  29	  A)	  and	  
RT-­‐qPCR	   (Fig.	   29	   D,E)	   on	   EHNA	   treated	   NSC34	   cells.	  While	   EHNA	   treatment	   did	   not	  
affect	   the	  mRNA	   nor	   the	   protein	   levels	   of	   the	   HSC70	   (Fig.	   29	   A,	   29	   B	   and	   29	   D),	   it	  
significantly	  increased	  both	  the	  mRNA	  and	  protein	  levels	  of	  Lamp2A.	  These	  increased	  
expression	  levels	  of	  CMA	  markers	  confirm	  that	  the	  impairment	  of	  dynein	  transport	  and	  
then	  of	  autophagic	  flux	  may	  be	  balanced	  also	  by	  CMA.	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Figure	  29	  -­‐	  EHNA	  effects	  on	  chaperone	  mediated	  autophagy	  (CMA).	  	  
NSC34	  cells	  treated	  with	  DMSO	  or	  100	  µM	  EHNA	  for	  48	  hours,	  (A)	  WB	  analysis	  shows	  Lamp2A	  and	  Hsc70	  
protein	  levels,	  β-­‐actin	  was	  used	  as	  loading	  control;	  (B,	  C)	  histograms	  represent	  densitometric	  analysis	  of	  
nine	  samples	  (*=p<0.05	  vs.	  ctrl);	  (D,	  E)	  RT-­‐qPCR	  analysis	  of	  Hsc70	  and	  Lamp2A	  mRNA	  levels	  normalized	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EHNA	  effects	  on	  fALS	  cell	  models	  
ALS-­‐related	   proteins	   are	   misfolded	   and	   aggregated.	   Here	   we	   want	   to	   investigate	  
whether	   the	   effects	   of	   dynein	   inhibition	   described	   above	   would	   exert	   its	   pro-­‐
degradative	  activities	  also	  on	  other	  mutant	  proteins	  responsible	  for	  ALS.	  We	  selected	  
two	  proteins	  that	  have	  been	  associated	  to	  ALS:	  i)	  the	  enzyme	  superoxide	  dysmutase	  1	  
(SOD1),	  which	  has	  been	  found	  mutated	  in	  approximately	  20%	  of	  the	  familial	  forms	  of	  
ALS	   (fALS),	   ii)	   a	   truncated	   form	  of	  TDP-­‐43	   (TDP-­‐43	  ΔC)	  which	  has	  been	   found	   in	   few	  
cases	  of	  fALS.	  The	  mutant	  G93A	  SOD1	  and	  the	  TDP-­‐43	  ΔC	  misfold	  and	  accumulate	  into	  
cytoplasmic	   aggregates;	   as	   shown	   for	   ARpolyQ	   their	   autophagic	   clearance	   can	   be	  
enhanced	   by	   the	   HSPB8/BAG3	   complex.	   We	   thus	   evaluated	   whether	   also	   in	   these	  
cases	   dynein	   inhibition	   resulted	   in	   increased	   solubility	   and/or	   degradation	   of	   the	  
aggregates	   of	  misfolded	   proteins.	   FRA	   clearly	   shows	   that	   in	   two	  different	  models	   of	  
ALS,	   G93A	   SOD1	   transiently	   (Fig.	   30	   A)	   or	   inducible	   stably	   transfected	   (Fig.	   30	   B)	  
motoneuronal	  NSC34	  cells,	  EHNA	  treatment	  results	  in	  a	  massive	  reduction	  of	  the	  total	  
amount	  of	  insoluble	  misfolded	  mutant	  SOD1.	  Similarly,	  it	  shows	  in	  the	  TDP-­‐43	  ΔC	  ALS	  
model	   (Fig.	   31	   A),	   proving	   that	   dynein	   inhibition	   reduces	   insoluble	   species	   of	   the	  
truncated	  fragment	  of	  TDP-­‐43.	  We	  then	  analysed	  if	  EHNA	  pro-­‐degradative	  effect	  was	  
mediated	   PQC	   degradative	   pathway.	   As	   in	   the	   case	   of	   ARpolyQ,	   EHNA	   requires	   a	  
functional	  proteasome	  activity	  to	  prevent	  the	  aggregation	  of	  mutant	  SOD1	  (Fig.	  30	  C)	  
and	  TDP-­‐43	  ΔC	  (Fig.	  31	  B);	  conversely,	  autophagy	  inhibition	  with	  3-­‐MA	  does	  not	  impair	  
the	   pro-­‐degradative	   effects	   exerted	   by	   EHNA	   on	   these	   two	   ALS-­‐associated	   proteins	  
(Fig.	  30	  C	  and	  31	  B).	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Figure	  30	  -­‐	  Effects	  of	  dynein	  inhibition	  on	  SOD1	  insoluble	  fraction.	  	  
(A)	  NSC34	  expressing	  SOD1	  wt	  and	  G93A	  treated	  with	  DMSO	  or	  100	  µM	  EHNA	  for	  last	  48h.	  FRA	  shows	  
SOD1G93A	   accumulation	   and	   SOD1G93A	   reduction	   after	   100	   µM	   EHNA	   treatment;	   (**=p<0.01	   vs.	  
SOD1wt;	  ##=p<0.01	  vs.	  SOD1G93A).	   (B)	  NSC34	  stably	  transfected	  with	  SOD1	  wt	  or	  G93A	   induced	  with	  
doxycycline	  and	  treated	  with	  DMSO	  or	  100	  µM	  EHNA	  for	  last	  48h.	  FRA	  shows	  SOD1G93A	  accumulation	  
and	   SOD1G93A	   reduction	   after	   100	   µM	   EHNA	   treatment;	   (##=p<0.01	   vs.	   SOD1wt;	   *=p<0.5	   vs.	  
SOD1G93A).	  (C)	  NSC34	  expressing	  SOD1	  G93A	  treated	  with	  DMSO,	  100	   M	  EHNA	  and/or	  10	  mM	  3-­‐MA	  
last	  48h	  and	  10	   M	  MG132	  for	   last	  16	  hours.	  FRA	  shows	  SOD1G93A	  accumulation	  after	  10	  mM	  3-­‐MA	  
and	  10	  µM	  MG132	  treatment.	  100	  µM	  EHNA	  treatment	  counteracts	  10	  mM	  3-­‐MA	  activity	  but	  not	  10	   M	  
MG132	   activity;	   (*=p<0.5	   vs.	   SOD1G93A	  3-­‐MA).	  Histograms	   represent	   densitometric	   analysis	   of	   three	  









Figure	  31	  -­‐	  Effects	  of	  dynein	  inhibition	  on	  TDP43	  insoluble	  fraction.	  
(A)	  NSC34	  expressing	  FL	  and	  ∆C	  TDP-­‐43	  treated	  with	  DMSO	  or	  100	  µM	  EHNA	  for	  last	  48h.	  FRA	  shows	  ∆C	  
TDP-­‐43	  accumulation	  and	  ∆C	  TDP-­‐43	  reduction	  after	  100	  µM	  EHNA	  treatment;	   (**=p<0.01	  vs.	  FL	  TDP-­‐
43;	  *=p<0.05	  vs.	  ∆C	  TDP-­‐43	  DMSO);	  (B)	  NSC34	  expressing	  ∆C	  TDP-­‐43	  treated	  with	  DMSO,	  100	  µM	  EHNA	  
and/or	  3-­‐MA	  last	  48h	  and	  10	  µM	  MG132	  for	  last	  16	  hours.	  FRA	  shows	  ∆C	  TDP-­‐43	  accumulation	  after	  10	  
mM	  3-­‐MA	  and	  10	  µM	  MG132	  treatment.	  100	  µM	  EHNA	  treatment	  counteracts	  10	  mM	  3-­‐MA	  activity	  but	  
not	   10	  µM	  MG132	   activity.	   Histograms	   represent	   densitometric	   analysis	   of	   three	   replicates	   for	   each	  
sample;	  (*=p<0.05	  vs.	  ∆C	  TDP-­‐43	  3-­‐MA).	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  pro-­‐degradative	  effect	  on	  C9ORF72	  ALS	  cell	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We	   then	   investigated	   whether	   HSB8	   may	   also	   act	   on	   aggregate-­‐prone	   dipeptides	  
produced	   by	   RAN	   translation	   in	   patients	   with	   C9ORF72	   exanucleotide	   expansion.	  
Interestingly,	  these	  long	  dipeptides,	  generated	  by	  ATG	  independent	  (RAN)	  translation	  
of	  all	  three	  lecture	  frames	  of	  sense	  and	  anti-­‐sense	  mRNA,	  seem	  to	  have	  no	  function	  in	  
the	  cell,	  but	  were	  found	  accumulated	  in	  neuronal	  cells	  of	  C9ORF72	  expanded	  carriers.	  
This	  clearly	  shows	  that	  C9ORF72-­‐related	  poly-­‐dipeptideds	  are	  sticky	  and	  prone	  to	  form	  
aggregates	  as	  well	  as	  the	  misfolded	  proteins	  involved	  in	  motor	  neuronal	  and	  neuronal	  
diseases.	   Then,	   we	   first	   transfected	   the	   NSC34	   cell	   with	   plasmid	   encoding	   for	   66	  
GGGGCC	  repeats	  without	  ATG,	  without	  a	  stop	  codon	  and	  tagged	  with	  one	  peptide-­‐tag	  
per	  frame	  (polyGA-­‐HA;	  polyGP-­‐Myc;	  polyGR-­‐FLAG)	  in	  order	  to	  evaluate	  the	  production	  
of	   RAN	   translated	   dipeptide.	   FRA	   (Fig.	   32	   A)	   shows	   that	   in	   our	   cells	   polyGP-­‐Myc	  
peptide	  is	  detectable	  as	  retained	  on	  cellulose	  acetate	  membrane,	  indicating	  that	  RAN	  
translation	   polyGP	   dipeptide	   was	   produced	   and	   was	   prone	   to	   aggregate.	  
Unfortunately,	   we	   detected	   only	   polyGP	   dipeptide.	   Accordingly,	   to	   study	   the	   PQC	  
processing	  of	  all	  C9ORF72	  dipeptide,	  we	  decided	  to	  use	  synthetic	  cDNAs	  encoding	  for	  
100	   repeats	   of	   poly-­‐GA,	   poly-­‐GP,	   poly-­‐GR,	   poly-­‐PR	   and	   poly-­‐PA	   with	   a	   start	   codon,	  
avoiding	   GGGGCC	   repeats	   (Yamakawa	   et	   al.,	   2015).	   FRA	   (Fig.	   32	   B)	   shows	   that	   all	  
dipeptides	   are	   retained	   on	   cellulose	   acetate	   membrane	   and	   perturbation	   of	   PQC	  
degradative	   pathway	   increases	   the	   retained	   dipeptide	   levels.	   In	   particular,	   polyGP	  
accumulation	   is	   drastically	   worsened	   by	  MG132	   and	   3MA	   treatment.	  We	   next	   used	  
polyGP	   construct	   to	   investigate	   if	   HSPB8	   plays	   its	   pro-­‐degradative	   action	   also	   on	  
C9ORF72	   dipeptides.	   In	   FRA	   in	   Fig.	   33	   A-­‐B,	   we	   observed	   that	   HSPB8	   silencing	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significantly	   increases	   the	   retained	   PBS	   insoluble	   polyGP	   species	   and	   HSPB8	   over-­‐
expression	   drastically	   reduces	   polyGP	   aggregation.	   These	   data	   show	   that	   polyGP	  
dipeptide	  is	  recognized	  by	  HSPB8	  as	  other	  MNDs	  related	  proteins	  here	  studied.	  HSPB8	  
pro-­‐degradative	  action	  is	  also	  confirmed	  on	  total	  soluble	  polyGP	  in	  WB	  (Fig.	  33	  C).	  We	  
then	  evaluated	  the	  HSPB8	  effect	  on	  other	  C9ORF72	  dipeptides.	  By	  FRA	  (Fig.	  33	  D),	  we	  
evaluated	   the	   PBS	   insoluble	   levels	   that	   are	   significantly	   reduced	   by	   HSPB8	   over-­‐
expressions	   and	   also	   in	   this	   case	   confirmed	   by	  WB	   analysis	   (Fig.	   33	   E).	   Collectively,	  
these	   data	   confirm	   that	   all	   C9ORF72	   dipeptides	   can	   be	   managed	   by	   PQC	   and	   in	  
particular	  can	  be	  recognized	  by	  HSPB8	  to	  route	  dipeptides	  to	  autophagy.	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Figure	  32	  -­‐	  dipeptide	  models	  of	  C9ORF72	  exanucleotide	  expantion.	  
A)	   NSC34	   cells	   transfected	  with	   0,6	   ug	   or	   0,8	   ug	   G4C2	   66	   repeats	   plasmid.	   FRA	   shows	   PBS	   insoluble	  
fraction	   of	   polyGP	   frame	   detected	  with	   anti-­‐myc	   TAG.	   B)	  NSC34	   cells	   transfected	  with	   synthetic	   poly	  
(GA,	   PR,	  GP,	   PA	   or	  GR)	  with	   100	   repeats	   and	   treated	  with	  MG132	   or	   3MA.	   FRA	   shows	   PBS	   insoluble	  
fraction	  of	  different	  dipeptide.	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Figure	   33	   -­‐	   HSPB8	   pro-­‐degradative	   effect	   on	   polydipeptide	   produced	   by	   C9ORF72	   exanucleotide	  
expantion.	  
NSC34	  cells	  transfected	  with	  synthetic	  poly	  (GP,	  GA,	  GR,	  PA	  and	  PR)	  with	  100	  repeats,	  HSPB8	  plasmid	  or	  
HSPB8	   siRNA.	   A)	   FRA	   shows	   PBS	   insoluble	   polyGP	   levels	   (upper	   panel),	   histograms	   represent	   the	  
densitometric	  analysis	  of	  three	  replicates	  for	  each	  sample	  (**=p<0.01	  vs	  ctrl),	  WB	  (lower	  panel)	  shows	  
polyGP	  FLAG	  tagged	  and	  HSPB8	  protein	  levels,	  α-­‐tubulin	  was	  used	  as	  loading	  control;	  B)	  FRA	  shows	  PBS	  
insoluble	   polyGP	   levels	   (upper	   panel),	   histograms	   represent	   the	   densitometric	   analysis	   of	   three	  
replicates	  for	  each	  sample	  (*=p<0.05	  vs	  pcDNA3);	  C)	  WB	  shows	  polyGP	  FLAG	  tagged	  and	  HSPB8	  protein	  
level,	  α-­‐tubulin	  was	  used	  as	  loading	  control.	  D)	  FRA	  shows	  PBS	  insoluble	  poly	  (GA,	  GR,	  PA	  and	  PR);	  E)	  WB	  
shows	  poly	  (GA,	  GR,	  PA	  and	  PR)	  FLAG	  tagged	  and	  HSPB8	  protein	   levels,	  α-­‐tubulin	  was	  used	  as	   loading	  
control.	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  As	   autophagy	   clearly	   manages	   ARpolyQ,	   SOD1	   and	   TDP-­‐43,	   it	   may	   also	   manage	  
C9ORF72	   dipeptides.	   We	   then	   tested	   if	   dynein	   inhibition	   perturbs	   dipeptides	  
concentration	   at	  MTOC	   and	   consequently	   the	   aggregation	   process.	   The	   NSC34	   cells	  
have	   been	   transfected	   with	   polyGP	   construct	   and	   treated	   with	   EHNA.	   We	   then	  
performed	   FRA	   to	   evaluate	   the	   PBS	   insoluble	   fraction	   of	   polyGP	   dipeptide.	   Fig.	   34	  
shows	  that,	  as	  occurs	  for	  other	  misfolded	  proteins	  related	  to	  MNDs,	  EHNA	  drastically	  
reduces	  the	  level	  of	  PBS	  insoluble	  species	  of	  polyGP	  also	  when	  autophagy	  is	  blocked	  by	  
3-­‐MA	  treatment.	  The	  EHNA	  effect	  is	  counteracted	  only	  by	  proteasome	  inhibition	  with	  
MG132.	  	  
Collectively,	   these	   data	   clearly	   show	   that	   dynein	   transport	   inhibition	   reduces	   the	  
C9ORF72	  dipeptide	  aggregation	  by	  disrupting	  the	  concentration	  at	  MTOC	  and	  routing	  
C9ORF72	  dipeptides	  to	  proteasome	  degradation.	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Figure	  34	  -­‐	  Effects	  of	  dynein	  inhibition	  on	  poly-­‐GP	  insoluble	  fraction.	  	  
NSC34	  cells	  expressing	  poly-­‐GP	  (100	  repeat)	  treated	  with	  10	  mM	  3MA	  and/or	  100	  µM	  EHNA	  for	  last	  48	  
hours	   and/or	   10	   µM	   MG132	   for	   last	   16	   hours.	   FRA	   shows	   poly-­‐GP	   insoluble	   fraction;	   histograms	  
represent	   densitometric	   analysis	   of	   three	   replicates	   for	   each	   sample	   (**=p<0.01	   vs.	   not	   treated;	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Misfolded	  proteins	  responsible	  for	  Kennedy’s	  disease	  (or	  SBMA)	  and	  ALS	  are	  managed	  
by	   PQC	   system	   to	   facilitate	   their	   re-­‐folding,	   to	   prevent	   their	   aggregation	   and	   to	  
promote	   their	   degradation.	   It	   has	  been	  proven	   that	   autophagy	  and	  UPS	  degradative	  
PQC	   pathways	   are	   impaired	   in	  MNDs.	   Indeed,	   the	   ubiquitinated	  misfolded	   proteins	  
accumulating	   into	   the	   inclusions	   might	   be	   degraded	   by	   UPS.	   Autophagy	   also	  
contributes	   to	   counteract	   neurodegeneration	   and	   autophagic	   flux	   blockage	   may	  
worsen	   the	   neurodegenerative	   process;	   in	   fact	   autophagic	   vacuoles	   are	   known	   to	  
accumulate	   in	  affected	  motor	  neurons	   (Crippa	  et	  al.,	  2010b;	  McCray	  &	  Taylor,	  2008;	  
Nixon	   et	   al.,	   2005;	   Anglade	   et	   al.,	   1997).	   It	   has	   been	   confirmed	   that	   increased	  
autophagy	   activity	   is	   beneficial	   for	   SBMA	   and	   ALS	   cell	   models	   preventing	   inclusions	  
(Rusmini	  et	  al.,	  2013;	  Crippa	  et	  al.,	  2010b;	  Gurney	  et	  al.,	  1994).	  In	  ad	  dition,	  also	  HSP90	  
chemical	   inhibition	   promotes	   AR	   degradation	   by	   dissociation	   of	   client	   proteins	   from	  
the/a	   cytoplasmic	   chaperone.	   This	   allows	   the	   recognition	   and	   degradation	   of	  
misfolded	  proteins	  by	  the	  proteasome.	  Both	  UPS	  and	  autophagy	  play	  an	  essential	  role	  
in	   SBMA	   and	   ALS	   pathogenesis;	   in	   this	   thesis	   we	   investigated	   their	   activation	   and	  
regulation	   in	   affected	   tissue	   in	   order	   to	   better	   understand	   these	   mechanisms	   and	  
identify	  new	  potential	  therapeutic	  targets.	  	  
First	  of	  all,	  we	  analysed	  the	  role	  of	  the	  PQC	  response	  in	  skeletal	  muscles	  and	  in	  spinal	  
cords	   in	  mice	   expressing	  mutant	   ARpolyQ	   as	   primary	   degenerated	   tissues	   in	   SBMA.	  
Indeed,	  Lieberman	  et	  al.,	  2014	  showed	  that	  in	  the	  peripheral	  tissues	  the	  mutant	  AR	  is	  
an	  important	  contributor	  to	  SBMA	  pathology	  in	  mice.	  In	  their	  study	  they	  showed	  that	  
the	   suppressions	   of	   mutant	   AR	   in	   peripheral	   tissues	   rescued	   deficits	   in	   muscles,	  
reversed	   ARpolyQ	   induced	   alterations	   in	   muscle	   gene	   expression,	   and	   extended	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lifespan	  of	  the	  SBMA	  male	  mice	  (Lieberman	  et	  al.,	  2014).	  These	  mice	  carried	  AR113Q	  
mutation	   and	   developed	   motoneuronal	   phenotype	   and	   were	   analysed	   at	   the	   pre-­‐
symptomatic	   stage	   and	   at	   the	   symptomatic	   stage.	   Previous	   studies	   have	   established	  
that	  AR113Q	  male	  mice	  show	  symptoms	  by	  24	  weeks	  of	  age.	  Also	  from	  this	  age	  they	  
show	   muscle	   atrophy	   but	   not	   motor	   neurons	   degeneration	   (Chua	   et	   al.,	   2014;	  
Lieberman	  &	  Robins,	  2008;	  Yu	  et	  al.,	  2006b).	  As	  controls,	  we	  used	  normal	  male	  mice	  
and	   age-­‐matched	   non	   symptomatic	   AR113Q	   female	   mice.	   We	   observed	   that	  
expression	   levels	   of	   the	  AR	  mRNA	   in	  muscles	   and	   spinal	   cords	   of	   symptomatic	  mice	  
were	   equal,	   suggesting	   that	   the	   absence	   of	   either	   positive	   or	   negative	   selection	   of	  
muscle	  and	  motor	  neuronal	   cells	  was	  directly	  mediated	  by	  ARpolyQ	  at	   this	   stages	  of	  
disease.	  We	  then	  analysed	  whether	  the	  autophagic	  pathway	  alterations	  were	  present	  
in	   our	   AR113Q	  mice.	   Indeed,	   previous	   observation	   demonstrated	   that	   AR	  mediated	  
toxicity	   in	   skeletal	   muscles	   is	   sufficient	   to	   cause	   motor	   neuron	   disease	   comparable	  
with	  the	  toxicity	  exerted	  by	  the	  polyQ	  expanded	  protein	  (Monks	  et	  al.,	  2007).	  Also,	  it	  
has	  already	  been	  reported	  that	  the	  autophagy	  master	  regulator	  TFEB	  is	  up-­‐regulated	  in	  
muscles	  of	  SBMA	  mice	  and	  patients	   (Chua	  et	  al.,	  2014).	  These	  changes	   in	  autophagy	  
have	   been	   correlated	   with	   enhanced	   responsiveness	   to	   physiological	   stimuli.	   This	  
study	   showed	   that	   autophagy	   regulation	   was	   compromised,	   confirmed	   by	   the	  
increasing	   of	   the	   p62-­‐SQSTM1	   and	   LC3-­‐II	   autophagic	   markers.	   They	   postulate	   that	  
autophagy	  may	  contribute	  to	  the	  SBMA	  pathogenesis,	  including	  muscle	  atrophy.	  Also,	  
they	  proved	  that	  enhanced	  autophagic	   response	  to	  exercise	  was	   implicated	   in	  SBMA	  
and	   it	   is	   to	   be	   considered	   in	   the	   evaluation	   of	   the	   benefits	   of	   exercise	   observed	   in	  
clinical	  trials	  (Chua	  et	  al.,	  2014).	  Here,	  we	  found	  that	  the	  gene	  expression	  of	  Beclin-­‐1,	  
Discussion	  
	  
	   	  
115	  
ATG10,	   p62/SQSTM1,	   LC3	   autophagic	   markers	   was	   increased	   in	   the	   muscles	   of	  
symptomatic	  AR113Q	  male	  mice.	  We	   also	   found	   either	   p62/SQSTM1	   stabilization	   or	  
LC3	  reduction	  in	  the	  overall	   levels	  of	  the	  corresponding	  coded	  proteins.	  Interestingly,	  
both	   p62/SQSTM1	   and	   LC3	   proteins	   are	   normally	   cleared	   by	   activated	   autophagy.	  
Notably,	  the	  increased	  turnover	  of	  total	  LC3	  protein	  was	  accompanied	  by	  an	  increased	  
LC3-­‐II/LC3-­‐I	  ratio.	  Collectively,	  these	  data	  strongly	  suggest	  that	  autophagy	  activation	  is	  
sustained	   by	   a	   regular	   flux	   in	   the	   atrophic	   skeletal	  muscles	   of	   symptomatic	   AR113Q	  
male	  mice.	   This	   confirmed	   that	   autophagy	   is	   activated	   in	   SBMA	  muscle	   as	   show	   by	  
Chua	  et	  al.,	  2014,	  but	  suggests	  that	  autophagy	  activation	  has	  a	  protective	  in	  muscles.	  
On	   these	   observations,	   we	   proved	   that	   the	   HSPB8-­‐mediated	   PQC	  machinery	   is	   also	  
activated	   in	   the	  muscles	   of	   symptomatic	  AR113Q	  male	  mice.	   Indeed,	  HSPB8	  protein	  
and	  mRNA	  levels	  were	  up-­‐regulated	  in	  skeletal	  muscles	  of	  symptomatic	  AR113Q	  male	  
mice.	  In	  addition,	  also	  the	  HSPB8	  co-­‐chaperone	  BAG3	  was	  greatly	  up-­‐regulated.	  Thus,	  
the	   entire	   HSPB8-­‐mediated	   autophagic	   machinery	   seems	   to	   be	   stimulated	   by	   the	  
presence	  of	  mutant	  ARpolyQ	  in	  the	  skeletal	  muscle	  of	  SBMA	  affected	  mice.	  These	  data	  
are	  consistent	  with	  the	  results	  of	  study	  on	  muscles	  of	  fALS	  (G93A-­‐SOD1)	  mice	  (Crippa	  
et	   al.,	   2013a;	   Crippa	   et	   al.,	   2013b).	   In	   this	   previous	   study,	   we	   clearly	   proved	   that	  
misfolded	  mutant	  SOD1	  activates	  autophagy	  in	  muscle	  of	  fALS	  mice.	  Indeed,	  we	  found	  
that	   HSPB8	  mRNA	   and	   protein	   levels	   were	   highly	   induced	   in	   transgenic	   G93A-­‐SOD1	  
female	  and	  male	  mice.	  Likewise,	  BAG3,	  BAG1	  mRNA	  and	  protein	  levels	  were	  higher	  in	  
male	   and	   female	   G93A-­‐SOD1	   mice	   than	   in	   the	   control	   mice.	   Interestingly,	   the	  
BAG3:BAG1	  ratio	  was	  increased,	  confirming	  that	  G93A-­‐SOD1	  promotes	  the	  autophagy	  
activation.	  In	  addition,	  autophagy	  activation	  was	  confirmed	  by	  the	  increased	  levels	  of	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p62-­‐SQSTM1	   and	   LC3	  mRNA	   and	   protein	   levels.	   As	  we	   found	   in	   SBMA	  mice,	   also	   in	  
fALS	  mice	  muscle	  we	  observed	  a	  potent	  activation	  of	  autophagy	  if	  compared	  to	  spinal	  
cord,	   suggesting	   that	   muscle	   tissue	   is	   efficiently	   protected	   by	   autophagy	   from	  
misfolded	  proteins	  toxicity	  (Crippa	  et	  al.,	  2013a).	  Moreover,	  the	  levels	  of	  the	  muscle-­‐
specific	  small	  heat	  shock	  protein	  HSPB2	  and	  HSPB3	  (den	  Engelsman	  et	  al.,	  2009)	  were	  
found	  to	  be	  up-­‐regulated	  in	  the	  same	  animals.	  Moreover,	  the	  BAG3:BAG1	  ratio	  (both	  
at	   mRNA	   and	   protein	   levels)	   was	   increased,	   suggesting	   that	   misfolded	   proteins	   are	  
preferentially	  routed	  to	  autophagy	  rather	  than	  to	  UPS	  (Carra	  et	  al.,	  2013;	  Gamerdinger	  
et	  al.,	  2011).	  We	  then	  analysed	  the	  spinal	  cord	  of	  the	  same	  animals;	  we	  did	  not	  detect	  
variation	   in	   the	   mRNA	   levels	   of	   all	   autophagic	   genes	   observed,	   only	   the	   relative	  
BAG3:BAG1	  ratio	  was	  found	  increased	  in	  symptomatic	  AR113Q	  male	  mice.	  This	  is	  the	  
only	  observation	  that	  suggests	  the	  autophagy	  activation,	  instead	  of	  the	  UPS	  pathway,	  
in	  the	  spinal	  cords	  of	  affected	  mice.	  This	  may	  show	  that	  motor	  neurons	  are	  not	  highly	  
affected	  at	  this	  stage	  of	  the	  disease,	  or	  possibly	  the	  lack	  of	  variation	  is	  due	  to	  the	  fact	  
that	  the	  large	  fraction	  of	  AR-­‐negative	  cells	  (interneurons,	  glial	  cells,	  etc.)	  in	  the	  spinal	  
cord	   “diluted”	   the	   mild	   variations	   of	   the	   mRNA	   levels	   present	   in	   AR-­‐positive	   cells.	  
Therefore,	  all	  data	  here	  found	  proves	  that	  the	  presence	  of	  mutant	  ARpolyQ	  in	  muscle	  
cells	  activates	  autophagy,	  possibly	   to	   remove	   toxic	  misfolded	  species.	   In	   this	   context	  
HSPB8-­‐mediated	   PQC	   machinery	   seems	   to	   be	   involved	   in	   agreement	   with	   its	   pro-­‐
autophagic	  activity.	  	  
Next,	  we	  analysed	  how	  the	  inhibition	  of	  the	  dynein-­‐mediated	  retrograde	  transport	  of	  
misfolded	   proteins	   to	  MTOC	  may	   affect	  misfolded	   proteins	   intracellular	   aggregation	  
and	   clearance.	   Previous	  data	   show	   that	  HSPB8	  exhibits	   its	   pro-­‐autophagic	   activity	   in	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complex	  with	  BAG3	  and	  HSC70/CHIP	  complex.	  Indeed,	  misfolded	  proteins	  interact	  with	  
HSPB8/BAG3/HSC70/CHIP	  complex	  for	  their	  ubiquitination	  and	  p62	  mediated	  insertion	  
into	   the	   nascent	   autophagosome	   at	  MTOC	   (Crippa	   et	   al.,	   2010a;	   Arndt	   et	   al.,	   2010;	  
Crippa	  et	  al.,	  2010b).	  This	  process	  requires	  the	  activity	  of	  14-­‐3-­‐3	  proteins	  that	  connect	  
BAG3	   and	   dynein	   to	   allow	   complex	   transport	   to	  MTOC	   (Xu	   et	   al.,	   2013;	   Jia	   et	   al.,).	  
Given	   this	   evidence,	   dynein	   inhibition	   should	   cause	   the	   increased	   accumulation	   of	  
insoluble	   and	   aggregated	   misfolded	   ARpolyQ.	   Conversely,	   we	   found	   that,	   in	   motor	  
neuron	   cells,	   the	   depletion	   or	   chemical	   inhibition	   of	   dynein	   decreases	   the	   insoluble	  
and	  aggregate	  fractions	  of	  misfolded	  ARpolyQ.	  Also,	  the	  inhibition	  of	  dynein	  mediated	  
transport	   with	   EHNA,	   a	   typical	   cytoplasmic	   mechanism,	   in	   PC12/AR.Q112	   SBMA	  
inducible	   model,	   characterized	   by	   inclusions	   localized	   in	   the	   nuclei,	   was	   able	   to	  
counteract	   insoluble	   misfolded	   ARpolyQ	   accumulation,	   even	   when	   this	   occurs	   at	  
nuclear	   level	   (Walcott	  &	  Merry,	  2002).	   This	   strongly	   suggests	   that	   the	   total	  ARpolyQ	  
clearance	   may	   have	   been	   decreased	   by	   the	   treatment.	   Therefore,	   the	   inhibition	   of	  
dynein	   transport	  of	  misfolded	  ARpolyQ	  species,	  by	  preventing	   their	   concentration	  at	  
the	   MTOC,	   counteracts	   their	   aggregation,	   enhancing	   their	   solubility.	   As	   expected,	  
dynein	   inhibition	   resulted	   in	   autophagy	   impairment.	   This	   is	  probably	  due	   to	   the	   fact	  
that	   dynein	   is	   essential	   to	   the	   transport	   of	   autophagosomes	   to	   lysosomes	   and	   to	  
facilitate	   their	   fusion	   into	   autophago-­‐lysosomes.	   Indeed,	   we	   proved	   that	   in	   this	  
condition	   autophagy	   is	   impaired	   and	   LC3-­‐II,	   that	   decores	   autophagosomes	   of	   large	  
size,	  accumulates	  in	  the	  cell	  cytoplasm	  altering	  the	  autophagic	  flux.	  As	  a	  consequence,	  
also	  p62/SQSTM1	  oligomerizes	  into	  the	  p62-­‐bodies.	  These	  data	  suggest	  that,	  contrary	  
to	   what	   had	   been	   predicted,	   the	   inhibition	   of	   dynein-­‐mediated	   transport	   in	   cells	   in	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which	  autophagy	   is	   impaired	  prevents	   the	   formation	  of	  ARpolyQ	  aggregated	  species,	  
possibly	  by	  preventing	  the	  concentration	  of	  the	  misfolded	  species	  at	  the	  MTOC,	  where	  
aggresomes	   are	   formed.	   Interestingly,	   we	   also	   observed	   the	   up-­‐regulation	   of	   the	  
HSC70	  co-­‐chaperone	  BAG1	  and	  Lamp2a,	  which	  are	   involved,	   respectively,	   in	   the	  UPS	  
and	   CMA	   degradations	   of	   clients	   bound	   by	   HSC70	   (Kettern	   et	   al.,	   2011;	   Bejarano	  &	  
Cuervo,	   2010;	   Gamerdinger	   et	   al.,	   2009;	   Rohde	   et	   al.,	   2008;	   Alberti	   et	   al.,	   2002;	  
Demand	  et	  al.,	  2001;	  Lüders	  et	  al.,	  2000).	  In	  basal	  conditions,	  the	  narrow	  barrel-­‐shape	  
of	  UPS	  may	  not	  properly	  digest	  dimeric	  and/or	  oligomeric	  forms	  of	  misfolded	  ARpolyQ.	  
As	  a	  consequence,	  these	  species	  could	  be	  targeted	  for	  degradation	  to	  autophagy	  in	  a	  
dynein-­‐dependent	   manner.	   Then,	   the	   inhibition	   of	   the	   transport	   of	   the	   misfolded	  
ARpolyQ	   proteins	   might	   delay	   their	   association	   into	   aggregates,	   maintaining	   the	  
protein	   into	  a	  monomeric	   (or	  small	  oligomeric)	   form	  that	  may	  be	  efficiently	  digested	  
by	   the	  UPS.	   Thus,	  when	  misfolded	   proteins	   cannot	   be	   efficiently	   transported	   to	   the	  
aggresome	   and	   autophagosomes	   for	   proper	   disposal,	   the	   cells	   up-­‐regulate	   a	  
chaperone	   system	   that	   does	   not	   require	   an	   active	   transport	   of	   clients,	   such	   as	   the	  
BAG1-­‐mediated	   binding	   of	   HSC70	   clients,	   which	   can	   be	   efficiently	   directed	   to	   the	  
proteasome	  via	  the	  UBL	  domain	  of	  BAG1	  or	  to	  the	  lysosomes	  via	  interaction	  of	  BAG1-­‐
HSC70	  with	  Lamp2a.	  This	  explains	  why	  the	  dynein	   inhibition	  resulted	   in	  an	  enhanced	  
clearance	   of	   misfolded	   proteins	   preventing	   their	   accumulation	   into	   insoluble	  
aggregates.	   The	   effect	   of	   BAG1	   protein	   over-­‐expression	   is	   congruent	   with	   the	   data	  
obtained	  using	  EHNA	  on	  SBMA	  cells,	  which	   suggest	   that	   the	  pro-­‐degradative	  activity	  
responsible	  for	  ARpolyQ	  clearance	  is	  exerted	  more	  on	  its	  insoluble	  misfolded	  fraction	  
than	  on	  the	  entire	  pool	  of	  the	  protein	  also	  largely	  folded	  in	  the	  cells.	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We	  also	  evaluated	  the	  effects	  of	  EHNA	  on	  misfolded	  proteins	   responsible	   for	  ALS.	   In	  
accord	   with	   the	   previous	   data	   on	   SBMA	   models,	   dynein	   transport	   impairments	  
significantly	   reduced	   the	  misfolded	   and	   aggregate	   fraction	   of	  mutant	   SOD1,	   TDP-­‐43	  
and	  polyGP	  dipeptide.	   In	  addition,	  both	  the	  pro-­‐degradative	  activity	  of	  BAG1	  and	  the	  
effects	  of	  dynein	  inhibition	  were	  counteracted	  by	  the	  blockage	  of	  proteasome	  with	  a	  
selective	  inhibitor	  MG132,	  but	  not	  by	  autophagic	  flux	  blockage	  with	  3-­‐MA.	  These	  data	  
suggest	   that	  by	  preventing	  the	  HSPB8/BAG3(14-­‐3-­‐3)	  dynein-­‐directed	  accumulation	  of	  
misfolded	   proteins	   at	   the	   MTOC,	   where	   their	   concentration	   may	   favour	  
oligomerization	   and	   aggregation,	   the	   cells	   allow	   an	   optimized	   BAG1	   intervention	   on	  
the	  monomeric	  misfolded	  species	  facilitating	  the	  high	  selectivity/low	  capacity	  action	  of	  
the	  UPS	  for	  their	  degradation.	  Therefore,	  the	  increased	  expression	  of	  Lamp2a	  indicates	  
that,	  when	  autophagic	  clearance	  is	  prevented	  (inhibition	  of	  transport),	  BAG1	  may	  not	  
only	   re-­‐route	   misfolded	   substrates	   to	   proteasome,	   but	   may	   also	   enhance	   the	   CMA	  
activity.	   Unfortunately,	   no	   CMA	   selective	   inhibitors	   were	   available	   to	   deeply	  
investigate	   the	   possible	   contribution	   of	   CMA	   in	   BAG1	   pro-­‐degradative	   effect.	  
Collectively,	   these	   data	   extended	   the	   previous	   observation	   showing	   that	   nocodazole	  
treatment	   inhibits	   aggresome	   formation	   of	   mutant	   hungtintin	   and	   ARpolyQ	   by	  
microtubule	  disruption	  (Webb	  et	  al.,	  2004;	  García-­‐Mata	  et	  al.,	  1999;	  Johnston,	  1998).	  
In	   addition,	   these	   studies	   showed	   that	   a	   reduced	   aggregation	   correlates	   with	   an	  
increased	   toxicity	   of	   misfolded	   proteins	   analysed,	   supporting	   at	   least	   the	   initial	  
protective	   role	   of	   aggregates	   (Simeoni,	   2000;	   Saudou	   et	   al.,	   1998;	   Klement	   et	   al.,	  
1998).	   In	   this	   study,	   thanks	   to	   a	  more	   specific	   approach	   to	   block	  misfolded	   protein	  
concentration	  at	  MTOC,	  we	  observed	  that	  the	  neuronal	  cells	  respond	  to	  the	  toxicity	  of	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the	  monomeric	  mutant	  misfolded	   proteins	   by	   enhancing	   the	   UPS	   routing	   via	   BAG1.	  
This	   suggests	   that	   the	  alteration	  of	  equilibrium	  of	  protein	   routing	   to	  PQC	  may	  affect	  
the	  accumulation	  of	  neurotoxic	  species,	  rather	  than	  the	  impairment	  or	  overwhelming	  
of	  a	  single	  degradative	  pathway.	  	  
These	   data	   apparently	   contrast	   with	   the	   observations	   obtained	   in	   transgenic	   mice	  
carrying	  missense	  point	  mutations	   in	   the	   cytoplasmic	  dynein	  heavy	   chain.	   Indeed,	   in	  
heterozygous	  mice	  a	  motor	  neuron	  degeneration	  was	  found	  without	  accumulation	  of	  
proteinaceous	  material,	  while	  homozygous	  mice	   showed	  also	  accumulation	  of	   Lewy-­‐
like	  inclusion	  bodies	  (Hafezparast	  et	  al.,	  2003).	  In	  addition,	  mutation	  in	  the	  p150Glued	  
subunit	   of	   dynactin	   (DCTN1),	   responsible	   for	   cytoplasmic	   dynein	   activation,	   causes	  
specific	   motor	   neuron	   loss,	   with	   the	   formation	   of	   p150Glued	   protein	   aggregates	  
(Kuźma-­‐Kozakiewicz	  et	  al.,	  2011;	  Levy	  et	  al.,	  2006;	  Puls	  et	  al.,	  2003)	  (see	  also	  (Schiavo	  
et	   al.,	   2013)	   for	   extensively	   review	   on	   dynein	   mutations	   in	   humans	   and	   mice).	  
However	   several	   mice	   in	   which	   dynein/dynactin	   functions	   were	   altered	   (either	  
because	  of	  dynein	  mutations	  (Legs	  at	  odd	  angles	  (Loa))	  (El-­‐kadi	  et	  al.,	  2010;	  Kieran	  et	  
al.,	  2005),	  or	  because	  of	  neuron	  specific	  expression	  of	  Bicaudal	  D2	  N-­‐terminus	  (BICD2-­‐
N)	   (Teuling	  et	  al.,	  2008)),	  when	  they	  were	  crossed	  with	  tg	  G93A	  SOD1	  mice,	  showed	  
the	  reduction	  of	  ALS-­‐like	  phenotype	  and	  improved	  lifespan.	  So,	  the	  ALS-­‐like	  phenotype	  
of	   these	   double	   transgenic	  mice	   was	   also	   bettered	   in	   comparison	   to	   the	   fALS	  mice	  
expressing	   the	  mutant	   SOD1	   (Cortes	   et	   al.,	   2014;	   Teuling	   et	   al.,	   2008;	   Kieran	   et	   al.,	  
2005).	  
On	  the	  basis	  of	  the	  data	  here	  presented,	  dynein	  may	  contribute	  to	  prevent	  the	  toxic	  
effects	   of	   mutant	   misfolded	   proteins	   on	   motor	   neurons	   by	   significantly	   inhibiting	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misfolded	   proteins	   transport	   at	   the	   the	   MTOC	   where	   aggregation	   may	   block	  
autophagic	  flux,	  while	  dynein	  mutations	  per	  se	  are	  deleterious	  to	  motor	  neurons.	  
In	   conclusion,	   in	   this	  work	  we	  contributed	   to	   show	  the	  new	  mechanisms	   involved	   in	  
misfolded	  proteins	  response	  in	  MNDs.	  Data	  here	  reported	  in	  the	  first	  part	  of	  this	  work	  
clearly	   confirm	   the	   HSPB8	   pro-­‐degradative	   activity	   and	   they	   underline	   that	   HSPB8-­‐
mediated	   PQC	   response	   is	   present	   in	   muscle	   tissue	   at	   the	   symptomatic	   stage	   of	  
disease.	  Therefore,	   the	  modification	  of	   the	  expression	  of	   specific	  genes	  encoding	   for	  
proteins	   involved	   in	   this	   response,	   may	   provide	   muscle-­‐specific	   biomarkers	   which	  
could	  allow	  to	  follow	  the	  progression	  of	  disease	  in	  SBMA	  mice	  and	  in	  patients.	  	  
Data	  presented	  in	  the	  second	  part	  of	  this	  work	  confirmed	  the	  HSPB8	  pro-­‐degradative	  
activity	  in	  SBMA	  and	  in	  fALS	  motor	  neuronal	  cell	  models	  and	  show	  the	  primary	  role	  of	  
dynein	  mediated	  transport	   in	  the	  autophagy	  and	  in	  the	  aggregate	  formation	  process.	  
Moreover,	  when	   autophagy	   is	   overwhelmed	  dynein	   inhibition	   strongly	   suggests	   that	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